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Abstract 
Bacterial drug resistance is an increasingly serious problem that threatens public 
health and researchers need to develop new drugs. The biosynthetic pathway of 
the bacterial peptidoglycan is a known and good target for the development of 
novel antibacterial agents.  
This research project focused on the first lipid-linked step of peptidoglycan 
biosynthesis. The enzyme required for this step is Phospho-MurNAc-pentapeptide 
Translocase MraY. Our aim was to screen for novel inhibitors of MraY. A 
continuous fluorescence MraY assay was developed and optimised to test known 
and potential inhibitors such as nucleoside natural products, antimicrobial 
peptides and structurally new small molecule potential inhibitors.  
The fluorescence assay was adapted to a high-throughput fluorescence assay in 
microtitre plate format and around 2,000 compounds were screened from the 
diversity set of the National Cancer Institute (NCI) against MraY in order to 
identify novel inhibitors. However, around 22 % of the test compounds from the 
diversity set interfered with fluorescence. Therefore, a radiochemical MraY assay 
was developed as an independent method. We eventually identified one potential 
MraY inhibitor from the diversity set, the naphthylisoquinoline alkaloid, 
michellamine B, with IC50 values of 400 and 340 µg/ml against E. coli and 
B. subtilis MraY respectively. The compound showed antibacterial activity 
against B. subtilis with an MIC value of 16 µg/ml. 
It was established that MraY inhibition from the pacidamycin producer, 
S. coeruleorubidus, was detectable directly from culture supernatants by the 
fluorescence and by the radiochemical MraY assays. Therefore, we tested culture 
supernatants and cell extracts from various Streptomyces strains. MraY inhibition 
was observed using cell extracts from Streptomyces venezuelae, and higher levels 
of inhibition were observed from a gbnB/gbnR S. venezuelae mutant, though it 
was not possible to identify the active species present. 
Following an earlier report of halogenated fluoresceins identified from a 
combined MraY/MurG screen, we also tested several halogenated fluoresceins, 
and found that phloxine B, a tetra-bromo fluorescein analogue, was an inhibitor of 
E. coli MraY with an IC50 value of 32 µM, and also inhibited MraY from 
P. aeruginosa, B. subtilis, M. flavus and S. aureus with IC50 values ranging 
between 100 and 210 µg/ml. 
1 
 
1 Introduction 
Modern medicine seemed to fight successfully against bacterial infections over 
the last century, however the appearance of bacterial resistance to commonly used 
antibiotics is constantly increasing. Methicillin-resistant Staphylococcus aureus
1
, 
vancomycin-resistant Enterococcus faecium
2
 and fluoroquinolone-resistant 
Pseudomonas aeruginosa
3
 represent a serious threat to public health while in the 
developing world, bacterial infections still count as a major cause of death, and 
even tuberculosis has returned
4
. There is a need for developing novel antibacterial 
agents with new mechanisms of action as some bacteria have the worrying ability 
to adapt and gain resistance. New alternatives to treat bacterial infections could be 
derived from bacteriophages, antimicrobial peptides and monoclonal antibodies
5
. 
One way to search for new antibacterial agents is screening structurally diverse 
compound libraries of several thousands of compounds against potential targets 
such as proteins, enzymes and receptors
6
. 
The success of antibacterial agents is due to the fact that bacterial and animal cells 
have important differences in their structure and biosynthetic pathways, thus they 
can act selectively against bacteria. Important differences between prokaryotic 
and eukaryotic cells are that the bacterial cell does not have a defined nucleus or 
organelles, has to synthesise enzymes to produce vitamins and they possess a cell 
wall
4
. Bacteria can be divided into two groups by Hans Christian Gram’s dye 
staining method (1884); Gram-positive and Gram-negative bacteria. Gram-
positive bacteria retain the dye while Gram-negative bacteria do not. The 
differences in the staining response are due to structural differences in their cell 
wall
7
(Figure 1-1).  
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The cell wall, located at the outer side of the cytoplasmic phospholipid membrane, 
is one of the most important elements of a bacterial cell because it provides 
rigidity and structural strength to bacteria and also maintains the osmotic pressure 
of the cytoplasm. Gram-negative bacteria have a thin peptidoglycan layer and an 
outer membrane that contains lipoproteins, phospholipids and lipopolysaccharides 
facing into the outer side of the cell wall, and porins for passive nutrient transport. 
On the other hand, Gram-positive bacteria have a significantly thicker 
peptidoglycan layer and thus retain the Gram-staining dye. The cell wall of Gram-
positive bacteria contains polysaccharides, anionic polymers called teichoic acids 
within the peptidoglycan layer, and lipoteichoic acids which are linked to the 
lipids from the cytoplasmic membrane and most importantly, Gram-positive 
bacteria lack the outer membrane
8
 (Figure 1-1).  
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Figure 1-1: Differences in the Gram-negative and Gram-positive cell wall; prepared in 
Microsoft PowerPoint based on a similar figure in Maliničová et al. (2010) 
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Peptidoglycan (Figure 1-2) is a major heteropolymer of the cell wall of bacteria 
consisting of linear glycan chains of alternating N-acetylmuramoyl-peptides 
(MurNAc-peptides) and N-acetylglucosamine (GlcNAc) that are cross-linked by 
peptide chains
29
. The linear chains of alternating N-acetylglucosamine and N-
acetylmuramic acid sugars are linked by a β-(1,4)-glycosidic bond. The N-
acetylmuramic acid moieties are linked via a lactyl group to the pentapeptide L-
Ala-γ-D-Glu-X-D-Ala-D-Ala; where X at the third position is a diamino acid, 
either meso-diaminopimelic acid (m-Dap), lysine (L-Lys), or rarely ornithine 
(Orn), depending on the bacterial species (Figure 1-3). Most Gram-negative 
bacteria have m-Dap while Gram-positive bacteria have L-Lys at the third 
position of the pentapeptide chain. These peptide chains are cross-linked in the 
final transpeptidation step between the ε-amino group of the third position amino 
acid (m-Dap or L-Lys) and the carboxyl group of the fourth position amino acid 
(D-Ala) of the next strand
10
. Figure 1-2 shows the example for the Gram-negative 
E. coli peptidoglycan. 
 
Figure 1-2: Representation of the forming peptidoglycan heteropolymer for E. coli, β-(1,4)-
glycosidic bond between GlcNAc and MurNAc and lactyl linkage between MurNAc and L-
Ala 
n 
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Figure 1-3: Examples of diamino acids at the third position of the peptide chains in 
peptidoglycan, AA: amino acid 
Some bacteria also have interstrand linkages made up of one or more amino acids. 
The Gram-positive S. aureus peptidoglycan (Figure 1-4) contains pentaglycine 
bridges between the pentapeptides of the glycan chains. The ε-amino group of L-
lysine is bonded to the carboxy-terminal glycine residue of the interchain 
pentaglycine peptide bridge by FemX. The subsequent glycine residues are added 
by FemA and FemB. Finally, the fifth glycine residue is linked to the carboxy-
terminus of the fourth position D-Ala of the next strand by transpeptidases while 
D-Ala at the fifth position is released
11
. 
 
Figure 1-4: S. aureus peptidoglycan 
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Altough B. subtilis belongs to the Gram-positive bacteria, its peptidoglycan cell 
wall (Figure 1-5) unusually contains meso-diaminopimelic acid at position 3 
instead of L-lysine
12
. 
 
Figure 1-5: B. subtilis peptidoglycan 
While the peptidoglycan heteropolymer grows, it is synthesised and broken down 
at the same time by synthases and hydrolases. Peptidoglycan hydrolases are a 
numerous group of enzymes that are able to cleave chemical bonds in 
peptidoglycan and take part in the regulation and turnover of peptidoglycan cell 
wall growth, cell division and autolysis
8
. Glycosidases, N-acetylmuramidase and 
N-acetylglucoseaminidase hydrolyse the β-(1,4) glycosidic bonds between 
MurNAc and GlcNAc sugars to give 1,8-dehydromuramyl units
13
, while 
carboxypeptidases and endopeptidases cleave amide bonds between amino acids 
in peptide chains and bridges. Carboxypeptidases remove a C-terminal amino 
acid, D,D-peptidases cleave between two D-amino acids while D,L- or L,D-
peptidases cleave between an L- and a D-amino acid. Endopeptidases cleave 
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within the peptide. D,D-carboxypeptidases cleave the fifth position D-alanine 
from the peptide chain and this changes the substrate properties because 
tetrapeptides can only be acceptors while pentapeptides containing the terminal D-
Ala-D-Ala moiety can be donors and acceptors as well for a peptidoglycan 
transpeptidation reaction. N-acetylmuramoyl-L-alanine amidases hydrolyse the 
amide bond between MurNAc and L-alanine of the peptide cross-bridge8, 14, 15.  
 
 
 
Maintaining the balance between the constructive activities of peptidoglycan 
synthases (see Figure 1-7) and the destructive activities of the above mentioned 
peptidoglycan hydrolases is crutial for the survival of the bacterial cell, or the 
process results in cell lysis. However, the mechanism of their regulation is yet 
unknown
15
.  
 
 
 
 
D,D-carboxypeptidase 
N-acetylmuramoyl-L-
alanine amidase 
N-acetylmuramidase 
endopeptidases 
 D,L-carboxypeptidase 
N-acetylglucoseaminidase 
Figure 1-6: Peptidoglycan hydrolases 
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Figure 1-7: Peptidoglycan biosynthetic pathway adapted to E. coli 
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1.1 Peptidoglycan biosynthesis and inhibitors 
Since the bacterial cell wall is a crucial component for the survival of bacteria but 
eukaryotic cells do not possess a peptidoglycan cell wall, enzymes involved in 
peptidoglycan biosynthesis are highly desirable and selective targets for 
antibacterial agents.  
The peptidoglycan biosynthetic pathway can be divided into three major stages, 
the cytoplasmic steps where UDPMurNAc-pentapeptide assembles following a 
series of steps catalysed by the Mur enzymes A-F, the lipid linked steps where the 
monomeric peptidoglycan building blocks lipid I and II are formed by MraY and 
MurG, and finally the periplasmic steps where the polymerisation reactions take 
place catalysed by transglycosylase and transpeptidase enzymes
16
 (Figure 1-7).  
This section summarises the function of the enzymes of the peptidoglycan 
biosynthetic pathway and their published inhibitors. 
1.1.1 Cytoplasmic steps 
The cytoplasmic steps have been targets for high-throughput screening by several 
companies and academic groups because of the availability of spectrophotometric 
assays and three-dimensional structures of the enzymes determined by X-ray 
crystallography
16
.  
1.1.1.1 MurA 
The first step in peptidoglycan biosynthesis is catalysed by UDPGlcNAc 
enolpyruvoyl transferase, the transfer of an enolpyruvyl unit from 
phosphoenolpyruvate (PEP) to UDPGlcNAc
17
 (Figure 1-8).   
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Figure 1-8: The reaction catalysed by MurA 
Some Gram-positive bacteria, such as S. aureus, have two distinct genes encoding 
these enzymes, murA and murZ
18, 19
. Fosfomycin (Figure 1-9) was shown to 
irreversibly inhibit UDPGlcNAc enolpyruvyl transferase by forming a covalent 
bond with the active site cysteine residue, Cys-115
20, 21
, and kinetic studies 
showed that fosfomycin inhibited MurA and MurZ from S. aureus with IC50 
values of 1.36 µM and 1.37 µM respectively
19
. However, fosfomycin resistant 
bacteria express the Asp-115 variant of MurA
22
. The quinine ring of the fungal 
terreic acid (Figure 1-9) was also found to be covalently attached to the thiol 
group of Cys-115 by X-ray crystallography (IC50: 15 µM)
23
. In addition, synthetic 
2-aminotetralones were identified as inhibitors of MurA and its homologue MurZ 
(IC50: 3-28 µM) with some antimicrobial activity against S. aureus (MIC: 8-
128 µg/ml)
24
. The sesquiterpene lactone cnicin (Figure 1-9) was found to form an 
adduct with enolpyruvyl-UDPGlcNAc as a noncovalent suicide inhibitor 
(IC50: 17 µM)  and was suggested to have the potential to inhibit the Asp-115 
mutant as well.
25
 Figure 1-9 shows the chemical structures of MurA inhibitors and 
the formation of the covalent adducts with the Cys-115 residue of E. coli MurA. 
2- 
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Figure 1-9: Chemical structures of MurA inhibitors: fosfomycin, terreic acid, 2-
aminotetralone analogue and cnicin where fosfomycin, terreic acid and the most potent 2-
aminotetralone analogue (MIC: 8 µg/ml against S. aureus) covalently bind to Cys-115 of 
MurA 
Peptide inhibitors of MurA emerged from phage display library screens, the most 
potent synthetic peptide (HESFWYLPHHQSY) was a competitive inhibitor of 
UDPGlcNAc and had an IC50 value of 200 µM
26
. 
1.1.1.2 MurB 
MurB, a NADPH dependant enolpyruvyl reductase, is responsible for the second 
committed step of bacterial peptidoglycan biosynthesis, reducing the carbon-
carbon double bond of UDP-enolpyruvate to give UDPMurNAc. A series of 
imidazolinone analogues (Figure 1-10) with IC50 values ranging between 12-
49 µM and MICs ranging between 2-4 µg/ml against S. aureus were discovered
27
. 
2- 
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4-Thiazolidinones (Figure 1-10) were identified as possible diphosphate mimics 
with IC50s ranging between 7.7 and 28.4 µM
28
. Pyrazolidine-3,5-dione analogues 
(Figure 1-10) with IC50 values in the low micromolar range were reported to act as 
MurB inhibitors and they also possessed antibacterial activity against S. aureus. 
The pyrazolidine-3,5-dione analogue in Figure 1-10 has an IC50 of 25.1 µM and 
an MIC value of 8 µg/ml against both S. aureus and E. faecalis and 4 and 
32 µg/ml against S. pneumoniae and E. coli
16, 29
. 
 
Figure 1-10: Examples of MurB inhibitors 
1.1.1.3 MurC 
MurC catalyses the ATP-dependent ligation of UDPMurNAc with L-Ala to form 
UDPMurNAc-L-Ala. The reaction begins with the attack of the carboxylate end 
of MurNAc on the γ-phosphate of ATP to produce an acyl-phosphate 
intermediate, followed by the attack of the amino group of L-Ala to yield a 
tetrahedral adduct. Then the elimination of inorganic phosphate leads to the 
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formation of the new peptide bond. All the ATP-dependent Mur ligases were 
suggested to follow a similar mechanism
30
 (Figure 1-11). 
 
Figure 1-11: Proposed mechanism of ATP-dependent Mur ligases (C to F): the reaction 
begins with the attack of the carboxylate end of the MurNAc peptide (MurNAc for MurC) 
on the γ-phosphate of ATP to produce an acyl-phosphate intermediate, followed by the 
attack of the amino group of the amino acid to be added to yield a tetrahedral adduct. Then 
the elimination of inorganic phosphate leads to the formation of the new peptide bond 
High-throughput screening of compound libraries and structure-based design have 
led to the discovery of new lead-compounds against MurC
31
. Benzofuran acyl-
sulphonamides (Figure 1-12) were shown to be potent MurC inhibitors with an 
IC50 value of 2.3 µM for the most active compound, competing with both ATP 
and UDPMurNAc and a competitive inhibitor of ATP, and the possibility of 
acting via compound aggregation was excluded
32
. A quinoxaline analogue (Figure 
1-12) was published with IC50 values of 30.2, 26.4 and 41.6 µM against MurC 
from E. coli, Klebsiella pneumoniae and Proteus mirabilis respectively, and it was 
shown to be a competitive inhibitor of ATP
16, 33
.  
 
Figure 1-12: Chemical structure of the most potent analogues of benzofuran acyl 
sufonamides 
2- 2- 
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1.1.1.4 Glutamate racemase (MurI inhibition) 
The enzyme glutamate racemase is responsible for the biosynthesis of D-glutamic 
acid from L-glutamic acid in many bacteria. From a high-throughput screen, a 
group of pyrazolopyrimidinediones were identified with selective activity against 
Helicobacter pylori with MIC values ranging between 0.5-16 µg/ml. The most 
potent of the series had an elevated MIC for a strain overexpressing MurI showing 
that inhibition was achieved by targeting MurI
34
 (Figure 1-13).  
 
Figure 1-13: The most potent pyrazolopyrimidinediones inhibitor of glutamate racemase 
1.1.1.5 MurD 
MurD is the second ATP-dependent ligase of the cycle adding D-glutamic acid to 
UDPMurNAc-L-Ala. Phosphinate inhibitors have been designed which mimic a 
tetrahedral reaction intermediate, the most potent compound (Figure 1-14), 
containing a mixture of diastereoisomers, had an IC50 of 78 µM
35
. A series of 
glutamic acid-containing 5-benzylidenerhodanine and 5-benzylidenethiazolidine-
2,4-dione inhibitors were designed based on the crystal structure of a MurD-
thiazolidine-2,4-dione inhibitor complex with the most potent (Figure 1-14) 
having an IC50 of 28 µM
36
. Moreover, macrocyclic inhibitors developed by 
computer-based molecular design based on X-ray crystallographic data were 
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found to inhibit E. coli MurD by binding to the active site with IC50 values in the 
low-micromolar range (0.7-9 µM)
37
 (Figure 1-14). 
 
Figure 1-14: Chemical structure of MurD inhibitors, the most potent phosphinate analogue 
(phosphinoalanine derivative), the most potent benzylidenethiazolidine-4-one analogue and 
the most potent of the macrocyclic inhibitors with an IC50 of 0.7 ± 0.3 µM against E. coli 
MurD 
1.1.1.6 MurE 
MurE, another ATP-dependent ligase of the series, is responsible for the addition 
of the third amino acid, most commonly L-lysine or meso-diaminopimelic acid to 
UDPMurNAc-L-Ala-D-Glu
31
.  Aporphine alkaloids, 3-methoxynordomesticine 
analogues (Figure 1-15) showed inhibition against M. tuberculosis MurE with 
IC50 values in the micromolar range and 3-methoxynordomesticine hydrochloride 
also showed potent anti-tuberculosis activity (MIC: 4-16 µg/ml)
38
. Figure 1-15 
shows the chemical structure of the 3-methoxynordomesticine analogues, 
compounds 1 and 2 were isolated from O. macrophylla and 3-
methoxynordomesticine hydrochloride (3) was obtained from 1 by HCl treatment 
in ethanol
38
. 
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Figure 1-15: Chemical structure of 3-methoxynordomesticine analogues 
In addition, a peptide inhibitor (NHNMHRTTQWPL) with an IC50 of 500 µM 
was also identified as the most potent sequence from a phage display library 
screen
39
. 
1.1.1.7 Alanine racemase 
Alanine racemase is a pyridoxal 5’-phosphate-dependent enzyme that catalyses 
the racemization of L-alanine to D-alanine
40-45
. D-cycloserine (Ki of 6.5 *10
-4 
M) 
is a well-known irreversible inhibitor of E. coli alanine racemase
46
, and O-
carbamoyl-D-serine was shown to inhibit (Ki of 4.8 *10
-4
 M) alanine racemase of 
Streptococcus faecalis
47, 48
. L-cycloserine acts reversibly and is less active with a 
Ki value of 2.1 *10
-3 
M
46
. In addition, thiadiazolidinones analogues were found to 
inhibit alanine racemase irreversibly with IC50s ranging from 0.36 to 6.4 µM. The 
series also had growth inhibitory activity against S. aureus, including MRSA 
strains, with MICs values ranging from 6.25 to 100 µg/ml
49
 (Figure 1-16).  
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Figure 1-16: Inhibitors of alanine racemase: D-cycloserine, O-carbamoyl-D-serine and an 
example for the thiadiazolidinone analogues 
1.1.1.8 D-Ala-D-Ala ligase (DdlB) 
DdlB is another ATP-dependant ligase that assists the addition of D-Ala to D-Ala. 
The proposed mechanism (Figure 1-17) for the D-Ala-D-Ala dipeptide formation 
begins with attack of the first D-Ala on the γ-phosphate of ATP to produce an 
acyl-phosphate intermediate, followed by the attack of the amino group of the 
second D-Ala to yield a tetrahedral adduct. Then the elimination of inorganic 
phosphate leads to the formation of the D-Ala-D-Ala dipeptide
50, 51
. The 
mechanism is similar to that of the Mur ligases (Figure 1-11).  
 
Figure 1-17: Chemical structure of the tetrahedral adduct formed during D-Ala-D-Ala 
formation (A), transition state analogue phosphinate inhibitor (B) and phosphinophosphate 
(C) 
A 
B C 
2- 
2- 
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Phosphinate and phosphonate transition state analogues of the tetrahedral adduct 
showing time-dependant inhibition had Ki values ranging between 2-13 nM by 
binding to the free E. coli DdlB enzyme
52
. An S,R-methylphosphinate and 
adenosine triphosphate were co-crystallized with E. coli DdlB
50, 53
 and the 
structures are shown in Figure 1-18. 
 
Figure 1-18: E. coli DdlB co-crystallized with ATP and a phosphinate inhibitor, Tyr-216, 
Ser-150 and Glu-15 residues in blue, red spheres are Mg
2+
 ions; figure was prepared using 
PyMOL molecular graphics software 
The important role of a hydrogen-bonded triad of tyrosine, serine, and glutamate 
residues and a helix dipole was suggested to be involved in catalysing the binding 
and deprotonating steps of D-Ala-D-Ala formation
50
. 
D-cycloserine inhibits D-Ala-D-Ala ligase as an analogue of D-alanine
54
. Studies 
on M. tuberculosis DdlB showed that the inhibition is reversible and competitive 
versus D-Ala with Ki values of 25 and 14 µM for the C- and the N-terminal D-Ala 
ADP 
S,R-methylphosphinate 
Tyr
216
 
Glu
15
 
Ser
150
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respectively, but uncompetitive against ATP. It was also shown that ATP binds 
first and ADP dissociates last from the active site
55
.  
Moreover, a series of hydroxyethylamines as analogues of tetrahedral 
intermediates of proteases were synthesised based on computer-aided design for 
DdlB and VanA responsible for D-Ala-D-Lac formation in vancomycin resistant 
bacteria (Section 5.2). The two most successful compounds had IC50 values in the 
micromolar range against both E. coli DdlB and E. faecium VanA. Figure 1-19 
shows these two compounds. The compound with R: MeO is a slightly better 
inhibitor, may be due to the ability of the methoxy group to accept hydrogen 
bond, had IC50 values of 224 ± 19 µM against DdlB and 110 ± 28 µM against 
VanA. The compound with R: F had IC50 values of 290 ± 23 µM and 
136 ± 12 µM against DdlB and VanA respectively
53
. 
 
Figure 1-19: Chemical structure of hydroxyethylamines, inhibitors of DdlB and VanA, R: 
MeO or F 
1.1.1.9 MurF 
MurF, the last ATP-dependent ligase of the series of Mur synthetases, assists the 
addition of D-Ala-D-Ala unit to UDPMurNAc tripeptide to form UDPMurNAc-
pentapeptide (Figure 1-20)
31
.  
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Figure 1-20: Chemical structure of UDPMurNAc-pentapeptide containing meso-
diaminopimelic acid at the third position 
A series of arylsulfonamide inhibitors (Figure 1-21) were reported with IC50s in 
the range of 22-70 nM but they lacked antibacterial activity
56
. However, a 4-
phenylpiperidine (IC50: 26 µM) also showed growth inhibition against S. aureus 
with MIC values ranging between 8-16 µg/ml
57
 (Figure 1-21). In addition, 
diarylquinolines were identified as MurF inhibitors with an IC50 values ranging 
between 24-30 µM and growth inhibition against S. aureus with an MIC of 
8 µg/ml and against E. faecalis
58, 59
 (Figure 1-21). 
 
Figure 1-21: Chemical structure of MurF inhibitors, one of the arylsulfonamide lead 
compounds (IC50: 1 µM), 4-phenylpiperidine and diarylquinolines analogues 
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Phage display screening identified the peptide sequence TMGFTAPRFPHY 
(MurFp1) with half maximal inhibitory activity of 250 µM
60
. 
Figure 1-22 shows the crystal structure of the E. coli apo enzyme
61
 and MurF 
from S. pneumonia co-crystallised with an arylsulfonamide inhibitor
62
.  
 
 
 
 
 
 
 
A considerable difference can be observed in the conformation of the open and the 
inhibitor bound enzyme as the C-domain moves towards the N-domain which is 
thought to be induced following binding by the compound
62
. Similar domain 
closure behaviour was observed for MurD upon ATP binding
63
. 
1.1.1.10 Synthesis of undecaprenyl phosphate 
The polyisoprenoid undecaprenyl phosphate (C55-P, chemical structure in Figure 
1-23 and peptidoglycan biosynthetic pathway in Figure 1-7) is the lipid carrier 
molecule in bacteria that assists the translocation of hydrophilic cell wall 
intermediates across the hydrophobic membrane bilayer
64
. In the cytoplasm, 
undecaprenyl pyrophosphate synthase generates undecaprenyl pyrophosphate 
 
Figure 1-22: E. coli MurF (left) and S. pneumonia MurF co-crystallized with a small 
molecule inhibitor (right), C-domains in blue, central domains in green and N-domains in 
red; figures were prepared using PyMOL molecular graphics software 
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containing a mixed cis, trans isoprenoid chain
65
. At the cytoplasmic membrane 
undecaprenyl pyrophosphatase dephosphorylates it to yield undecaprenyl 
phosphate. Undecaprenyl phosphate transfers the glycan components of the 
acceptor molecules to the periplasmic phase of the membranes where 
undecaprenyl pyrophosphate is regenerated, and it was also suggested to be 
recycled by recycling pyrophosphatases to undecaprenyl phosphate
65, 66
. 
 
Figure 1-23: Chemical structure of undecaprenyl phosphate (C55-P) 
Bacitracin (Figure 1-24), a cyclic peptide natural product, which was isolated 
from Bacillus subtilis, is known to inhibit peptidoglycan biosynthesis in Gram-
positive bacteria by forming a complex with undecaprenyl pyrophosphate in the 
presence of divalent metal ions
67, 68
.  
 
Figure 1-24: Chemical structure of bacitracin 
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1.1.2 The lipid-linked steps of peptidoglycan biosynthesis 
Fluorescence-based and radiochemical assays have been developed for screening 
the lipid-linked steps (Figure 1-25), however very few inhibitor screens have been 
published. One example is a screen using a combined MraY-MurG assay which 
resulted in the identification of chemical structures of new inhibitors
69
. The 
inhibitory potential and selectivity of the halogenated fluorescein hits from the 
above mentioned screen was investigated further in Section 5.4. 
 
Figure 1-25: Schematic representation of the lipid-linked steps of the peptidoglycan 
biosynthetic pathway, catalysed by MraY and MurG 
1.1.2.1 MraY 
The first lipid-linked step of the peptidoglycan biosynthetic pathway is catalysed 
by the integral membrane protein phospho-MurNAc-pentapeptide translocase 
MraY. More specifically, the MraY enzyme catalyses the phospho-transfer 
reaction between UDPMurNAc-pentapeptide and the lipid carrier undecaprenyl 
phosphate (Figure 1-25). The reversible reaction generates undecaprenyl-
diphospho-MurNAc-pentapeptide referred to as lipid I (Figure 1-26) and UMP. 
undecaprenyl  
phosphate lipid I 
UDPMurNAc-pentapeptide 
UDPGlcNAc 
lipid II 
PERIPLASM 
CYTOPLASM 
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Thus, the MurNAc-pentapeptide is transferred from the water soluble UDP 
moiety to a membrane component, undecaprenyl phosphate
16
. The MraY enzyme 
is described in more detail in Section 1.2. 
 
Figure 1-26: Chemical structure of lipid I (C55) with meso-diaminopimelic acid at the third 
position of the pentapeptide unit 
1.1.2.2 MurG 
The second lipid-linked step of the cycle, the transfer of N-acetyl-D-glucosamine 
(GlcNAc) from UDPGlcNAc to the C-4 hydroxyl group of lipid I to form lipid II 
is catalysed by glycosyltransferase MurG (Figure 1-25 and Figure 1-27)
9, 70
.  
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Figure 1-27: Chemical structure of lipid II (C55) with meso-diaminopimelic acid at the third 
position of the pentapeptide unit 
MurG is an extrinsic membrane protein and was first overproduced, solubilized 
from membranes, and purified by Crouvoisier et al. using anion exchange 
chromatography
71
. The MurG reaction was suggested to follow an ordered 
bisubstrate (Bi-Bi) mechanism in which the sugar substrate binds first
72
 and the 
process is thought to go through an oxocarbenium-ion-like transition state just like 
for the other enzymes of the GT-B glycosyltransferase superfamily. The reaction 
(Figure 1-28) was suggested to start with the deprotonation of the C-4 hydroxyl 
group of MurNAc from lipid I by an active site residue of MurG, possibly His-19 
of E. coli MurG. The generated oxyanion than attacks C-1 of GlcNAc to form the 
oxocarbeniun-ion-like transition state and during the final step UDP is released to 
generate lipid II
9
.  
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Figure 1-28: Suggested mechanism of action for MurG, R=-C(CH3)CO-pentapeptide 
An 1.9 Å crystal structure of E. coli MurG revealed two protein molecules in an 
asymmetric unit each containing an N-terminal and a C-terminal domain with 
minimal sequence but high structural homology separated by a deep cleft
73
. 
Another 2.5 Å crystal structure of E. coli MurG, co-crystallized with its substrate 
UDPGlcNAc, showed that only one of the substrate molecules of the dimer was in 
the right orientation for catalytic activity
74
. Interestingly, a hydrophobic patch was 
identified in the enzyme which could be the interaction site of this extrinsic 
 δ+ 
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membrane protein with the membranes
73
. Figure 1-29 shows the E. coli MurG 
dimer UDPGlcNAc complex. 
 
Figure 1-29: Crystal structure of MurG dimer with its substrate UDPGlcNAc in the active 
conformation, residues of the hydrophobic patch for membrane interaction in dark blue; 
figure was prepared using PyMOL molecular graphics software 
The 2.2 Å crystal structure of P. aeruginosa MurG with UDPGlcNAc was also 
published recently. The authors compared it with the E. coli MurG complex and 
found a close overlap in the structural superposition of the two enzyme complexes 
despite their moderate, 45 % sequence similarity
75
. 
Ramoplanin and the structurally related enduracidin are cyclic 
lipoglycodepsipeptides that were shown to inhibit MurG and the transglycosylases 
by forming complexes with lipid I and II
76, 77
 but ramoplanin was also suggested 
to interact with MurG directly and an IC50 of 20 µM was measured by Helm et 
al.
78
. Moreover, ramoplanin has excellent antibacterial activity against Gram-
positives, such as VRE (MIC: 0.39-1.6 µg/ml)
79
, MRSA (killed 99.9 % at 
20 µg/ml)
80
 and Clostridium difficile (MIC  < 0.5 µg/ml)
81, 82
.  
hydrophobic patch in blue 
UDPGlcNAc 
  
 
28 
 
A high-throughput MurG assay using a fluoresceinated UDPGlcNAc analogue 
was used to screen a 50,000 member compound library at 25 µg/ml and led to the 
identification of a family of inhibitors containing a five-membered heterocyclic 
core (Figure 1-30) that appears to function as a diphosphate mimic of 
UDPGlcNAc
83
. Further compound libraries were tested by the same method with 
hits showing more than 40 % inhibition at 2.5 µg/ml, however no antibacterial 
activity has been reported
84
. Trunkfield et al. synthesised a series of uridine-
linked proline-containing transition state mimics, the most potent showed 
inhibition against E. coli MurG with an IC50 value of 400 µM
85
. Figure 1-30 
shows the chemical structure of a diphosphate mimic with an IC50 value of 
1.4 µM and Ki value of 1.3 µM, and the most potent compound from the series of 
synthetic uridine linked proline-containing transition state mimics. 
 
Figure 1-30: MurG inhibitors, diphosphate mimic containing a five-membered heterocyclic 
core, and the most active uridine-linked proline-containing transition state mimic 
In order to screen compound libraries against MurG a fluorescence resonance 
energy transfer (FRET) assay was developed with the potential to be adapted to 
microtitre plate format. FRET means the transfer of fluorescence energy from a 
donor substrate to an acceptor substrate or reaction product. The assay used 
dansyl-labelled lipid I (λex: 340 nm, λem: 500 nm) and an indole-3-acetic acid 
fluorophore for UDPGlcNAc (λem: 345 nm)
86
. 
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Colicin M, a protein produced by some strains of E. coli to kill competitors from 
the same species was shown to block the biosynthesis of peptidoglycan, by 
presumably hydrolysing the phosphoester bond of lipid II in the periplasm
87, 88
. 
The membrane-permeabilizing 34-amino-acid polycyclic peptide antibiotic nisin 
was shown to use lipid II as a receptor molecule for increasing its antimicrobial 
activity (Gram-positives) and based on experiments with pyrene-labelled lipid II it 
was suggested that lipid II also plays a role in pore formation
89
. Another antibiotic 
that was suggested to act by binding to lipid II by forming an equimolar 
stoichiometric complex is the fungal defensin peptide containing 40-amino acids 
called plectasin with antimicrobial activity against Gram-positive bacteria
90, 91
. 
1.1.2.3 FemABX, MurM and MurN ligases, non-ribosomal 
peptide bond-forming enzymes 
In the case of some Gram-positive bacteria peptide cross-bridges are formed by 
additional amino acids to the third position L-lysine residue of the pentapeptide 
linked to the fourth position D-Ala residue of the next strand. Such cases are the 
addition of pentaglycine bridges to S. aureus peptidoglycan monomers by the Fem 
ligases (Figure 1-4) or Ala/Ser and Ala additions by MurM
92
 and MurN
93
 to the 
monomer units from S. pneumoniae. These peptide cross-bridge transferases were 
suggested to play a role in methicillin resistance and utilize aminoacyl-tRNA as a 
substrate
94, 95
. A deoxyadenosine phosphonate transition state analogue was found 
to inhibit MurM with an IC50 value of 100 µM but did not show growth inhibition 
against penicillin-resistant S. pneumoniae at 1 mM concentration and did not 
affect the MIC of penicillin
96
. Furthermore, an aminoacyl-tRNA based analogue 
containing an 1,2,4-oxadiazol ring was reported to inhibit FemX with an IC50 
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value of 1.4 µM but without antimicrobial activity or synergistic effects with 
penicillin
16, 97
 (Figure 1-31). 
 
Figure 1-31: 2'deoxyadenosine phosphonate inhibitor of MurM and aminoacyl-tRNA 
analogue inhibitor of FemX 
1.1.3 Periplasmic steps 
The lipid II monomer unit that was synthesised at the cytoplasmic face of the 
membrane gets flipped across the membranes by a possible ‘flippase’ protein 
(Figure 1-7), activity of which was suggested to be linked to transglycosylase 
activity
98
. At the periplasmic face of the membranes, the bifunctional penicillin 
binding proteins (PBBs) carry out the transglycosylation and transpeptidation 
reactions using the modified or unmodified lipid II monomer units. However, due 
to the complicated nature of these reactions and the difficulties of enzyme and 
substrate preparations, the development of high-throughput assays for these steps 
has proved to be very challenging so far
16
. 
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1.1.3.1 Transglycosylases (glycosyltransferases) 
Glycosyltransferases can be present as monofunctional or more often bifunctional 
proteins with N-terminal glycosyltransferase (GT) and C-terminal transpeptidase 
(TP) domains separated by a small linker region. The membrane-bound GT 
domain polymerises lipid II into β-(1,4)-linked MurNAc-peptide – GlcNAc 
polymers
99
. During the reaction undecaprenyl pyrophosphate is released (see 
Section 1.1.1.10). Lovering et al. proposed a mechanism for the GT51 domain of 
S. aureus PBP2, according to which E-114 (Enz B
-
) acts as a base to deprotonate 
the C-4 OH of GlcNAc of the acceptor lipid II, which attacks C-1 of MurNAc of 
the donor. E-171 may assist this process by direct protonation of the phosphate-
sugar bond (Enz A-H) or by coordinating the pyrophosphate group
99
 (Figure 
1-32).  
 
Figure 1-32: Proposed mechanism of the transglycosylation reaction of lipid II monomers 
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The natural product moenomycin (Figure 1-33) from Streptomyces is a well 
characterized inhibitor of the transglycosylase reaction (IC50: 31 nM
100
, and 
MIC: 5-300 ng/ml against Gram-positive bacteria
101
) mimicking the forming 
glycan chain but does not inhibit the monofunctional transglycosylase from E. coli 
or M. flavus
100, 102, 103
. Unfortunately, moenomycin is not useful for clinical drug 
development because it is poorly absorbed by the human body
99
.  
 
Figure 1-33: Chemical structure of moenomycin A 
An iminocyclitol-based pyrophosphate mimic inhibitor was developed for the GT 
active site of E. coli PBP1b by structure-based design with > 80 % inhibition at 
100 µM concentration, also showed > 80 % inhibition at the same concentration 
against C. difficile, S. aureus and H. pylori transglycosylases but it only showed 
weak antibacterial activity against S. aureus with an MIC value of 125 µM
102
 
(Figure 1-34).  
 
Figure 1-34: Chemical structure of the most potent iminocyclitol-based pyrophosphate 
mimic inhibiting transglycosylase activity 
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It was proposed that the natural product vancomycin (see chemical structure in 
Section 5.2 Figure 5-12) complexes the D-Ala-D-Ala termini of lipid II which 
leads to the inhibition of utilization of these substrates by transglycosylases
104, 105
, 
and an IC50 value of 0.38 µM was determined against E. coli PBP1b
106
. In 
addition, semisynthetic vancomycin analogues incorporating hydrophobic sugar 
substituents were suggested to interact directly with bacterial membrane proteins, 
such as transglycosylases, since they exhibit activity against D-Ala-D-Lac 
containing vancomycin-resistant Enterococci
107
. 
1.1.3.2 Transpeptidases 
Transpeptidation is the ultimate enzymatic reaction of the peptidoglycan 
biosynthetic pathway giving more strength and rigidity to the peptidoglycan 
heteropolymer. These reactions are catalysed by either monofunctional 
transpeptidases or the solvent exposed TP domain of the bifunctional penicillin 
binding proteins
99
. Most commonly the peptide chains of the glycan strands are 
cross-linked between the ε-amino group of the third position amino acid (m-Dap 
or L-Lys) and the carboxyl group of the fourth position amino acid (D-Ala) of the 
next strand
10
. Figure 1-2 illustrates the E. coli peptidoglycan structure while 
Figure 1-5 shows the example of the cross-linked B. subtilis peptidoglycan. 
However, there could be some rare m-Dap-m-Dap linkages in E. coli 
peptidoglycan
108
. Some Gram-positive bacteria have interstrand linkages made up 
of one or more amino acids. The Gram-positive S. aureus peptidoglycan (Figure 
1-4) contains pentaglycin bridges between the pentapeptides of the glycan 
chains
11
. 
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During the transpeptidation reaction the active-site serine residue of TP attacks 
the C-terminal D-Ala-D-Ala peptide bond forming an acyl-enzyme intermediate 
and the terminal D-Ala is released. The acyl-enzyme intermediate is either 
hydrolysed to form a shortened peptide chain for the carboxypeptidases reaction 
or cross-linked with the amino group of the amino acid of the neighbouring 
strand
70
. The transpeptidation reaction is the target of the β-lactam antibiotics such 
as penicillin and cephalosporin analogues since the β-lactam-thiazolidine rings 
have a steric analogy with D-alanyl-D-alanine
109
 (Figure 1-35).  
 
Figure 1-35: Mechanism of the transpeptidation reaction: acylation of the catalytic serine 
residue of TP by D-Ala at position 4 of the first stem peptide, then the acyl-enzyme 
intermediate is attacked by the amine of the L-Lys or m-Dap residue at position 3 of the 
adjacent stem peptide, mode of action of the β-lactam antibiotics: the active site serine 
residue of TP forms a covalent bond with the β-lactam ring  
β-lactam antibiotic 
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Unfortunately, there are several forms of bacterial resistance against the β-lactam 
antibiotics, such as producing modified versions of PBPs with lower affinity to β-
lactam antibiotics
110
 or β-lactamase enzymes that deactivate the antibiotic by 
hydrolysing the β-lactam ring111. Still, these reactions are very attractive targets 
for drug design because their inhibitors do not need to cross the phospholipid 
bilayer of the cytoplasmic membrane
16
. 
Vancomycin is thought to prevent transpeptidases from completing the cross-
linking process by binding to the D-Ala-D-Ala terminus of the peptidoglycan 
precursors
112
. 
A few assays have been reported, one of them is an HPLC assay to follow the 
transpeptidation reaction by incorporating D-Cys-D-Ala into peptidoglycan 
followed by fluorescent labelling and enzymatic digestion
113
. However, further 
input is necessary to develop quantitative assays that are amenable for high-
throughput screening as well
16
. 
In summary, the majority of antibiotic drugs in clinical use target the cytoplasmic 
and periplasmic steps of the peptidoglycan biosynthetic pathway
16
. The aim of 
this project is to find novel inhibitors for the first lipid-linked step of the cycle 
catalysed by the MraY enzyme which is discussed in the following section. 
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1.2 Enzymology of translocase MraY  
Translocase MraY catalyses the reversible phospho-transfer reaction between 
UDPMurNAc-pentapeptide and the lipid carrier undecaprenyl phosphate with the 
simultaneous release of UMP (Figure 1-25)
9
.  
1.2.1 Initial studies of the MraY reaction 
It was first shown by the research groups of Strominger and Neuhaus that 
membranes from S. aureus and M. lysodeikticus in the presence of Mg
2+ 
were able 
to transfer phospho-MurNAc-pentapeptide from the soluble cytoplasmic 
precursor, UDPMurNAc-pentapeptide to the lipid carrier, undecaprenyl 
phosphate, and generate undecaprenyl-phospho-MurNAc pentapeptide, more 
recently referred to as lipid I
114, 115
.  
 
 
Moreover, translocase MraY was shown to be able to exchange 
3
H-labelled UMP 
with the unlabelled UMP moiety of UDPMurNAc-pentapeptide
115, 116
: 
    
 
 
Ikeda et al successfully identified the E. coli mraY gene within a large cluster of 
genes (mra) where all the tightly packed genes encode proteins involved in 
peptidoglycan biosynthesis and cell division. The overexpression of this gene was 
shown to lead to an increase in phospho-MurNAc-pentapeptide translocase 
UMP + [
3
H]-UDPMurNAc pentapeptide [
3
H]-UMP + UDPMurNAc pentapeptide 
Mg
2+
 
Figure 1-37: The “exchange” reaction 
UMP + C55-PP-MurNAc pentapeptide (lipid I) C55-P + UDPMurNAc pentapeptide 
Figure 1-36: The “transfer” reaction (translocase MraY reaction) 
Mg
2+
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activity
117
. One copy of the mraY gene was found in all bacteria apart from 
archeabacteria
117
 and eukaryotic organisms with the exception of the eukaryotic 
Arabidopsis thaliana where a similar gene was identified
118
. In addition, the 
MraY activity was shown to be essential for cell wall growth and survival of the 
Gram-negative E. coli
119
 and the Gram-positive pathogen 
Streptococcus pneumoniae
120
 by gene knockout studies. 
Levels of MraY are very low in the bacterial cell, there are not more than 700 and 
2,000 cell copies for lipid I and II respectively in Gram-negative bacteria such as 
E. coli because of their thin cell wall
121
. However, in Gram-positive bacteria such 
as Micrococcus flavus where the cell wall is much thicker, there are higher levels 
of MraY and MurG, so membranes of M. flavus can be used to generate lipid I 
and II in up to 50 mg quantities
89
. 
Sequence alignment analysis revealed that the MraY enzyme is part of a 
superfamily of enzymes called polyisoprenyl-phosphate N-acetylhexosamine-1-
phosphate transferases
10
. Other prokaryotic members of this family are WecA, 
WbcO, TagO, WbpL and RgpG, involved in the biosynthesis of bacterial 
exopolysaccharides, and catalyse reactions involved in the membrane-associated 
polyprenol phosphate acceptor (undecaprenyl phosphate) and a UDP-N-acetyl-
hexosamine donor from the cytoplasm
122, 123
. These bacterial enzymes show more 
specificity towards the use of the sugar nucleotide donor, while MraY uses 
UDPMurNAc-pentapeptide; the other enzymes use UDPGlcNAc
9, 124
. There are 
similar lipid-linked steps in the eukaryotic asparagine-linked glycoprotein 
synthesis where a paralogue enzyme uses UDPGlcNAc as the sugar nucleotide 
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donor and dolichyl phosphate as a lipid carrier 
125-127 
(Figure 1-53 in Section 
1.3.1.1).  
1.2.2 Topological model for MraY 
The presence of alternating hydrophobic and hydrophilic units in the primary 
structure of MraY
117
, and the requirement of lipid microenvironment for 
activity
128
 indicated that MraY protein spanned the cytoplasmic membrane ten 
times
9
. Sequence alignment of the MraY prokaryotic orthologues revealed 14 
conserved polar residues of the family on five hydrophilic sequences
129
. Bouhss et 
al. studied the secondary structure of E. coli and S. aureus MraY by β-lactamase 
fusions and developed a topological model for the enzyme as an integral 
membrane protein (Figure 1-38) containing 10 transmembrane helices, five 
cytoplasmic and four periplasmic loops with both N- and C-termini located at the 
periplasmic face of the cytoplasmic membrane
129
.  
 
 
Figure 1-38: Membrane topology of MraY, PL: periplasmic loop, CL: cytoplasmic loop, H: 
transmembrane helix 
PERIPLASM 
CYTOPLASM 
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Sequence alignment and membrane topology studies suggested that the invariant 
residues of the polyisoprenyl-phosphate N-acetylhexosamine-1-phosphate 
transferase superfamily were all located at the cytoplasmic face of the 
membranes
123, 129, 130
. 
1.2.3 Catalytic mechanism for the MraY reaction 
Heydanek et al. proposed a two-step mechanism (Figure 1-39) for the MraY 
catalysed phospho-transfer reaction based on kinetic evidence
131
. According to 
this two-step mechanism, the reaction starts with the attack of an active site 
nucleophile of MraY on the β-phosphate of UDPMurNAc-pentapeptide and forms 
a covalent enzyme-phospho-MurNAc-pentapeptide intermediate while UMP is 
released. The second step consists of the attack of an oxyanion from undecaprenyl 
phosphate on the phosphate of the covalent intermediate leading to the formation 
of the native form of MraY and lipid I
9, 131
. 
 
Figure 1-39: Two-step catalytic mechanism for MraY 
Since only three amino acid residues with nucleophilic side chains were found by 
sequence alignments, Asp-115, Asp-116, and Asp-267 in E. coli, which are 
completely conserved in MraY and its related prokaryotic and eukaryotic 
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homologues, Lloyd et al. performed site-directed mutagenesis on the three 
conserved residues and proposed that Asp-267 could play the role of the catalytic 
active site nucleophile
130
. The MraY activity has an absolute requirement for 
Mg
2+
 at 5-40 mM concentrations which could be replaced by Mn
2+
 but with 
significant loss of activity
132, 133
. Lloyd et al. suggested that Asp-115 and Asp-116 
could be involved in Mg
2+
 coordination which itself is involved with binding the 
pyrophosphate bridge of UDPMurNAc-pentapeptide
108 
(see Figure 1-43 in 
Section 1.2.4). This suggestion was based on the fact that there are examples for a 
DDXXD motif to be involved in coordination of Mg
2+
 in the family of prenyl 
transferases
130, 134
.  
The two-step catalytic mechanism is supported by the exchange reaction (Figure 
1-37) experiments of Pless and Neuhaus using S. aureus MraY confirming that 
3
H-labelled UMP can be exchanged into UDPMurNAc-pentapeptide via isotope 
exchange in the absence of the lipid acceptor undecaprenyl phosphate. Phospho-
MurNAc-pentapeptide was formed during the reaction indicating that the enzyme-
phospho-MurNAc-pentapeptide intermediate forms first during the transfer 
reaction. Addition of undecaprenyl phosphate stimulated the forward reaction 
while addition of the radiolabelled UMP or dodecylamine favoured the reverse 
reaction by inhibiting lipid I synthesis
9, 135
. However, the non-purified enzyme 
preparation of Pless and Neuhaus could have contained phosphatases and 
endogenous undecaprenyl phosphate
9
. 
An alternative one-step mechanism (Figure 1-40) was also proposed for the MraY 
reaction consisting of a direct attack of the phosphate oxyanion of undecaprenyl 
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phosphate onto the β-phosphate of UDPMurNAc-pentapeptide leading to the 
formation of lipid I and UMP in one step
9
. 
 
Figure 1-40: One-step catalytic mechanism for MraY 
Al-Dabbagh et al. have carried out site-directed mutagenesis studies using 
purified  B. subtilis MraY and favour the one-step mechanism in the interpretation 
of their data, suggesting that the Asp-98 invariant residue corresponding to Asp-
115 in E. coli MraY, plays an important role in catalysis
136
. 
1.2.4 Crystal structure for Aquifex aeolicus MraY 
Chung et al. have recently overexpressed, purified and crystallized recombinant 
MraY from a rod-shaped thermophilic bacterium, Aquifex aeolicus. It was shown 
that MraY crystallizes in both detergent micelles and in the membranes as a dimer 
in an asymmetric unit, which was confirmed by cross-linking studies, and the axis 
is perpendicular to the plane of the membrane
137
. Figure 1-41 shows the 3.3 Å 
MraY dimer structure as seen from the membranes and from the cytoplasm with 
an oval-shaped tunnel at the centre of the dimer surrounded by hydrophobic 
amino acids
137
. 
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Each monomer contains ten transmembrane helices and five cytoplasmic loops (A 
to E) with both termini located on the periplasmic side of the membrane as it was 
suggested by Bouhss et al. In addition there is an N-terminal interfacial helix (IH), 
a periplasmic β hairpin (PB between helices 4 and 5) and a periplasmic helix (PH 
between helices 6 and 7). Transmembrane helix 9 breaks into two fragments (9a 
10 
8 
7 
6 
5 
2 
4 
3 
1 
9b 
9a 
E (fifth 
cytoplasmic loop) 
9a 
9b 
loop E 
Figure 1-41: Structure of the MraY dimer from Aquifex aeolicus, view from within the 
membrane (top) and cytoplasmic view (bottom), only the transmembrane helices of one 
protomer are coloured, red spheres are Mg
2+
, transmembrane helices are numbered (1-10); 
figures were prepared using PyMOL molecular graphics software 
Cytoplasm 
Periplasm 
5 
55 Å 
72 Å 
interfacial helix at the N-
terminal 
periplasmic β hairpin 
between helix 4 and 5 
periplasmic helix 
between helix 6 and 7 
4 
10 
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and 9b) with 9b showing a significant bend in the middle of the membrane and 
protruding ~20 Å into the membrane (Figure 1-41 and Figure 1-42)
137
. 
 
Figure 1-42: Membrane topology of A. aeolicos MraY, transmembrane helices are 
numbered, cytoplasmic loops have letters (A-E), IH: interfacial helix, PB: periplasmic β 
hairpin, PH: periplasmic helix
137
 
According to Lloyd et al. the conserved Asp-115 and Asp-116 residues are 
involved in Mg
2+
 chelation while Asp-267 is an active site nucleophile of E. coli 
MraY
130. The NCBI’s sequence alignment program revealed 48 % identities and 
66 % similarities in and E. coli and Aquifex aeolicus MraY sequences and Asp-
115, Asp-116 and Asp-267 residues correspond to Asp-117, Asp-118 and Asp-
265 of Aquifex aeolicus MraY respectively. Figure 1-43 shows the proposed 
catalytic mechanism by Lloyd et al. and the corresponding conserved aspartate 
residues of Aquifex aeolicus MraY. The distances between Mg
2+
 and the three 
aspartate residues were measured as 5.8 Å, 4.9 Å and 2.2 Å for Asp-117, Asp-118 
and Asp-265 respectively. Chung et al. performed anomalous scattering studies 
with Mn
2+
 and concluded that the divalent metal ions interacted with the Asp-265 
residue and this residue was suggested to interact with Mg
2+
 as well
137
. 
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However, it should be noted that 100 mM MgCl2 was needed to obtain these 
crystals, so these results are perhaps not conclusive, further studies and an MraY-
substrate complex structure could help elucidate the catalytic residues and their 
role in the mechanism of action of MraY. 
Amer and Valvano reported the presence of an HHH motif in MraY sequences, 
His-326, His 327 and His-328 in E. coli MraY. A similar HXH motif is found in 
WecA sequences, His-279 and His-281 in E. coli WecA. This motif is completely 
absent in the eukaryotic enzymes and a role was proposed in the specificity of 
nucleotide substrate binding
130, 138
.  Figure 1-44 shows the conserved HHH motif 
of loop E (fifth cytoplasmic loop) of  Aquifex aeolicus MraY (His-324, His-325 
and His-326), but only the mutation of His-324 resulted in significant loss of 
MraY activity for Chung et al.
137
. 
 
Asp
118
 Asp
117
 
Asp
265
 
Mg
2+
 
267 
115 116 
2+ 
Figure 1-43: MraY active site, suggested active site mechanism by Lloyd et al. for E. coli 
MraY (left) and distance between Mg
2+
 and the conserved active site residues Asp
117
, Asp
118
 
and Asp
265
 of Aquifex aeolicus MraY (right); figure on the right was prepared using PyMOL 
molecular graphics software 
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In Figure 1-45 the amphipathic helix 9b with highly conserved polar amino acid 
residues together with the HHH motif containing loop E point towards the region 
of the active site cleft with the Mg
2+
 and the highly conserved aspartate 
residues
137
.  
 
Figure 1-45: transmembrane helix 9b, loop E and the active site of MraY with the three 
conserved aspartate residues as sticks, red sphere Mg
2+
; figure was prepared using PyMOL 
molecular graphics software 
His
324
 
His
325
 
His
326
 
Asp
117
 
Asp
118
 
Asp
265
 Mg
2+
 
Figure 1-44: HHH motif on loop E and the conserved aspartate residues as sticks, red 
spheres are Mg
2+
; figure was prepared using PyMOL molecular graphics software 
 
loop E 
active site cleft 
helix 9b 
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The surface representation of the enzyme revealed an inverted-U-shaped 
hydrophobic groove surrounding transmembrane (TM) helix 9b and extending 
towards the active site encompassing the aspartate residues and Mg
2+
 suggesting a 
possible undecaprenyl phosphate binding site (Figure 1-46)
137
. 
 
Figure 1-46: Representation of the hydrophobic groove by dashed lines (right), yellow 
sphere: Mg
2+
, Asp-117 in red, transmembrane (TM) helices 3 and 9b are also shown
137
 
 
1.2.5 Solubilisation, expression and purification of MraY 
The preparation of a pure, stable, soluble and active form of the low-abundance 
integral membrane protein MraY is the first step in order to investigate its 
biochemical properties
9, 10
. A series of detergents have been tried for the 
solubilisation of the protein from the membranes over the years such as Triton X-
100 or CHAPS
13, 128
 and n-dodecyl-β-D-maltoside and N-lauroyl-sarcosine were 
claimed to be the most effective
133
. Attempts to purify detergent solubilized MraY 
often failed and resulted in significant loss of activity and SDS-PAGE showed 
many protein bands
13
. Only partially purified enzymes were used for enzymatic 
assays in the presence of phosphatidylglycerol which enhanced the activity of 
Periplasm 
Cytoplasm 
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solubilized S. aureus
135
 and E. coli
13
 MraY. Several attempts have been made to 
express E. coli MraY as a fusion protein. No active enzyme was obtained using N-
terminal (His)6-MraY, or C-terminally labelled MBP-MraY. C-terminal (His)6-
MraY could be overexpressed and visualised by Western blotting
130
, but attempts 
to purify this protein to homogeneity were unsuccessful, and the activity of the 
(C-His)6-MraY was significantly lower than that of the wild type MraY
13, 130
.  
Bouhss et al. described the high-level overexpression of N-terminal (His)6-B. 
subtilis MraY and its purification by affinity chromatography to homogeneity in 
milligram quantities for the first time. Interestingly, SDS-PAGE and Western blot 
indicated a lower mass (31 kDa) than expected (36 kDa) for B. subtilis MraY but 
the purity and homogeneity of the protein was confirmed by MALDI-TOF mass 
spectrometry analysis
133
.  
Due to difficulties in the production of large integral membrane proteins in 
conventional cellular expression systems, cell-free expression technologies have 
been optimised in recent times in the presence of detergents. Expression of these 
membrane proteins in a cell-free environment has several advantages over in vivo 
systems, such as minimizing toxic effects, high hydrophobicity, inefficient 
translocation and degradation. The preparative scale cell-free production of 
Escherichia coli and Bacillus subtilis MraY with a C-terminal poly-(His)10 tag has 
been reported. The two MraY enzymes have similar topology with 47 % sequence 
identity and 64 % similarity (Table 2-1), and the E. coli enzyme has a slightly 
higher molecular mass than the B. subtilis enzyme, 40 and 36 kDa respectively. 
The two MraY proteins showed different characteristics upon applying different 
cell-free expression systems. While the B. subtilis protein seemed to be highly 
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stable and functionally folded, the E. coli protein was unstable and required the 
presence of preformed liposomes during expression for stability
139
. 
1.2.6 MraY assays 
MraY catalyses the first step in the membrane cycle of events which utilises 
undecaprenyl phosphate as the lipid carrier. Alternative substrates as lipid carriers 
such as heptaprenyl and dodecaprenyl phosphate were shown to be accepted in 
vitro by E. coli MraY
13
.  
The MraY activity could be determined by means of radiochemical assays
10
. One 
of the options is the transfer assay (Figure 1-47) which consists of the incubation 
of radiolabelled (most commonly 
14
C) UDPMurNAc-pentapeptide with the lipid 
acceptor and MraY and the reaction is monitored by extraction of the 
radiolabelled lipid product into an organic solvent, 1-butanol or 
chloroform/methanol (1:1)
140
.   
 
Figure 1-47: The “transfer” radiochemical MraY assay 
extraction into 1-butanol 
or chloroform/methanol 
radiolabelled UDPMurNAc-
pentapeptide  
radiolabelled lipid I  
 liquid scintillation counting  
 HPLC 
 
undecaprenyl  
phosphate  
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The other possibility, the exchange assay (Figure 1-48) involves the incubation of 
radiolabelled (
3
H) UMP with unlabelled UDPMurNAc-pentapeptide and the lipid 
acceptor, undecaprenyl phosphate. The assay relies on the reversible nature of the 
reaction since the reverse reaction results in the incorporation of the radiolabel 
into UDPMurNAc-pentapeptide which is then separated from radiolabelled UMP 
by thin layer chromatography and counted
140
. Unfortunately, these stopped assays 
are not suitable for kinetic studies or high-throughput screening
10
.  
  
 
Figure 1-48: The “exchange” radiochemical MraY assay 
Weppner and Neuhaus used a dansyl fluorophore attached to the ε-amino group of 
the amino acid at the third position of UDPMurNAc-pentapeptide (Figure 1-50) 
which was an accepted substrate for MraY. The reaction resulted in a 30 nm blue 
shift in the fluorescence emission spectrum and a 6-fold increase in quantum yield 
indicating that the dansyl moiety was transferred from a hydrophilic environment 
of the cytoplasm to a more hydrophobic environment of the membranes and/or 
detergent micelles
141
 (Figure 1-49).  
separation of radiolabelled UMP and radiolabelled 
UDPMurNAc pentapeptide by TLC and then counting 
 
radiolabelled 
UDPMurNAc- 
pentapeptide  
 
lipid I  
undecaprenyl 
phosphate  
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Figure 1-49: Fluorescence MraY assays 
The effectiveness of the dansylated substrate in the transfer reaction proved to be 
higher than the unlabelled UDPMurNAc-pentapeptide either at low or high 
concentrations but this is not the case for the exchange reaction indicating the 
dansyl group’s preference for the hydrophobic environment. However, in the 
biosynthesis of peptidoglycan the dansylated substrate cannot form peptidoglycan 
since it is blocked at position 3, and hence cannot cross-link. In conclusion, the 
dansylated substrate can be used to assess the activity of MraY but it is a poor 
substrate for the full synthesis of nascent peptidoglycan
141
.  
P. Brandish developed further the fluorescence MraY assay into a continuous 
fluorescence assay also using the dansyl fluorophore
13
 which he used to study the 
slow-binding inhibition of mureidomycin A
142
 and liposidomycin B
143
. Stachyra 
et al. adapted this method to 96- and 384-well plates and also developed an HPLC 
assay to separate the fluorescent labelled UDPMurNAc-pentapeptide and 
fluorescent labelled lipid I
144
.  
hydrophobic environment 
dansyl-labelled  
UDPMurNAc-pentapeptide  
  
aqueous environment 
dansyl-labelled lipid I  
 fluorescence monitoring 
 HPLC separation 
undecaprenyl phosphate 
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In addition, N-fluorescamine-labelled and N-o-phthalaldehyde-labelled 
derivatives (Figure 1-50) were prepared by labelling the amino acid residue at 
position 3
145
, or D-cysteine was incorporated into UDPMurNAc-pentapeptide by 
MurF at position 4 or 5. D-Ala-D-Cys or D-Cys-D-Ala was either enzymatically 
or chemically synthesised. The D-Cys-containing UDPMurNAc-pentapeptides 
were labelled with pyrene maleimide (Figure 1-50) and gave 1.5-150-fold changes 
in fluorescence upon transformation to lipid I by M. flavus membranes
146
. 
 
Figure 1-50: Fluorescent labels introduced into UDPMurNAc-pentapeptide 
Solapure et al. developed a scintillation proximity MraY assay for high 
throughput screening of large compound libraries. Wild type E. coli membranes 
were incubated with UDP-MurNAc-(
3
H-propionate) pentapeptide and lipid I was 
captured by the addition of wheat germ agglutinin coated beads. The radiolabelled 
lipid I molecules trigger the bead to emit light which can be then detected. Lipid I 
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formation was confirmed by specific inhibitors of MraY such as tunicamycin and 
vancomycin
147
.  
There have been several coupled MraY-MurG assays (Figure 1-51) reported 
where radiolabelled UDPGlcNAc is added to membranes in which lipid I was pre-
formed by incubation with UDPMurNAc-pentapeptide and undecaprenyl 
phosphate. The lipid product is either extracted into an organic solvent
85, 130
 or 
separated by solid-phase extraction such as streptavidin-coated beads
148
 or wheat 
germ agglutinin coated beads
69, 149
 
 
 
 
 
 
Figure 1-51: Schematic representation of the coupled radiochemical MraY-MurG assays 
 
 
undecaprenyl  
phosphate lipid I 
radiolabelled UDPGlcNAc 
UDPMurNAc-pentapeptide 
radiolabelled  
lipid II 
 extraction into 1-butanol or 
chloroform/methanol 
 solid phase extraction by 
beads 
 
counting  
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1.3 Known inhibitors of MraY 
1.3.1 Uridyl-peptide inhibitors of MraY 
There are five classes of uridine-containing nucleoside natural antibiotic products 
that target MraY, tunicamycins, mureidomycins, liposidomycins, muraymycins 
and capuramycins, and they were suggested to target the active site of MraY at the 
cytoplasmic face of the membrane. Some of them have been the target of detailed 
structure-activity relationship, kinetic or mechanistic studies
9
 but none of them 
has been progressed to a clinical drug so far, mainly due to very small available 
quantities. Drug candidates also need to have good pharmacokinetic properties, 
low toxicity, and progress through clinical trials successfully. One of the 
caprazamycin analogues from the family of uridyl-peptide MraY inhibitors, 
CPZEN-45 is a candidate today for clinical trials for the treatment of tuberculosis 
in Japan (Section 1.3.1.3). 
1.3.1.1 Tunicamycins 
The tunicamycins are a family of nucleoside disaccharides containing a unique 
11-carbon core and varying fatty acid side chains (Figure 1-52) that were first 
isolated from Streptomyces lysosuperficus in 1971 and showed antibacterial 
activity against B. subtilis with MIC values ranging between 0.1-20 µg/ml
150
. 
They were also reported to have antiviral
151
 and antitumor activities
152
.  
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Figure 1-52: Chemical structure of tunicamycins, n: 7-11 
They inhibit prokaryotic enzymes from the polyisoprenyl-phosphate N-
acetylhexosamine-1-phosphate transferase family including MraY and the 
eukaryotic paralogue GlcNAc-1-phosphate transferase involved in the first step of 
mammalian N-linked glycoprotein biosynthesis
153
. Consequently the 
tunicamycins are toxic to humans (Figure 1-53).  
 
Figure 1-53: Biosynthesis of dolichyl-pyrophosphoryl-GlcNAc in mammalian N-linked 
glycoprotein biosynthesis 
Tunicamycins were the first antibiotics reported to inhibit MraY and their 
inhibition kinetics were studied in detail by means of a continuous fluorescence 
assay showing that tunicamycin was a reversible inhibitor of MraY with a 
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Ki value of 0.6 µM
143
. IC50 values were determined against MraYs from various 
organisms in Section 5.1.4. 
Since the tunicamycins are isolated as mixtures, separation of which is tedious, it 
was important to develop their chemical synthesis in order to enable the study of 
the biological activities of the individual structures
154
. Efforts are being made to 
date in order to elucidate the biosynthetic pathway of tunicamycins, which could 
perhaps be used to prepare more selective and clinically useful drugs
155
. 
1.3.1.2 Mureidomycins, pacidamycins, napsamycins and 
sansanmycins 
The mureidomycins, pacidamycins, napsamycins and sansanmycins (Table 1-1) 
are peptidyl nucleoside natural products sharing a common structural skeleton 
containing a 3’-deoxyuridine nucleoside attached via an enamide linkage to an N-
methyl 2,3-diaminobutyric acid (DABA) residue. To the α-amino group of DABA 
amino acid 4 (AA4) is attached (either Met or Ala) and it is linked to the C-
terminal amino acid 5 (AA5) via a urea linkage. This amino acid has an aromatic 
side-chain. The β-amino group of DABA is linked to amino acid 2 (A2A) which is 
most commonly m-Tyr, Ala or a bicyclic amino acid
156
. 
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Table 1-1: Chemical structure of mureidomycins, pacidamycins, napsamycins and 
sansanmycins 
 
Name R A2A AA4 AA5 Other 
mureidomycin A H m-Tyr Met m-Tyr  
mureidomycin B H m-Tyr Met m-Tyr dihydrouracil 
sansanmycin A H m-Tyr Met Trp  
sansanmycin C H m-Tyr MetSO Trp  
pacidamycin 4 H m-Tyr Ala Trp  
pacidamycin 5 H m-Tyr Ala Trp  
pacidamycin 5T H m-Tyr Ala m-Tyr  
sansanmycin B H m-Tyr Leu Trp  
pacidamycin D H Ala Ala Trp  
pacidamycin 1 Ala m-Tyr Ala Trp  
pacidamycin 2 Ala m-Tyr Ala Phe  
pacidamycin 3 Ala m-Tyr Ala m-Tyr  
mureidomycin C Gly m-Tyr Met m-Tyr  
mureidomycin D Gly m-Tyr Met m-Tyr dihydrouracil 
pacidamycin 6 Gly m-Tyr Ala Trp  
pacidamycin 7 Gly m-Tyr Ala Phe  
mureidomycin E H bicyclic a Met m-Tyr  
napsamycins A,  
mureidomycin  F 
H bicyclic b Met m-Tyr  
napsamycins B H bicyclic c Met m-Tyr  
napsamycins C H bicyclic b Met m-Tyr  
napsamycins D H bicyclic c Met m-Tyr dihydrouracil 
pacidamycin 4N H bicyclic a Ala Trp dihydrouracil 
 
The mureidomycins were discovered in 1989 when mureidomycins A-D were 
isolated from Streptomyces flavidovirens SANK 60486 and showed antimicrobial 
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activity against Pseudomonas species with MIC values ranging between 1.5-
12.5 µg/ml and mureidomycin A had an ED50 value of 69 mg/kg for protecting 
mice against Pseudomonas aeruginosa infections
157-159
. Mureidomycin A was 
shown to selectively inhibit MraY over teichoic acid biosynthesis and mammalian 
N-linked glycoprotein biosynthesis
160, 161
 and was found to be a slow-binding 
inhibitor of E. coli MraY with Ki
*
: 2.2 nM, competitive versus both substrates 
(UDPMurNAc-pentapeptide and polyprenyl phosphate lipid) which was 
determined by a continuous fluorescence enhancement assay
142
. Further analogues 
were discovered in 1993 from the same Streptomyces flavidovirens SANK 60486, 
mureidomycin E and F
162
. 
Pacidamycins 1-7 were isolated from S. coeruleorubidus strain AB 1183-64 in 
1989 as well
163-165
 and pacidamycin D, 4N and 5T were isolated later from strain 
NRRL 18730
166
. They showed antibacterial activity against Pseudomonas species 
with MIC values ranging from 4-125 µg/ml
165, 166
. It was possible to reduce the 4′-
exoenamidofuranosyl moiety of pacidamycin D by hydrogenation and the 
resulting dihydropacidamycin analogues retained activity
167
. The configuration of 
all naturally occurring amino acids in the pacidamycins has been elucidated to be 
(S) configuration, and the DABA residue is of (S,S) configuration
168
. Structure-
activity relationship studies were carried out on the dihydropacidamycins and it 
was shown that the lack of the ribose sugar or uracil base caused complete loss of 
activity while amino acids at position 2, 4 and 5 could be replaced without 
significant loss of antibacterial activity (Figure 1-54)
156, 168
. 
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Figure 1-54: Structure-activity relationship studies on pacidamycins 
The pacidamycin gene cluster was identified which facilitates the identification of 
their biosynthetic pathway
169
. The inhibitory potential of pacidamycin 1,2 and 
pacidamycin D against E. coli and P. aeruginosa MraY was investigated by the 
means of a continuous fluorescence assay and described in Section 5.1.3. 
The napsamycins A-D containing N-terminal bicyclic amino acids were isolated 
from Streptomyces sp. HIL Y-82 in 1994
170
 and the sansanmycins were isolated 
from Streptomyces sp. SS in 2007
171
, both showing similar anti-pseudomonal 
activity as the mureidomycins and the pacidamycins
156
. In addition, sansanmycin 
B was also found to be active against Mycobacterium tuberculosis with MIC 
values of 8-20 µg/ml
172
. 
1.3.1.3 Liposidomycins, caprazamycins 
The liposidomycins and caprazamycins are structurally related liponucleoside 
natural products and their structure is derived from 5'-(β-O-aminoribosyl)-
glycyluridine with a unique N,N'-dimethyldiazepanone ring. The liposidomycins 
contain a sulphate group at the 2’’-position of the aminoribose while the 
caprazamycins possess a permethylated L-rhamnose
173, 174
. The name of the 
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liposidomycin and caprazamycin analogues (A – G) comes from the attached β-
hydroxy-fatty acids of different chain length
173
 (Figure 1-55).  
 
Figure 1-55: Chemical structure of the caprazamycins and the liposidomycins 
The liposidomycins were first isolated from Streptomyces griseosporeus in 1985 
with growth inhibitory activity against Mycobacterium sp.
175
 and were shown to 
inhibit MraY selectively, more precisely only affected glycoprotein and teichoic 
acid biosynthesis at very high concentrations
176
. Liposidomycin B is a slow-
binding inhibitor of solubilised E. coli MraY with Ki
*
: 80 nM, non-competitive 
versus UDPMurNAc-pentapeptide and competitive versus the polyprenyl 
phosphate lipid, which was determined by a continuous fluorescence enhancement 
assay
143
.  
The caprazamycins, potent liponucleoside inhibitors of MraY were isolated from 
Streptomyces sp. MK730-62F2. They have potent antibacterial activity against 
mycobacteria and do not exhibit significant toxicity in mice
177-180
. Hirano et al 
synthesized a palmitoylcaprazol analogue which had antimicrobial activity against 
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MRSA with an MIC value of 6.25 µg/ml and against VRE with an MIC of 
12.5 µg/ml
180
.  
Caprazamycins A-G have some antibacterial activity against a whole range of 
Gram-positive bacteria and they were modified by acid hydrolysis to increase and 
optimise their activity against Mycobacteria and target tuberculosis. CPZEN-45, a 
4-butylanilide derivative of the caprazene core structure (Figure 1-56), was chosen 
as the most promising derivative
181, 182
 possessing a narrower antibacterial 
spectrum towards Mycobacteria with MIC values ranging between 0.2-
1.56 µg/ml. CPZEN-45 inhibited B. subtilis MraY with an IC50 value of 
400 ng/ml and was also found to inhibit the first step of teichoic acid biosynthesis 
in B. subtilis catalysed by TagO (IC50: 50 ng/ml) and its ortholog, WecA in 
M. tuberculosis (4.4 ng/ml)
181
. Today, CPZEN-45 is going through preclinical 
studies in Japan and no mutagenicity or cytotoxicity has been reported so far
181, 
183-185
.  
 
Figure 1-56: Chemical structure of the caprazene core structure (no antibacterial activity) 
and the antibacterial drug candidate CPZEN-45, a 4-butylanilide derivative of caprazene 
A series of new caprazamycin analogues were tested against E. coli MraY by a 
continuous fluorescence enhancement assay and the results are shown in Section 
5.1.2. 
  
 
61 
 
1.3.1.4 Muraymycins 
The core structure of the muraymycin nucleoside antibiotics consists of a peptide-
appended glycosylated uronic acid and different analogues have different fatty 
acid chains (R)
156
 (Figure 1-57).  
 
Figure 1-57: Chemical structure of the muraymycins 
The muraymycins were first isolated from Streptomyces sp. and the analogues 
with a lipophilic side-chain showed antimicrobial activity against Gram-positive 
bacteria such as Staphylococcus aureus with MICs ranging between 2-16 µg/ml 
and Enterococcus strains with the lowest MIC measured as 16 µg/ml which makes 
them attractive candidates for drug development
186
. Structure-activity relationship 
studies showed that the lipophilic side-chain plays a key role in antibacterial 
activity but not essential for MraY activity, simplification of the urea-peptide 
moiety seemed possible and the aminoribosyluridine group was proposed to 
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interact with the active site of MraY
187
. A new synthetic muraymycin analogue 
lacking the 5’O-aminoribose was assayed against MraYs from various organisms 
by a continuous fluorescence enhancement assay and the results are shown in 
Section 5.1.1. 
1.3.1.5 Capuramycins 
Capuramycins are uracil nucleoside antibiotics containing a caprolactam 
substituent (Figure 1-58). 
 
Figure 1-58: Chemical structure of the capuramycins 
A compound named capuramycin was isolated from S. griseus 446-S3 in 1985
188, 
189
 with antibacterial activity against S. pneumoniae with and Mycobacterium 
smegmatis with MIC values of 12.5 µg/ml and 3.13 µg/ml respectively
188, 190
. 
Further analogues were isolated from the same Streptomyces strain, A-500359 A 
and E with MIC values of 6.25 µg/ml and >100 µg/ml respectively against 
Mycobacterium smegmatis
191
. Capuramycin, A-500359 A and E were assayed 
against MraY with IC50 values of 18 nM, 17 nM and 27 ng/ml respectively
192, 193
. 
Therefore, it was obvious that the replacement of the caprolactam moiety to a 
methoxy group reduced activity against MraY and antibacterial activity was not 
even detected
191
. Methylated and acylated derivatives also showed very potent 
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antibacterial activity against Mycobacteria with the most potent MIC value of 
0.06 µg/ml
194
. The inhibitory potential of two known capuramycin analogues was 
investigated against E. coli and B. subtilis MraY by a continuous fluorescence 
enhancement assay and it is described in Section 5.1.5. 
 
1.3.2 Inhibition of MraY by E lysis protein from phage ɸX174 
Double stranded DNA phages cause cell lysis by producing a soluble, muralytic 
enzyme known as endolysin that requires a small membrane protein called holin 
to get access to the cell wall for bacteriolytic action
195
. However, the single-
stranded DNA phage ɸ174 uses a single lysis gene, E, to cause lysis of the host 
cell
195, 196
. E encodes a 91-amino-acid membrane protein that was shown to inhibit 
E. coli MraY
197, 198
. SlyD, an FKBP-type peptidyl-prolyl cis-trans isomerase, was 
reported to play an essential role in stabilizing E protein and allowing it to 
accumulate to the necessary levels for causing host cell lysis but its precise role is 
uncertain
199
.  
Mutation of Phe-288 to lysine in E. coli MraY resulted in resistance to 
E protein
197
. This phenylalanine residue E. coli MraY is located at the periplasmic 
face of the membranes next to a conserved glutamate residue (Glu-287)
129
 while 
the proposed catalytic active site of MraY is at the cytoplasmic face of the 
membranes
130
.  
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Very recently the crystal structure of MraY from Aquifex aeolicus was solved
137
 
and NCBI sequence alignment of E. coli and A. aeolicus MraY revealed that the 
A. aeolicus MraY has a phenylalanine residue (Phe-286 in A. aeolicus sequence) 
at the same position as Phe-288 in E. coli MraY. 
Figure 1-59 shows the position of the Phe-286 residue of the unusually bent helix 
9 of Aquifex aeolicus MraY at the periplasmic face of the membranes in relation 
to the proposed catalytic active site of MraY at the cytoplasmic face of the 
membranes.  
gi|190905134|gb|EDV64779.1|       YLAGKDTPATQLVVPFFKDVMPQLGLFYILLAYFVIVGTGNAVNLTDGLD 198 
gi|15605650|ref|NP_213025.1|      YYWADID--TILYFPFFKELYVDLGVLYLPFAVFVIVGSANAVNLTDGLD 196 
                                  *  ..    * * .****::  :**::*: :* *****:.********** 
 
gi|190905134|gb|EDV64779.1|       GLAIMPTVFVAGGFALVAWATGNMNFASYLHIPYLRHAGELVIVCTAIVG 248 
gi|15605650|ref|NP_213025.1|      GLAIGPAMTTATALGVVAYAVGHSKIAQYLNIPYVPYAGELTVFCFALVG 246 
                                  **** *:: .* .:.:**:*.*: ::*.**:***: :****.:.* *:** 
 
gi|190905134|gb|EDV64779.1|       AGLGFLWFNTYPAQVFMGDVGSLALGGALGIIAVLLRQEFLLVIMGGVFV 298 
gi|15605650|ref|NP_213025.1|      AGLGFLWFNSFPAQMFMGDVGSLSIGASLATVALLTKSEFIFAVAAGVFV 296 
                                  *********::***:********::*.:*. :*:* :.**::.: .**** 
 
gi|190905134|gb|EDV64779.1|       VETLSVILQVGSFKLRG-QRIFRMAPIHHHYELKGWPEPRVIVRFWIISL 347 
gi|15605650|ref|NP_213025.1|      FETISVILQIIYFRWTGGKRLFKRAPFHHHLELNGLPEPKIVVRMWIISI 346 
                                  .**:*****:  *:  * :*:*: **:*** **:* ***:::**:****: 
 
gi|190905134|gb|EDV64779.1|       MLVLIGLATLKVR 360 
gi|15605650|ref|NP_213025.1|      LLAIIAISMLKLR 359 
                                  :*.:*.:: **:* 
E. coli MraY 
A. aeolicus MraY   
Phe-286 
Glu-285 
active site residues  
and Mg
2+
 
 
he-286 
Phe-288 
Periplasm Cytoplasm 
Figure 1-59: Position of the phenylalanine residue of helix 9 of Aquifex aeolicus MraY, 
essential for E protein inhibition of MraY at the periplasmic phase of the membranes, 
proposed catalytic active site with three conserved aspartate residues, Asp-117, Asp-118 
and Asp-265, red sphere Mg
2+
; figure was prepared using PyMOL molecular graphics 
software 
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A 37-amino-acid synthetic peptide containing the N-terminal transmembrane 
domain of E protein was reported to inhibit particulate E. coli MraY but not the 
solubilized enzyme, and it was proposed that it blocks a protein-protein 
interaction involving MraY
200
. This seems quite possible given the location of 
Phe-288 in the MraY structure, on the outside of the protein dimer. 
The inhibitory activity of E peptide was investigated against MraY from various 
organisms in Section 5.3.1.  
1.3.3 Inhibition of MraY by cyclic peptides and small molecules 
Amphomycin (Figure 1-60) and tsushimycin are known inhibitors of MraY where 
20 µg/ml amphomycin caused 45 % inhibition in a radiochemical assay by 
forming a complex with undecaprenyl phosphate
201, 202
. The eukaryotic enzyme 
responsible for mannosylphosphoryldolichol synthesis was also inhibited by 
amphomycin forming a 1:1 complex with dolichylmonophosphate in the presence 
of Ca
2+ 203
. Further amphomycin analogues were identified such as friulimicin and 
glycinocins and their cyclic structure was confirmed by spectroscopic and 
chemical degradation studies
204
. 
 
Figure 1-60: Chemical structure of amphomycin 
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The glycopeptide vancomycin also inhibits MraY by complexing the D-Ala-D-
Ala termini of UDPMurNAc-pentapeptide, however its inhibitory potency 
strongly depends on the quantity of the substrates and the enzyme used for the 
assay
147
. Vancomycin was tested against MraY in Section 5.2 using a 
radiochemical assay. 
Heydanek et al observed in the course of testing various surfactants to be used for 
biochemical studies on MraY that dodecylamine was an effective inhibitor of 
S. aureus MraY with Ki value of 0.65 mM
131
. In addition, Porcion Yellow HE-3G 
dye was reported to bind to solubilised E. coli MraY and inhibit the enzyme with 
an IC50 value of 1 mg/ml
130
. 
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1.4 Aims and objectives of the project 
This research project focuses on the first lipid-linked step of peptidoglycan 
biosynthesis catalysed by phospho-MurNAc-pentapeptide translocase MraY. To 
date, there is no drug in clinical use that would target this enzyme and previous 
screening efforts concentrated mainly on the cytoplasmic steps of the pathway. 
The aim of the project was to screen for structurally new inhibitors of MraY.  
The U.S. National Cancer Institute’s (NCI) Development Therapeutics Program 
maintains a large screening collection of over 140,000 compounds. These have 
been evaluated as potential anticancer and anti-HIV agents and among them are 
synthetic compounds and natural products representing unique structural 
diversity. The NCI also has a small library of around 2,000 compounds ideal for 
beginning a screening process. Many hospitalised cancer patients treated with 
anticancer agents develop life-threatening bacterial infections so the National 
Cancer Institute will send their diversity set to academic groups able to 
demonstrate a microtitre-based assay for an antibacterial target enzyme. 
Following a request from Professor T. D. H. Bugg, the NCI generously provided 
the diversity set of 1,717 compounds in 2012. 
First of all, assay methods needed to be optimised for MraY screening since the 
fluorescence and radiochemical assays for MraY had not been used in our 
laboratory for several years. A continuous fluorescence MraY assay was to be 
developed and optimised and then to be adapted to a high-throughput assay in 96-
well microtitre plate format to screen the NCI diversity set against E. coli MraY. 
During the project it became apparent that we also needed a second independent 
assay method (many compounds interfered with fluorescence) to test possible hits, 
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so radiochemical and HPLC MraY assays were also investigated, even though 
these methods are not suitable for high-throughput screening. 
In addition, we aimed to assay new natural or synthetic analogues of the known 
MraY inhibitor families of nucleoside antibiotics such as the pacidamycins, 
muraymycins and the caprazamycins against E. coli MraY and against MraY from 
their antibacterial target organisms whenever it was possible, supplied by research 
groups working on uridyl-peptide analogue natural product biosynthesis and total 
synthesis.  
We also planned to investigate the inhibitory activity of the known E. coli MraY 
inhibitor, the bacteriolytic E peptide against S. aureus, B. subtilis, P. aeruginosa 
and M. flavus MraYs. Furthermore, we wished to assay more antibacterial 
peptides against MraY that were available to us, amongst them another lytic 
peptide, P1. 
Finally, we aimed to test halogenated fluorescein analogues against MraY and 
MurG since similar structures were published by Zawadzke et al. as potential 
MraY or MurG inhibitors (Figure 1-61) based on a combined MraY-MurG 
microtitre plate scintillation proximity-based assay
69
. 
 
Figure 1-61: Halogenated fluorescein analogues from the combined MraY-MurG screen of 
Zawadzke et al. (2003) 
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2 Development of assay methods for screening 
MraY 
The major goal of the project is to screen for structurally novel inhibitors against 
the bacterial peptidoglycan enzyme MraY. One of the options is to use a 
radiochemical MraY assay that was used by P. Brandish
13
. This assay can give 
accurate measurements of the lipid I product over a time-course assay (20-
30 minutes) by measuring the incorporation of a 
14
C label from UDPMurNAc-
pentapeptide into the butanol extractable product lipid I (Figure 2-1). 
 
 
Figure 2-1: Schematic representation of the radiochemical MraY assay 
However, this stopped assay is very difficult to use for enzyme kinetics, especially 
when the time-course of the reaction is non-linear or the inhibition is time-
dependent
13
. Moreover, this assay is not suitable to screen a large number of 
compounds for potential inhibition. P. Brandish developed a continuous 
fluorescence assay
9
 as well (Figure 2-2), using a dansyl fluorophore on 
UDPMurNAc-pentapeptide, which was further developed by S. Bagga into a 
high-throughput assay in micro-titre plate format
145
.  
 undecaprenyl phosphate 
extraction into 1-butanol 
[
14
C]-UDPMurNAc- 
pentapeptide  
                       
[
14
C]-lipid I  
6 M pyridinium acetate pH 4.2 
 liquid scintillation counting 
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Figure 2-2: Schematic representation of the fluorescence MraY assay 
The basis of the fluorescence assay relies on the fact that the dansyl fluorophore 
experiences a change in environment upon incorporation into the hydrophobic 
environment of the membranes and/or detergent micelles from an aqueous 
environment of the cytoplasm, and this phenomenon results in a 50 % 
enhancement in fluorescence
141
. 
The first step of the project was to optimise the fluorescence MraY assay so that it 
could be used for screening 2,000 compounds from the diversity set of the 
National Cancer Institute under the present conditions at the Chemical Biology 
Laboratory at the University of Warwick. 
2.1 MraY enzymes from various organisms 
Membrane proteins are low abundance proteins and generally extremely difficult 
to over-express, due to their toxic nature resulting from their disturbing the 
integrity and the content of the membrane. MraY has both the N and the C termini 
located in the periplasmic space
129
, therefore a high level overexpression of the 
protein is even more challenging, since N- or C-terminal fusion tags would need 
to be translocated across the cytoplasmic membrane
10, 205
. Previous efforts in our 
group for overexpressing MraY resulted in modest (28-fold) overproduction of 
 hydrophobic environment 
dansyl-labelled  
UDPMurNAc-pentapeptide  
  
 aqueous environment 
dansyl-labelled lipid I  
fluorescence monitoring 
 
undecaprenyl phosphate 
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enzyme activity with specific activities varying between 1-2 nmol min
-1
 mg
-1
 
protein by a radiochemical assay and 2-3 FAU min
-1
 mg
-1
 by a fluorescence assay 
with the E. coli MraY solubilised in 1 % Triton X-100, however SDS-PAGE 
showed many protein bands
13
.  
Several attempts have been made to express E. coli MraY as a fusion protein. No 
active enzyme was obtained using N-terminal (His)6-MraY, or C-terminally 
labelled MBP-MraY or GFP-MraY. C-terminal (His)6-MraY could be 
overexpressed and visualised by Western blotting
130
, but attempts to purify this 
protein to homogeneity were unsuccessful, and the activity of the (C-His)6-MraY 
was significantly lower than that of the wild type MraY
13, 130
.  
Due to the above mentioned problems related to the purification of the enzyme, P. 
Brandish and S. Bagga used E. coli MraY for their experiments by overexpressing 
the enzyme in E. coli membranes. While P. Brandish used detergent (Triton X-
100) solubilised enzyme
13, 142, 143
, S. Bagga used the overexpressed MraY 
membranes directly in the assays, avoiding having to prepare the solubilised 
enzyme every day because of its time-dependent loss of activity
139, 145
.  
As a general procedure, the overexpressed E. coli strain is grown in LB media 
containing the resistance marker antibiotic (ampicillin or kanamycin) up to 
OD600 0.4-1.3 and induced by the addition of 1 mM IPTG. Membranes are 
isolated by ultracentrifugation (> 100,000 x g), re-suspended and diluted in 
membrane buffer (50 mM Tris pH 7.5, 1 mM MgCl2, 2 mM β-mercaptoethanol) 
to achieve an optimal protein concentration for the assays. The total protein 
concentration of the membranes is estimated by a Bradford assay using albumin 
standards. In order to prepare the solubilised enzyme, the membranes are treated 
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with a detergent containing buffer (1 % Triton X-100 or 0.1 % CHAPS) and an 
extra ultracentrifugation step is introduced to eliminate the insolubilized material. 
These enzyme preparations are not as stable as the membranes which can be kept 
at -80 ºC for several months without manifesting significant loss of activity
13
.  
For this work, MraY membranes were used for the assays. At present, we are able 
to study the inhibition against Escherichia coli (360 amino acids), 
Pseudomonas aeruginosa (360 amino acids), Staphylococcus aureus (321 amino 
acids), Bacillus subtilis (324 amino acids) and Micrococcus flavus MraYs (375 
amino acids). The variety of enzymes enables us to test specificity of inhibition. 
The overexpression of the membranes with MraY leads to 6-10 and 6-13 fold 
increase in specific activity for the radiochemical and the fluorescence MraY 
assays respectively (see Sections 2.2.4 and 2.4.2.6). The MraY enzymes used for 
this project: 
 The E. coli mraY construct (pJFY3c) was provided by D. Boyle (Edinburgh 
University). The pJFY3c plasmid is under the control of a tac promoter 
regulated by the lacI^q repressor
130
. The MraY enzyme was expressed in C43 
(DE3) with ampicillin as described in Section 7.1. 
 The P. aeruginosa mraY construct was a gift from R. C. Lévesque (Laval 
University). This mraY gene was cloned into pET30c vector and it was called 
pMON2320. The production of MraY protein is possible from HMS174 
(λDE3) strain with a V-D-K-L-A-A-A-L-E-(His)6 tag at C-terminus end using 
kanamycin as an antibiotic resistance marker, see Section 7.3. 
 The S. aureus and B. subtilis MraYs were overexpressed as an N-terminal 
Strep-tag fusion protein in vector pET52b. They were cloned by A. O’Reilly 
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during her MOAC mini-project in 2012 at the Chemistry and the Life Sciences 
Departments of the University of Warwick. The constructs were transformed 
into C43 (DE3). The resistant antibiotic marker is ampicillin. 
 Moreover, it is possible to use M. flavus (formerly known as M. luteus) 
membranes for the MraY assays as these membranes naturally contain a high 
level of expression of MraY and MurG
59, 89
. For the preparation of M. flavus 
membranes, see Section 7.4. 
The five MraY protein sequences were aligned by the ClustalW2 multiple 
sequence alignment program (Figure 2-3).The identity and similarity of their 
sequences in pairs were determined by the NCBI’s sequence alignment program 
with identities ranging from 37-66 % and similarities from 54-80 %. The E. coli 
and P. aeruginosa MraYs are the two most closely related enzymes with 66 % 
sequence identity and 80 % similarity. It is also notable that the S. aureus and 
B. subtilis MraYs have 57 % identity and 76 % similarity in their sequences 
(Table 2-1). 
Table 2-1: MraY enzymes aligned in pairs, sequence identity and similarity (%) 
 E. coli P. aeruginosa S. aureus B. subtilis M. flavus 
E. coli x 80 61 64 59 
P. aeruginosa 66 x 63 63 56 
S. aureus 42 43 x 76 54 
B. subtilis 47 41 57 x 58 
M. flavus 40 39 37 38 x 
 
 
%
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Figure 2-3: From top to bottom: E. coli, P. aeruginosa, S. aureus, B. subtilis and M. flavus 
MraY sequence alignment, colour of the amino acids: small and hydrophobic: AVFPMILW, 
acidic: DE, basic: RK, hydroxyl + sulfhydryl + amine + G: STYHCNGQ 
 
gi|388476208|ref|YP_488392.1|       MLVWLAEHLVKYYSGFNVFSYLTFRAIVSLLTALFISLWMGPRMIAHLQK 50 E.coli 
gi|386064140|ref|YP_005979444.      MLLLLAEYLQQFYKGFGVFQYLTLRGILSVLTALSLSLWLGPWMIRTLQI 50 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        ------------------------MIFVYALLALVITFVLVPVLIPTLKR 26 S.aureus 
gi|305674250|ref|YP_003865922.      --------------------MLEQVILFTILMGFLISVLLSPILIPFLRR 30 B.subtilis 
gi|239917864|ref|YP_002957422.      ----------------------MIGLLIGGVLGLVLSAAGTPLFIRFLVK 28 M.luteus 
                                                              :.  : .: ::    * :*  *   
 
gi|388476208|ref|YP_488392.1|       LSFGQVVRNDGPESHFSKRGTPTMGGIMILTAIVIS--------VLLWAY 92 E.coli 
gi|386064140|ref|YP_005979444.      RQIGQAVRNDGPQSHLSKKGTPTMGGALILTAIAIS--------TLLWAD 92 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        MKFGQSIREEGPQSHMKKTGTPTMGGLTFLLSIVITSLV-----AIIFVD 71 S.aureus 
gi|305674250|ref|YP_003865922.      LKFGQSIREEGPKSHQKKSGTPTMGGVMIILSIIVTTIV-----MTQKFS 75 B.subtilis 
gi|239917864|ref|YP_002957422.      RGYGQFVRDDGPTTHKTKRGTPTMGGAVIIGSLVLAYLITHGLLAVLGVD 78 M.luteus 
                                       ** :*::** :* .* *******  :: :: ::               
 
gi|388476208|ref|YP_488392.1|       PSNPY--VWCVLVVLVGYGVIGFVDDYRKVVRKDTKGLIARWKYFWMSVI 140 E.coli 
gi|386064140|ref|YP_005979444.      LSNRY--VWVVLVVTLLFGAIGWVDDYRKVIEKNSRGLPSRWKYFWQSVF 140 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        QANP---IILLLFVTIGFGLIGFIDDYIIVVKKNNQGLTSKQKFLAQIGI 118 S.aureus 
gi|305674250|ref|YP_003865922.      EISPE--MVLLLFVTLGYGLLGFLDDYIKVVMKRNLGLTSKQKLIGQIII 123 B.subtilis 
gi|239917864|ref|YP_002957422.      FGGPTASGLILLLLTVGMAFVGFVDDFTKITKQRSLGLTPRGKIILQALI 128 M.luteus 
                                      .       :*.: :  . :*::**:  :  : . ** .: * :    : 
 
gi|388476208|ref|YP_488392.1|       ALGVAFALY----------LAGKDTPATQLVVPFFKDVMPQLG-LFYILL 179 E.coli 
gi|386064140|ref|YP_005979444.      GIGAAVFLY----------MTAETPIETTLIVPMLKSVEIQLG-IFFVVL 179 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        AIIFFVLSN----------VFHLVNFSTSIHIP-FTNVAIPLS-FAYVIF 156 S.aureus 
gi|305674250|ref|YP_003865922.      AIVFYA-------------VYHYYNFATDIRVP-GTDLSFDLG-WAYFIL 158 B.subtilis 
gi|239917864|ref|YP_002957422.      GTAFAVLALNFPDERGLTPASTAISFARDIPWLDLAFAGPAIGVILFVIW 178 M.luteus 
                                    .                            :           :.   :.:  
 
gi|388476208|ref|YP_488392.1|       AYFVIVGTGNAVNLTDGLDGLAIMPTVFVAGGFALVAWATGNMNFASY-- 227 E.coli 
gi|386064140|ref|YP_005979444.      TYFVIVGSSNAVNLTDGLDGLAIMPTVMVAGALGIFCYLSGNVKFAEY-- 227 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        IVFWQVGFSNAVNLTDGLDGLATGLSIIGFTMYAIMSFVLG--------- 197 S.aureus 
gi|305674250|ref|YP_003865922.      VLFMLVGGSNAVNLTDGLDGLLSGTAAIAFGAFAILAWNQS--------- 199 B.subtilis  
gi|239917864|ref|YP_002957422.      SNLITTATTNAVNLTDGLDGLATGATAMITGAYVLISLFQSSQSCALEGT 228 M.luteus 
                                      :  ..  ************    : :      :..   .          
 
gi|388476208|ref|YP_488392.1|       LHIPYLRHAGELVIVCTAIVGAGLGFLWFNTYPAQVFMGDVGSLALGGAL 277 E.coli 
gi|386064140|ref|YP_005979444.      LLIPNVPGAGELIVFCAALVGAGLGFLWFNTYPAQVFMGDVGALALGAAL 277 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        --------ETAIGIFCIIMLFALLGFLPYNINPAKVFMGDTGSLALGGIF 239 S.aureus 
gi|305674250|ref|YP_003865922.      --------QYDVAIFSVAVVGAVLGFLVFNAHPAKVFMGDTGSLALGGAI 241 B.subtilis 
gi|239917864|ref|YP_002957422.      RGCYEVRDPMDLALLAAILTGSLLGFLWWNTSPAKIFMGDTGSLGLGGAL 278 M.luteus 
                                               : :..  :  : **** :*  **::****.*:*.**. : 
 
gi|388476208|ref|YP_488392.1|       GIIAVLLRQEFLLVIMGGVFVVETLSVILQVGSFKLRG-QRIFRMAPIHH 326 E.coli 
gi|386064140|ref|YP_005979444.      GTIAVIVRQEIVLFIMGGVFVMETLSVMIQVASFKLTG-RRVFRMAPIHH 326 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        ATISIMLNQELSLIFIGLVFVIETLSVMLQVASFKLTG-KRIFKMSPIHH 288 S.aureus 
gi|305674250|ref|YP_003865922.      VTIAILTKLEILLVIIGGVFVIETLSVILQVISFKTTG-KRIFKMSPLHH 290 B.subtilis 
gi|239917864|ref|YP_002957422.      AGFAIFTRTEILVAVLAGLMVAITLSVIIQVGWFKVSGGKRVFLMAPLQH 328 M.luteus 
                                      :::: . *: : .:. ::*  ****::**  **  * :*:* *:*::* 
 
gi|388476208|ref|YP_488392.1|       HYELKGWPEPRVIVRFWIISLMLVLIGLATLKVR------------- 360 E.coli 
gi|386064140|ref|YP_005979444.      HFELKGWPEPRVIVRFWIITVILVLIGLATLKLR------------- 360 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        HFELIGWSEWKVVTVFWAVGLISGLIGLWIGVH-------------- 321 S.aureus 
gi|305674250|ref|YP_003865922.      HYELVGWSEWRVVVTFWTAGLLLAVLGIYIEVWL------------- 324 B.subtilis 
gi|239917864|ref|YP_002957422.      HFELKGWAEVTVVVRFWLLSLMCVTVGLAIFYGDWLIRQGGLAGVTP 375 M.luteus 
E. coli MraY 
P. aeruginosa MraY 
S. aureus MraY 
B. subtilis MraY 
M. flavus MraY 
E. coli MraY 
P. aeruginosa MraY 
S. aureus MraY 
B. subtilis MraY 
M. flavus MraY 
E. coli MraY 
P. aeruginosa MraY 
S. aureus MraY 
B. subtilis MraY 
M. flavus MraY 
E. coli MraY 
P. aeruginosa MraY 
S. aureus MraY 
B. subtilis MraY 
M. flavus MraY 
E. coli MraY 
P. aeruginosa MraY 
S. aureus MraY 
B. subtilis MraY 
M. flavus MraY 
E. coli MraY 
P. aeruginosa MraY 
S. aureus MraY 
B. subtilis MraY 
M. flavus MraY 
E. coli MraY 
P. aeruginosa MraY 
S. aureus MraY 
B. subtilis MraY 
M. flavus MraY 
E. coli MraY 
P. aeruginosa MraY 
S. aureus MraY 
B. subtilis MraY 
M. flavus MraY 
  
 
75 
 
2.2 Development of the fluorescence assay for MraY 
2.2.1 Preparation of UDP-N-acetylmuramyl-L-Ala-γ-D-Glu-m-
Dap -D-Ala-D-Ala (UDPMurNAc-pentapeptide)  
The UDPMurNAc-pentapeptide was purchased on a number of occasions from 
the BaCWAN facility of the University of Warwick where it was made 
enzymatically using enzymes MurA-F. On one occasion, it was isolated from 
antibiotic-treated cells of B. subtilis in mg quantities based on procedures used by 
P. Brandish and S. Bagga
13, 145
. Based on its cell wall structure, B. subtilis belongs 
to the family of Gram-positive bacteria, however it unusually uses diaminopimelic 
acid and not lysine at the third amino acid position of the UDPMurNAc-
pentapeptide as a peptidoglycan precursor
12
. 
B. subtilis was provided by Dr. Christophe Corre and cells were grown at 37 ºC 
into mid-logarithmic phase in a rich medium. Pellets were collected by 
centrifugation and kept cool on ice bath. Then the cells were re-suspended in a 
warm CWSM medium (cell wall synthesis medium) which contained 12.5 mg/ml 
vancomycin, 50 mg/ml chloramphenicol, and 50 mg/ml ampicillin. Vancomycin 
inhibits the formation of glycosidic bonds between the sugars by the 
transglycosidase enzymes and the formation of the peptide cross-links by the 
transpeptidase enzymes by complexing D-Ala-D-Ala of the pentapeptide unit of 
lipid II
107
, therefore helps accumulating UDPMurNAc-pentapeptide. 
Chloramphenicol has a detrimental effect on bacterial protein synthesis
206
 while 
ampicillin seemed to have improved the yield for P. Brandish
13
. The addition of 
uracil and amino acids, Ala, Glu and diaminopimelic acid helps to increase the 
yield of the product. Cells were grown for 45 minutes in Cell Wall Synthesis 
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Medium (CWSM). The cultures were chilled on ice again and cells collected by 
centrifugation, re-susupended in ice-cold 5 % (w/v) trichloroacetic acid (TCA) at 
5 ml/g cells. The pellet was extracted two more times with half volumes of ice-
cold TCA. The supernatants (60 ml) were pooled and extracted three times with 
an equal volume of ice-cold ether (3 x 60 ml) in order to remove the TCA. The 
aqueous phase was neutralised with 3 M NaOH. The traces of ether were 
evaporated by rotary evaporation and the sample was lyophilised overnight. The 
sample was clarified by microcentrifugation and subjected to gel filtration 
(Sephadex G25 3 x 80 cm) eluting with water. The highest molecular weight 
fractions with absorbance at 260 nm were pooled and lyophilised. UDPMurNAc-
pentapeptide was identified by a run on Agilent 1200 HPLC with a Bruker HCT 
Ultra Mass Spectrometer, m/z [M-H]
-
: 1192.3359 calculated for C41H65N9O28P2 
1192.3341.  The correct isotopic pattern was confirmed by high resolution LC-MS 
(HR LC-MS) by a run on a Dionex Ultramate3000 uHPLC with the Bruker 
MaXis (Figure 2-4). The yield was 15 mg from a 2 l culture. All the LC-MS from 
this project was run on the above mentioned two instruments; the high resolution 
analysis was performed by Philip Aston and Lijiang Song from the Mass 
Spectrometry Facility of the Chemistry Department of the University of Warwick. 
The procedure and the LC-MS conditions are detailed in Sections 7.5, 7.6 and 7.7. 
Figure 2-4 shows the isotopic pattern of the doubly and negatively charged ion for 
the UDPMurNAc-pentapeptide. 
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2.2.2 Preparation of UDP-N-acetylmuramyl-L-Ala-γ-D-Glu-(Nε-
dansyl)-m-Dap-D-Ala-D-Ala (dansyl-labelled UDPMurNAc-
pentapeptide) 
One of the substrates of the fluorescence MraY assay is the dansylated 
UDPMurNAc-pentapeptide. The procedure for the preparation of this derivative is 
based on the procedures of Weppner and Neuhaus
141
 and P. Brandish
13
.  
The procedure starts with the reaction between 1 equivalent UDPMurNAc-
pentapeptide and 96 equivalent dansyl chloride in a 50 % acetone NaHCO3 buffer 
at pH 9 (see 1. in Figure 2-5)  
 
 
 
Observed 
Predicted 
595.6628
596.1646
596.6659
597.1663
-MS, 1.1-1.2min #(66-71)
595.6634
596.1651
596.6667
597.1672
C 41 H 63 N 9 O 28 P 2  ,1191.33
0
1
2
3
4x10
Intens.
0
1
2
3
4x10
595.5 596.0 596.5 597.0 597.5 m/z
Figure 2-4: Isotopic pattern for the doubly and negatively charged ion 
of the UDPMurNAc-pentapeptide 
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Even though it is a relatively simple procedure, it proved to be very challenging. 
After a number of failed reactions, we identified that the UDPMurNAc-
pentapeptide that we purchased from the BaCWAN facility of the University of 
Warwick contained unexpected amounts of ammonium acetate (coming from the 
buffer used for purification by anion exchange) which led to the formation of 
dansyl amide with the dansyl chloride, instead of the desired dansyl 
UDPMurNAc-pentapeptide (see 2. in Figure 2-5). This mystery, together with 
problems in overexpression of MraY, delayed progress 12-18 months. Hence the 
UDPMurNAc-pentapeptide was purified from ammonium acetate by gel filtration 
(Sephadex G25 80 x 3 cm), after which the dansylation method worked well. 
dansyl chloride 
dansic acid  
Mw: 251.30 
  
dansyl-labelled UDPMurNAc-
pentapeptide 
+ 
+ H
2
O 
50 % acetone NaHCO
3
 buffer  
at pH 9 
UDPMurNAc-pentapeptide 
ammonium acetate 
dansyl amide 
Mw: 250.32 
3. 
1. 
2. + [NH
4
]
+ 
[
 
OAc]
-
 
Figure 2-5: Dansylation of the UDPMUrNAc pentapeptide, 1.: formation of the dansyl-
labelled UDPMurNAc-pentapeptide, 2.: formation of dansyl amide with ammonium acetate, 
3.: formation of the by-product, dansic acid with water  
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The procedure that we followed is described in Section 7.8. The most challenging 
part of the procedure is the separation of the labelled UDPMurNAc-pentapeptide 
from the by-product dansic acid (see 3. in Figure 2-5). The separation was carried 
out by using gel filtration (Sephadex G25 80 x 3 cm). The column was washed 
with water, and 5 ml fractions were collected. All fractions were monitored on a 
PerkinElmer UV/Vis spectrophotometer and a PerkinElmer fluorimeter. The 
absorbance spectrum of the dansyl-labelled UDPMurNAc-pentapeptide has two 
characteristic peaks, at 250 nm and 330 nm (Figure 2-6), while the fluorescence 
emission spectrum has a maximum at 530 nm with excitation at 340 nm (Figure 
2-7). These properties enabled the isolation of the fractions of interest. The 
fractions of interest were pooled and lyophilised overnight.  
 
 
Figure 2-6: UV-Vis absorbance spectrum of the dansyl-labelled UDPMurNAc-pentapeptide 
(in blue) and dansic acid (in red) 
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Figure 2-7: Fluorescence emission spectrum of the dansyl-labelled UDPMurNAc-
pentapeptide (in blue) and dansic acid (in red), excitation: 340 nm 
A sample of the material was analysed by HR LC-MS (Figure 2-8). For LC a 
linear gradient of methanol/water was used, with the percentage of methanol 
running up from 1 to 100 % starting at 5 minutes to 25 minutes at a flow rate of 
0.2 ml/min. The largest peak, the main compound of the spectrum is the dansyl-
labelled UDPMurNAc-pentapeptide (m/z [M-2H]
2-
: 712.1884) at 1.1-1.2 min 
retention time. There is evidence for the presence of an insignificant amount of 
dansic acid (m/z [M-H]
-
: 250.0530 see in Figure A 1 in Appendix 1) at ~10.8-
10.9 min (possibly formed during the MS analysis) and also for the formation of a 
small amount of a didansyl-labelled UDPMurNAc-pentapeptide (m/z [M-2H]
2-
: 
828.7073) at 12.5-12.7 minutes. The presence of the starting material, the 
UDPMurNAc-pentapeptide, was not detected in the sample. 
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Figure 2-8: HR LC-MS results, 1: Base Peak Chromatogram 2: Extracted Ion 
Chromatogram for the negatively and doubly charged dansyl-labelled UDPMurNAc-
pentapeptide (m/z: 712.19), 2: Extracted Ion Chromatogram for dansic acid (m/z: 250.06) 
and 3: Extracted Ion Chromatogram for the negatively and doubly charged didansyl-
labelled UDPMurNAc-pentapeptide (m/z: 828.71) 
Negative MS showed the correct isotopic patter for the doubly charged ion of the 
dansyl-labelled UDPMurNAc-pentapeptide (Figure 2-9). 
4. didansyl-labelled UDPMurNAc-pentapeptide 
3. dansic acid 
2. dansyl-labelled UDPMurNAc-pentapeptide 
1. Base Peak Chromatogram 
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Figure 2-9: The extracted ion chromatogram and the doubly and negatively charged ion for 
the dansyl-labelled UDPMurNAc-pentapeptide 
The chemical composition of the didansyl-labelled UDPMurNAc-pentapeptide 
was confirmed by HR LC-MS (Figure 2-10). However, the exact position of the 
second label would need to be confirmed by further tests.  
 
 
Observed 
Predicted 
Extracted ion chromatogram 
Figure 2-10: Suggested chemical structure (second label in red), the isotopic pattern for the 
negatively and doubly charged ion of the didansyl-labelled UDPMurNAc pentapeptide 
Predicted 
Observed 
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The pale yellow powder of the identified dansyl pentapeptide, the fluorescence 
substrate for the assays, was then dissolved in water and stored as a stock solution 
(3.75 mg/ml) at -20 ºC. Every preparation of the dansyl-labelled UDPMurNAc-
pentapeptide was routinely identified by a run on an Agilent 1200 HPLC coupled 
with the Bruker HCT-Ultra (LC-MS), see Figures in Appendix 1: Figures A 2 and 
A 3.   
2.2.3 Optimisation of the continuous fluorescence assay 
2.2.3.1 Changes in the fluorescence emission spectrum during the 
MraY reaction  
Weppner and Neuhaus experienced a 30 nm blue shift in the fluorescence 
emission spectrum and a 6-fold increase in the quantum yield during the MraY 
reaction, and they associated the changes with the formation of the dansyl 
derivative of lipid I
141
. However, P. Brandish only saw an 11 nm shift upon 
formation of the dansyl-labelled lipid I
13
. 
The first experiment we did in order to investigate the reliability of the assay was 
to incubate in a total volume of 400 µl 100 µM dansyl-labelled UDPMurNAc-
pentapeptide with 80 µg/ml undecaprenyl phosphate in 100 mM Tris pH 7.5, 
25 mM MgCl2 6 % glycerol, 0.15 % Triton X-100 and 240 µg E. coli MraY 
membranes as described in Section 7.9. We prepared two samples; one of them 
for the MraY reaction (Figure 2-11A) and the other one also contained 83 µg/ml 
tunicamycin (Figure 2-11B), a known inhibitor of MraY. The fluorescence 
emission spectrum was recorded a few minutes after sample preparation 
(excitation at 340 nm). The measurement was repeated after 30 minutes, then 
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0.1 mM UMP was added to both samples. UMP is one of the products of the 
MraY reaction, and addition of this was expected to favour the reverse 
reaction
10
.The spectrum of the sample with tunicamycin had a lower maximum in 
fluorescence intensity (FAU: Fluorescence Arbitrary Units) right from the start 
(FAU: 425). In Figure 2-11A the fluorescence maximum increased from 610 to 
660 FAU in 30 minutes; however, there was no change in fluorescence intensity 
after 30 minutes (FAU: 425) in the sample with inhibition (Figure 2-11B). When 
0.1 mM UMP was added to the samples, a significant decrease in fluorescence 
was observed for both samples. The fluorescence maximum decreased from 660 
to 375 FAU (Figure 2-11) and from 425 to 315 FAU for the tunicamycin-inhibited 
sample (Figure 2-11B).  
 
 
 
 
 
 
 
 
 
 
Figure 2-11: Emission spectrum of the dansyl-labelled UDPMurNAc pentapeptide 
incubated with E. coli MraY membranes recorded twice over 30 minutes and the effect of 
UMP addition, A: sample without inhibitor, B: sample with 83 µg/ml tunicamycin, λex: 
340 nm 
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A small blue shift in the fluorescence emission spectrum could be observed during 
the MraY reaction leading to the formation of lipid I. However, this shift is very 
small between the lowest maximum (UMP treated sample) and the highest 
maximum (lipid I formation) in the fluorescence emission spectrum, around 5 nm 
(the difference between 522 nm and 527 nm) which is even smaller than the 
11 nm observed by Brandish (Figure 2-12). However, this experiment did not 
determine the exact location of the maximum of the fluorescence emission 
spectrum of the MraY reaction at 0 minutes accurately.  
 
Figure 2-12: Observed small blue shift in the fluorescence emission spectrum associated with 
dansyl-labelled lipid I formation, same experiment as in Figure 2-11, (the two graphs are 
combined in one graph), λex: 340 nm 
2.2.3.2 Time-course of the E. coli MraY reaction  
The time-course behaviour of the reaction was investigated by the following 
experiment (Section 7.10.1). A master mix containing 26 µM dansyl-labelled 
UDPMurNAc-pentapeptide, 30 µg/ml undecaprenyl phosphate at final 
concentrations was prepared in the assay buffer (83 mM Tris pH 7.5, 21 mM 
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MgCl2) as described in Section 7.10. Note that the continuous fluorescence MraY 
assays always contains 6 % glycerol and 0.15 % Triton X-100 from the buffer that 
the undecaprenyl or heptaprenyl phosphate solution was made. The presence of 
detergent is essential for the MraY assay. The reaction was started with the 
addition of 90 µg protein containing overexpressed E. coli MraY membranes in a 
total volume of 180 µl. The reaction was monitored by a PerkinElmer fluorimeter 
over 15 minutes. A gradual increase was observed in fluorescence intensity, 
indicating the formation of dansyl-labelled lipid I. As each membrane preparation 
can contain a different level of MraY expression, it is important to find the 
optimal dilution for the membranes in order to see a gradual increase in 
fluorescence over 5-15 minutes so that the reaction kinetics can be studied, which 
meant ~6 mg total protein/ml stock solution for ~90 µg protein containing 
membranes for an assay of 180 µl total volume for this experiment. The repeated 
reaction containing 83 µg/ml tunicamycin did not result in a significant increase in 
fluorescence, showing that the reaction was inhibited (Figure 2-13).  
 
Figure 2-13: Gradual increase in fluorescence associated with the formation of dansyl-
labelled lipid I following addition of 90 µg E. coli MraY membranes and 83 µg/ml 
tunicamycin inhibition, λex: 340nm, λem: 530 nm 
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2.2.3.3 Experiment with inactivated MraY membranes 
Another experiment was carried out in a 180 µl total volume containing 20 µM 
dansyl-labelled UDPMurNAc-pentapeptide, 30 µg/ml undecaprenyl phosphate in 
the assay buffer (83 mM Tris pH 7.5, 21 mM MgCl2) and started with the addition 
of 90 µg protein (membranes) as described in Section 7.10.2. Under the same 
conditions previously boiled E. coli MraY membranes (C43) were added (90 µg), 
and no increase in fluorescence intensity was observed over time (Figure 2-14), 
indicating the lack of MraY activity and dansyl-labelled lipid I product formation.  
.  
Figure 2-14: No fluorescence changes were observed with 90 µg inactivated MraY enzyme, 
λex: 340nm, λem: 530 nm 
2.2.3.4 Reverse MraY reaction with UMP addition  
The MraY reaction is reversible (Figure 2-15), thus the addition of 0.1 mM UMP, 
one of the products, to a solution of dansyl labelled lipid I should result in a 
decrease in fluorescence intensity (Figure 2-16)
10
.  
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180 µl total volume containing 20 µM dansyl-labelled UDPMurNAc-
pentapeptide, 30 µg/ml undecaprenyl phosphate in the assay buffer (83 mM Tris 
pH 7.5, 21 mM MgCl2) was started with the addition of 90 µg protein containing 
membranes. After 13 minutes reaction time, 0.1 mM UMP was added, which 
induced a decrease in fluorescence intensity (Figure 2-16) indicating the 
formation of the dansyl-labelled UDPMurNAc-pentapeptide from dansyl-labelled 
lipid I (Section 7.10.3). 
 
Figure 2-16: Decrease in fluorescence following 0.1 mM UMP addition to the E. coli MraY 
reaction, λex: 340nm, λem: 530 nm 
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Figure 2-15: Schematic representation of the reversible fluorescence MraY assay 
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2.2.3.5 Effect of added heptaprenyl phosphate to the fluorescence 
substrate incubated with MraY membranes 
The MraY enzyme has two substrates, UDPMurNAc-pentapeptide and 
undecaprenyl phosphate (C55-P). Brandish showed that heptaprenyl phosphate 
(C35-P) is a good substrate for the E. coli MraY enzyme, and he successfully used 
it for his fluorescence and radiochemical assays, with similar kinetic properties to 
those of undecaprenyl phosphate
13
. The following experiments show that the lack 
of heptaprenyl phosphate does not result in significant increase in fluorescence 
intensity upon the reaction of the dansyl-labelled UDPMurNAc-pentapeptide with 
the MraY membranes. (The presence of some endogenous undecaprenyl 
phosphate in the membranes could lead to the formation of lipid I and some 
increase in the fluorescence intensity.) The master mix for the following 
experiment contained 20 µM dansyl-labelled UDPMurNAc-pentapeptide but no 
heptaprenyl phosphate, 83 mM Tris pH 7.5, 21 mM MgCl2, 6 % glycerol and 
0.15 % Triton X-100. 90 µg E. coli MraY membranes (C43) were added and no 
increase in fluorescence was observed over 10-minute reaction time. 8 µg/ml 
(final concentration) heptaprenyl phosphate induced the fluorescence changes, 
indicating the formation of the dansyl-labelled lipid I product (Figure 2-17 and 
Section 7.10.4). 
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Figure 2-17: Effect of heptaprenyl phosphate on the MraY reaction, λex: 340nm, λem: 530 nm 
2.2.3.6 Evidence for the dansyl-labelled lipid I by high resolution 
LC-MS (HR LC-MS) 
In order to identify the forming lipid I product, the dansyl-labelled lipid I, HR LC-
MS analysis was performed. Two samples were prepared, both containing 
~80 µM dansyl-labelled UDPMurNAc-pentapeptide, one with added 20 µg/ml 
undecaprenyl phosphate, the other with 20 µg/ml heptaprenyl phosphate. The 
reaction was started by the addition of 240 µg E. coli MraY membranes and 
incubated for 30 minutes at 37 ºC. Then 6 M pyridinium acetate was added in 
order to stop the reaction. The formed lipid products were extracted into 1-
butanol. HR LC-MS analysis that was performed in the conditions written in 
Section 7.13, showed the evidence for the existence of the dansyl-labelled lipid I 
in the sample (Figure 2-18). 
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Evidence was also found for the existence of the chemical composition of the 
dansyl-labelled C35 lipid I (formed with heptaprenyl phosphate) by HR LC-MS 
(Figure 2-19). 
Figure 2-18: Isotopic pattern of the negatively and doubly charged ion for the dansyl-
labelled C55 lipid I and the chemical structure 
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Interestingly, from this sample where the dansyl-labelled UDPMurNAc-
pentapeptide reacted with heptaprenyl phosphate, evidence was found that the 
dansyl-labelled lipid I also formed with endogenous undecaprenyl phosphate of 
the E. coli MraY membranes (Figure 2-20). However, the intensity of the peaks is 
very low, implying a very low concentration of the compound. 
 
Figure 2-20: Isotopic pattern for the negatively and doubly charged ion for the dansyl-
labelled C55 lipid I formed with endogenous undecaprenyl phosphate 
Figure 2-19: Isotopic pattern for the negatively and doubly charged ion for the dansyl-
labelled C35 lipid I and the chemical structure 
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2.2.4 Continuous fluorescence assays with MraY enzymes from 
bacteria other than E. coli 
In this section, examples are shown for the continuous fluorescence assay with the 
wild type E. coli, P. aeruginosa, S. aureus, B. subtilis and M. flavus MraYs. 
2.2.4.1 Background MraY activity in the wild type E. coli 
membranes 
When wild type E. coli (C43) membranes were used for the MraY reaction in a 
total volume of 180 µl assay containing 20 µM dansyl-labelled UDPMurNAc-
pentapeptide, 35 µg/ml heptaprenyl phosphate, 83 mM Tris pH 7.5, 21 mM 
MgCl2 and 60 µg protein membranes where the enzyme was not overexpressed, 
the increase in fluorescence intensity was less than 10 FAU over a 15 minutes 
reaction time. These changes in fluorescence are too small to determine the level 
of inhibition or perform kinetic studies (Figure 2-21).  
 
Figure 2-21: Fluorescence MraY assay with wild type 90 µg E. coli membranes (MraY is not 
overexpressed) λex: 340 nm, λem: 530 nm  
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This observation highlights the necessity of overexpressing the MraY enzyme in 
the membranes. 
2.2.4.2 P. aeruginosa MraY reaction and inhibition by a known 
inhibitor, pacidamycin D 
The P. aeruginosa MraY was overexpressed in E. coli C43 membranes as well. 
One example for the assay is the well-known inhibitor of MraY, pacidamycin D. 
The compound was a gift from Antoine Abou Fayad (University of St Andrews) 
and was tested against P. aeruginosa MraY, (see Section 5.1.3) in a total volume 
of 180 µl containing 30 µM dansyl-labelled UDPMurNAc-pentapeptide, 35 µg/ml 
heptaprenyl phosphate in buffer 83 mM Tris pH 7.5, 21 mM MgCl2 and 90 µg 
protein membranes. Figure 2-22 shows the MraY assay from the time point of the 
addition of 90 µg protein with only one curve for each concentration of 
Pacidamycin D. 
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Figure 2-22: P. aeruginosa MraY assay, pacidamycin D concentration 0-180 ng/ml, 90 µg 
protein, λex: 340 nm, λem: 530 nm 
2.2.4.3 S. aureus MraY reaction and inhibition by a synthetic 
muraymycin analogue 
S. aureus was overexpressed in E. coli C43 membranes. A synthetic muraymycin 
analogue was tested against S. aureus MraY (see Section 5.1.1). A total volume of 
180 µl contained 20 µM dansyl-labelled UDPMurNAc-pentapeptide, 83 mM Tris 
pH 7.5, 21 mM MgCl2 and 90 µg protein membranes. Figure 2-23 shows the 
MraY assay with only one curve for each concentration of the muraymycin 
analogue, starting from the membrane addition. 
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Figure 2-23: S. aureus MraY assay, testing a muraymycin analogue between 0-80 µM, 90 µg 
protein, λex: 340nm, λem: 530 nm  
2.2.4.4 B. subtilis MraY reaction and inhibition by a known 
inhibitor, A-503083 B 
B. subtilis MraY was expressed in E. coli (C43) membranes. The capuramycin 
analogue, A-503083 B, was tested against B. subtilis MraY in order to test 
inhibition (see Section 5.1.5) in a total volume of 180 µl containing 30 µM 
dansyl-labelled UDPMurNAc-pentapeptide, 35 µg/ml heptaprenyl phosphate in a 
buffer 83 mM Tris pH 7.5, 21 mM MgCl2 and 60 µg protein (overexpressed 
B. subtilis MraY containing E. coli membranes). The concentration of the 
inhibitor varied in the range of 0 to 2.5 µg/ml (see Figure 2-24). 
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Figure 2-24: Inhibition of a capuramycin analogue, A-503083 B, against B. subtilis MraY, 
concentrations of the inhibitor ranging from 0-2.5 µg/ml, 60 µg protein, λex: 340nm, λem: 530 
nm 
2.2.4.5 M. flavus MraY reaction and inhibition by a known 
inhibitor, tunicamycin 
Micrococcus flavus membranes which naturally contain high level of the MraY 
enzyme, were assayed in a total volume of 180 µl containing 23 µM dansyl-
labelled UDPMurNAc-pentapeptide in 83 mM Tris pH 7.5, 21 mM MgCl2 and 
100 µg protein membranes gave only 25 FAU changes over 15 minutes. These 
small changes are enough to detect inhibition but not ideal to perform detailed 
kinetic studies on the M. flavus MraY (Figure 2-25).  
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Figure 2-25: M. flavus MraY reaction and 83 µg/ml tunicamycin inhibition, 90 µg protein 
containing membranes, λex: 340nm, λem: 530 nm 
2.2.5 Specific activity of recombinant MraY enzymes in the 
fluorescence assay 
An experiment was carried out in order to estimate the specific activity in the 
fluorescence MraY assay of the membrane preparations containing MraYs from 
the 5 organisms in a total volume of 180 µl containing 20 µM dansyl-labelled 
UDPMurNAc-pentapeptide, 30 µg/ml heptaprenyl phosphate in 83 mM Tris 
pH 7.5, 21 mM MgCl2 and 15 µl wild type E. coli membranes (50 µg) or 
overexpressed E. coli membranes containing MraY from either E. coli (50 µg), or 
P. aeruginosa (45 µg) or S. aureus (50 µg) or B. subtilis (65 µg) or 15 µl 
M. flavus (75 µg) membranes. The initial rate of the reaction was calculated from 
the slope of the curves between 50 and 110 second reaction time (avoiding mixing 
effects after the addition of the membranes). The specific activity of the enzymes 
was calculated as fluorescence unit changes (∆FAU) minute-1 mg protein-1 (see 
Table 2-2 and Section 7.10).  
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Table 2-2: Increase in specific activity by the fluorescence MraY assay in the membranes by 
overexpressing MraY 
overexpressed 
MraY 
total 
protein/assay 
(mg) 
fluorescence 
changes (FAU) 
over 1 minutes 
(initial rate of 
the reaction) 
specific enzyme 
activity (FAU 
min
-1 
mg 
protein
-1
) 
overproduction of 
enzyme activity 
(FAU min
-1
mg 
protein
-1
) 
compared to the 
wild type E. coli 
C43 
wild type E. 
coli C43 
0.050 0.0186 0.372 - 
E. coli 0.060 0.136 2.27 6 fold 
P. aeruginosa 0.045 0.221 4.91 13 fold 
S. aureus 0.050 0.149 2.98 8 fold 
B. subtilis 0.065 0.176 2.71 7 fold 
wild type M. 
flavus  
0.075 0.053 0.707 2 fold 
 
P. Brandish calculated a specific activity of 2.66 FAU min
-1 
mg protein
-1
 for the 
fluorescence MraY assay using a dansyl-labelled UDPMurNAc-pentapeptide and 
solubilised E. coli MraY
13
. Our estimated specific activity for the E. coli MraY is 
within the same range with 2.3 FAU min
-1
 mg protein
-1
. In conclusion, the 
overexpression of the MraY enzymes resulted in 6-13 fold increase in enzyme 
activity in the fluorescence MraY assay. The specific fluorescence activity of the 
wild type M. flavus MraY was 2 fold higher than that of the wild type E. coli 
MraY. 
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2.2.6 Determination of IC50 values of potential MraY inhibitors 
The half maximal inhibitory concentrations of the known or novel MraY 
inhibitors were determined by the means of the continuous fluorescence MraY 
assay on a number of occasions. Examples for the known MraY inhibitors are the 
pacidamycins (1.3). A sample of a mixture of pacidamycin 1 and 2 (Mw: 874.3 
and 835.3 respectively) was provided by Antoine Abou Fayad (University of St 
Andrews). The MraY reaction was started by the addition of 60 µg protein 
containing E. coli MraY membranes (C43) as described in the experimental 
chapter (Section 7.11). The inhibitor concentration in the assays varied between 
0 and 9 µg/ml. Figure 2-26 shows the inhibition of E. coli MraY by the 
fluorescence assay with only one example for each inhibitor concentration. 
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Figure 2-26: Example for the fluorescence MraY assay: Pacidamycin 1,2 inhibition against 
E. coli MraY, 60 µg protein, showing only one curve for each inhibitor concentration, λex: 
340 nm, λem: 530 nm 
In Figure 2-26 a regression line was fitted to the data from a run of an individual 
inhibitor concentration between 140-190 seconds (50 seconds after membrane 
addition in order to avoid mixing effects) using GenStat. That provided an 
estimate for the slopes, e.g. the initial rates of the MraY reactions. The means of 
the slopes of the repetitions related to inhibitor concentrations were then used to 
calculate % activity, the control lacking inhibitor taken as 100 % activity (Table 
2-3). 
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Table 2-3 : Calculation of % activity versus inhibitor concentration 
 
A further non-linear regression was used to fit the activity against concentration: 
                                 
Where: 
A: 100% activity 
B: constant related to the gradient (slope) 
The calculation for 50 % activity with the standard error was estimated using a 
curve fitting program in GenStat (Figure 2-27).  
                                 
       
 
 
Pacidamycin 1,2 
concentration 
(µg/ml) 
Means of the 
slopes (FAU/sec) 
Standard 
deviation 
Activity (%) 
 
Error related to 
activity (%) 
0 0.243 0.009 100  3.70 
0.0441 0.141 0.012 58.5 5.06 
0.0882 0.132 0.017 54.2 6.99 
0.1470 0.064 0.007 26.2 2.68 
0.1764 0.073 0.009 30.3 3.91 
0.2210 0.029 0.002 11.8 0.86 
0.2940 0.024 0.003 10.0 1.19 
8.8200 0.0055 0.0009 2.3 0.38 
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The calculation of the value for the IC50 of the pacidamycin 1,2 sample resulted in 
83 ± 7 ng/ml (8 % error).  
The standard errors for the IC50s calculated by the program were typically in the 
range of 5-15 %. The curve fitting program is the work of Dr. Julie Jones from the 
Quantitative Biology Centre (QuiBic) of the University of Warwick.  
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Figure 2-27: IC50 for pacidamycin 1,2 inhibition of MraY 
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2.2.7 KM determination for the dansyl-labelled UDPMurNAc-
pentapeptide in the fluorescence MraY assay 
The KM parameter is known as the Michaelis constant for the enzyme, the 
concentration of the substrate at which half-maximal rate is observed. If the 
substrate bound tightly by the enzyme the KM is small. On the other hand, a 
weakly bound substrate has a large KM. KM can be determined by measuring the 
rate of the enzymatic reaction at a range of different substrate concentrations
207
. 
P. Brandish determined the KM for the dansyl-labelled UDPMurNAc-pentapeptide 
for the E. coli MraY enzyme as 19 µM
143
. For both Gram-negative and Gram-
positive MraYs, the reported values for KM for the UDPMurNAc-pentapeptide 
vary from 5 to 30 µM
10
. However, a KM value of 1 mM was reported for a 
purified B. subtilis enzyme with a N-terminal (His)6 fusion tag which was 
determined by a radiochemical transfer assay
10, 133
. In order to investigate whether 
the KM for the dansyl-labelled UDPMurNAc-pentapeptide with P. aeruginosa 
MraY enzyme (there is a C-terminal tag on the protein, see Section 2.1) is within 
the usual range, a series of assays were performed using various concentrations of 
the dansyl-labelled UDPMurNAc-pentapeptide between 0-180 µM (Section 7.12). 
It was not possible to increase further the concentration of the fluorescence 
substrate because it would have been out of the of the measurement range of the 
fluorimeter. The concentration of the heptaprenyl phosphate (20 µg/ml), the 
membranes and the buffer was kept constant over the experiments. The steady 
state approximation of the Michaelis Menten kinetics was assumed for the 
experiment. 
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In order to determine KM the concentrations of the dansyl-labelled UDPMurNAc-
pentapeptide [s], a non-linear regression was used to fit the initial rates (v) against 
concentration [s]: 
             
Where: 
A: maximum rate (vmax) 
B: constant related to the gradient (slope) 
Figure 2-28 shows the graph in GenStat plotted with the help of a curve fitting 
program made by Dr. Julie Jones. 
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Figure 2-28: dansyl-labelled UDPMurNAc-pentapeptide concentrations [s] versus initial 
rates (v) 
At higher concentrations, a maximum rate of the reaction is observed (vmax), when 
the enzyme is fully saturated with the substrate. In this case the estimated 
maximum rate by the curve fitting program is 0.338 FAU/sec. Therefore half vmax 
(A/2) is 0.169 FAU/sec.  
The curve fitting program in GenStat calculated the concentration at A/2 with the 
standard error as: 
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The KM, the concentration of the dansyl-labelled UDPMurNAc-pentapeptide at 
half maximum rate of the reaction with the standard error was estimated as 
12.2 ± 1.7 µM in GenStat.  
For the Eadie-Hofstee graphical KM determination method v/[s] and v were 
calculated and a linear curve was fitted in Excel (Figure 2-29). 
 
Figure 2-29: Eadie-Hofstee plot for KM of the dansyl-labelled UDPMurNAc-pentapeptide in 
the P. aeruginosa MraY assay 
The slope of this linear curve represents –KM for the dansyl-labelled 
UDPMurNAc-pentapeptide:  
v = -15.7 * v/[s] + 0.39 
The standard error on the slope of the fitted linear curve was determined in 
GenStat resulting in 15.7 ± 3.5 µM.  
1/v and 1/[s] were plotted for the Lineweaver-Burk plot (Figure 2-30): 
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Figure 2-30: Lineweaver-Burk plot for KM of the dansyl-labelled UDPMurNAc-pentapeptide 
for P. aeruginosa MraY 
The intercept with the horizontal axis means -1/KM = -0.051. Therefore, 
KM = 19.6 ± 4 µM. The error was calculated from the standard error of the 
gradient of the linear regression line. 
Figure 2-31 shows the Hanes-Woolf graphical method, where [s]/v is plotted 
versus [s]. 
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Figure 2-31: Hanes-Woolf method for the dansyl-labelled UDPMurNAc-pentapeptide KM 
determination for P. aeruginosa MraY  
For the Hanes-Woolf method, the intercept with the horizontal axis is –KM. 
KM = 15.0 ± 3 µM. The error is based on the standard error of the linear curve. 
Table 2-4 shows the results from the graphical methods used for calculating KM 
for the dansyl-labelled UDPMurNAc-pentapeptide. 
Table 2-4: KM determination for the dansyl-labelled UDPMurNAc-pentapeptide with 
P. aeruginosa MraY by graphical methods 
Graphical method KM  (µM) 
v versus [s] 12.2 ± 1.7 
Eddie-Hofstee 15.7 ± 3.5 
Lineweaver-Burk 19.6 ± 4 
Hanes-Woolf 15.0 ± 3 
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A. O’Reilly performed fluorescence assays in 2012 during her MOAC mini-
project and measured KM values for the S. aureus and B. subtilis MraYs of 20 and 
15 µM respectively. 
These results fit in the typical range for KM values previously determined by 
researchers (5-30 µM). It shows that there is no significant difference in the 
kinetic behaviour of the four MraY enzymes (E. coli, S. aureus, B. subtilis and 
P. aeruginosa) with respect to their KM for the dansyl-labelled UDPMurNAc-
pentapeptide.  
2.3 Attempted HPLC-based MraY assay 
During the screening of the NCI Diversity Set (Chapter 3) with the fluorescence 
enhancement MraY assay, it became evident that many compounds interfere with 
fluorescence and an independent method was needed in order to test these 
compounds. Lipid I and II are very difficult to detect using HPLC because of their 
weak absorbance properties, but S. Sandhu developed an HPLC method where he 
was able to detect 2,4-dinitrophenyl-labelled (DNP-labelled) lipid II where he 
used Sanger’s reagent (1-fluoro-2,4-dinitro-benzene) for labelling59. We therefore 
attempted to develop an HPLC MraY assay to detect the formation of labelled 
lipid I derivatives by making a more UV active derivative. 
2.3.1 Preparation of N-labelled UDPMurNAc-pentapeptides 
We prepared N-labelled UDPMurNAc-pentapeptides at the third position amino 
acid with DNP, fluorescamine and dansyl labels in order to make UV active 
derivatives (structures are shown in Figure 2-32 and Figure 2-33). DNP- and 
fluorescamine-labelled pentapeptides were prepared in NaHCO3 buffer at pH 9 
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and 50 % acetone as described in the experimental chapter (Sections 7.14 and 
7.15), based on the method for the dansylation of the UDPMurNAc-pentapeptide. 
The acetone was evaporated and the samples were purified on a Sephadex G25 gel 
filtration column, eluting with water. The fractions with the absorbance maxima at 
~250 nm (uridine) and 360 nm (DNP-label) were collected and lyophilised 
overnight to obtain the DNP-labelled UDPMurNAc-pentapeptide (Figure 2-32). 
In the case of the fluorescamine-labelled UDPMurNAc-pentapeptide fractions 
with absorbance maxima at 250 nm (uridine) and 390 nm were collected and 
lyophilised (Figure 2-33). 
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Figure 2-32: UV-Vis absorbance spectrum of the DNP-labelled UDPMurNAc-pentapeptide 
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Figure 2-33: UV-Vis absorbance spectrum of the fluorescamine-labelled UDPMurNAc-
pentapeptide 
The compounds were analysed using HR LC-MS (see Section 7.6). For LC a 
linear gradient of methanol/water was used, with the percentage of methanol 
running up from 1 to 100 % starting at 5 minutes to 25 minutes at a flow rate of 
0.2 ml/min. Evidence was found for the presence of the DNP-labelled 
UDPMurNAc-pentapeptide substrate (m/z [M-H]
-
: 1358.3045 predicted 
1358.3429). The sample also contained a trace of the pentapeptide with two DNP 
labels (m/z [M-H]
-
: 1524.3011 predicted 1524.3443), three DNP labels (m/z [M-
H]
-
: 1690.2986 predicted 1690.3458) and a fragment lacking UDP that possibly 
formed during analysis (m/z [M-H]
-
: 972.3213 predicted 972.3512 in Figure 
2-34), all of these compounds eluted with the same retention time (1.2-1.3 
minutes). 
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Figure 2-34: Possible DNP-labelled UDPMurNAc-pentapeptide fragment (m/z [M-H]
-
: 
972.3213 corresponding to predicted 972.3512) 
The sample containing the DNP-labelled UDPMurNAc-pentapeptide was not 
purified further. The isotopic patterns for the DNP-labelled compounds are shown 
in Appendix 2, A 4 - A 7. 
The fluorescamine-labelled UDPMurNAc-pentapeptide was detected at 
2.4 minutes (m/z [M-2H]
2-
: 734.6912 predicted 734.6924). The isotopic pattern for 
the fluorescamine labelled UDPMurNAc-pentapeptide is shown in Figure A 8 in 
Appendix 2. There was no sign of any remaining unlabelled UDPMurNAc-
pentapeptide in either of the samples (m/z [M-2H]
2-
 predicted: 595.6634). 
2.3.2 HPLC assay methods 
The MraY reaction containing 300 µg/ml UDPMurNAc-pentapeptide or one of 
the N-labelled pentapeptides, 20 µg/ml heptaprenyl phosphate in Tris buffer at 
pH 7.5 was started with the addition of 200 µg protein containing MraY 
membranes in 200 µl total volumes. The mixture was incubated at 37 ºC for 30 
minutes. Then 200 µl 6 M pyridinium acetate at pH 4.2 was added in order to 
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acidify and stop the reaction (see Section 7.16). The formed lipid products were 
then extracted into 400 µl 1-butanol. LC-MS analysis was performed using a C18 
reverse-phase HPLC column (4.6 x 150 mm) with 0.1 % ammonium 
water/methanol gradient at 0.8 ml/min, coupled with the Bruker HCT Ultra Mass 
Spectrometer. The conditions are written in Section 7.7.  
Table 2-5 shows the masses for the various lipid I products and their specific 
absorbance wavelengths. 
Table 2-5: Lipid I derivatives of the MraY reaction 
UDPMurNAc-
pentapeptide 
LC-MS 
C35 lipid I  
m/z [M-H]
-
 
Characteristic 
wavelengths 
(nm) 
Retention time 
(min) 
based on EIC 
unlabelled 1442.71 - 18.5 
dansyl-
labelled 
1675.76 330  19 
fluorescamine-
labelled 
1702.76 (-H2O) 
1720.77 
390  17 
DNP-labelled 1608.71 360  18 
 
We already saw the evidence for the dansyl-labelled lipid I (C35 and C55) 
formation during the MraY reaction by HR LC-MS in Section 2.2.3.6. Further 
evidence was found by LC-MS which revealed that it is possible to produce the 
fluorescamine- and the DNP-labelled derivatives of lipid I with MraY (see 
Appendix 2). The lipid I derivatives also formed with MraYs from P. aeruginosa, 
S. aureus and B. subtilis, however they were expressed in E. coli membranes, 
therefore the lipid I derivatives could have been produced by the catalytic activity 
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of the background E. coli MraY. The lipid I derivatives formed with M. flavus 
membranes as well. 
The DNP-labelled lipid I (C35) typically eluted at 18 minutes from the C18 
column (for the correct isotopic pattern see Figure A 9 and for the chemical 
structure see Figure A 10 in Appendix 2). However, surprisingly, no peak was 
observed by absorbance at 360 nm or any other wavelength on the HPLC 
chromatograms for the chemical composition of the DNP-labelled lipid I in Figure 
2-35. 
 
Figure 2-35: No peak detected for the DNP-labelled C35 lipid I at 210, 260 and 360 nm, EIC: 
1608.7 
The doubly and negatively charged fluorescamine-labelled lipid I formed by 
E. coli MraY was detected by LC-MS and the correct isotopic pattern was 
confirmed by HR LC-MS (Appendix 2, Figures A 11 and A 12 for the isotopic 
pattern and A 13 for the chemical structure). Only a small peak was observed at 
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390 and 210 nm that could be associated with the fluorescamine-labelled lipid I 
eluting at 17 minutes, and no peak was observed at 260 nm (Figure 2-36). 
 
Figure 2-36: Absorbance at 210, 260 and 390 nm for the fluorescamine-labelled lipid I (C35)- 
H2O EIC: 1702.8 
The dansyl-labelled lipid I (Figure 2-37) that formed with endogenous 
undecaprenyl phosphate (m/z [M-H]
-
: 1948.01, Figure A 14 in Appendix 2), 
typically eluted from the column 2-3 minutes later than the C35 analogue (Figure 
A 15 in Appendix 2).  
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Figure 2-37: Extracted ion chromatograms of the dansyl-labelled lipid Is, the C55 analogue 
eluting from the C18 column 2-3 minutes later than the C35 analogue formed by 
overexpressed S. aureus MraY membranes (E. coli) 
Interestingly, in the sample with the unlabelled UDPMurNAc-pentapeptide, not 
only the predicted mass for the chemical composition of C35 lipid I (m/z [M-H]
-
: 
1442.71, Figure A 16 in Appendix 2) was observed but we saw evidence for 
formation of C35 lipid II (m/z [M-H]
-
: 1645.79, Figure A 17 in Appendix 2), even 
though no UDPGlcNAc was added to the reaction. Lipid I and II eluted with the 
same retention time (18.5 minutes). The membranes could contain MurG 
(extrinsic membrane protein), but the source of UDPGlcNAc for lipid II formation 
is not clear. Figure 2-38 shows the example of lipid I and II with M. flavus 
membranes.  
dansyl-labelled C35 lipid I 
dansyl-labelled C55 lipid I 
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Figure 2-38: Lipid I and lipid II (C35) with M. flavus membranes 
Sodium adducts were often observed in the samples (Figure 2-39). 
 
Figure 2-39: An example for sodium adducts, C35 lipid I formed with E. coli MraY 
lipid II 
lipid I 
doubly charged lipid I 
sodium adducts 
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In order to be able to develop an HPLC assay, an HPLC peak associated with the 
expected masses for lipid I products should have been seen with satisfactory 
intensity, preferably at selective wavelengths. The peak with the highest intensity 
was observed for the dansyl C35 lipid I at 210 nm. However, only very low 
intensity peaks were observed, which were too small to be used for assays (Figure 
2-40). 
 
Figure 2-40: Absorbance at 210, 250 and 330 nm of the dansyl-labelled lipid I (C35), EIC: 
1675.8 
The LC-MS analysis showed that the DNP- and the fluorescamine-labelled 
UDPMurNAc-pentapeptides are all accepted substrates for the MraY enzyme just 
like the dansyl-labelled UDPMurNAc-pentapeptide. However, it is not possible to 
quantify the production of these compounds using mass spectrometry. In the 
control samples that lacked UDPMurNAc-pentapeptide and the N-labelled 
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derivatives, there was no sign of the presence of any of the lipid I derivatives 
(Table 2-5) or lipid II. The controls are shown in Figure A 18 in Appendix 2. 
The HPLC detection of the lipid products did not seem to be reproducible and 
sensitive enough to be used for an MraY assay under the above mentioned 
conditions. Increasing the concentrations of the substrates in the samples could 
improve HPLC detection; however it did not seem to be practical. We decided to 
develop a radiochemical MraY assay which was shown to be a more sensitive 
assay
13, 130
. It is not clear why the UV absorbance of lipid I derivatives were so 
small; perhaps the lipid environment reduced the extinction coefficient for 
UV/Vis spectroscopy. 
2.4 Development of the radiochemical MraY assay 
The radiochemical MraY assay follows the incorporation of 
14
C radiolabel from 
UDPMurNAc-pentapeptide into the butanol-extractable product, lipid I which is 
then measured by liquid scintillation counting. The first step is a radiochemical 
synthesis of the [
14
C]-UDPMurNAc-pentapeptide
13
.   
2.4.1 Radiochemical synthesis of [14C]-UDPMurNAc-
pentapeptide 
The synthesis of the radiolabelled substrate uses UDPMurNAc-tripeptide and 
14
C-
L-alanine. The reaction needs to be catalysed by three enzymes, alanine racemase, 
DdlB and MurF (Figure 2-41). Alanine racemase requires pyridoxal phosphate 
whereas DdlB and MurF are ATP dependant ligases. The procedure is based on a 
method used by P. Brandish at Smith Kline Beecham Pharmaceuticals in 1991, 
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and the method of Tanaka, where an E. coli extract contained the three enzymes
13, 
201
.  
 
 
 
 
 
 
 
 
 
The enzymatic synthesis was first optimised by a non-radiolabelled version. The 
method described by P. Brandish used a 1 eq. to 2 eq. ratio of UDPMurNAc-
tripeptide to 
14
C-L-alanine and an E. coli extract (see Section 7.17). This 
procedure was attempted using unlabelled substrates but did not seem to result in 
a satisfactory conversion because the presence of the UDPMurNAc tripeptide was 
also detected in the sample by LC-MS (m/z [M-H]
-
: 1050.2, predicted: 1050.26 
see Figure 2-42). The correct isotopic patterns for the two compounds are shown 
in Appendix 3, Figures A 19 and A 20. 
Figure 2-41: Steps of the radiochemical synthesis of the [
14
C]-UDPMurNAc-pentapeptide, 
the product is 
14
C-labelled at the D-Ala residues at position 4 and 5 (in red) 
+ 
[
14
C]-L-Ala 
10 µCi/µmol  
[
14
C]-D-Ala  
pyridoxal 
phosphate 
alanine racemase 
DdlB 
ATP 
[
14
C]-D-Ala-D-Ala 
MurF 
ATP 
UDPMurNAc-tripeptide 
[
14
C]-UDPMurNAc-
pentapeptide 
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Figure 2-42: UDPMurNAc tripeptide and pentapeptide by LC-MS at 2 minute retention time 
Therefore, the ratio of UDPMurNAc tripeptide and L-alanine was changed to 1:3 
in order to use the L-alanine in excess and help the conversion. In addition, the E. 
coli extract was replaced by the three purified enzymes, E. coli alanine racemase 
and DdlB and P. aeruginosa MurF. The enzymes were a gift from 
Dr. David Roper. 
The enzymatic synthesis consists of a single overnight incubation at 37 ˚C of 
1 µmol UDP-MurNAc tripeptide with 3 µmol L-alanine, 20 µl alanine racemase 
(9.7 mg/ml), 20 µl DdlB (3.5 mg/ml), 10 µl MurF (24 mg/ml), 100 µl ATP 
(200 mM) and 50 µl pyridoxal phosphate (8 mM) in 250 mM Tris pH 8.4 (total 
volume: 450 µl). The enzymes were removed by ultrafiltration with a Centricon 
membrane (cut off 10,000 Da). The filtrate was purified by gel filtration 
(Sephadex G25) where the high molecular weight fractions showing absorbance 
maxima at 210 nm and 260 nm were collected and lyophilised overnight. HR LC-
MS showed m/z [M-H]
-
: 1192.3359 for the negatively and singly charged 
UDPMurNAc-pentapeptide see Appendix 3 Figure A 21. The presence of the 
UDPMurNAc-tripeptide was not detected in the sample. 
UDPMurNAc-tripeptide 
UDPMurNAc-pentapeptide 
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The radiochemical synthesis was carried out under the same conditions using 
10 µCi/µmol [
14
C]-L-Ala. After gel filtration the high molecular weight fractions 
with absorbance maxima at 210 nm and 260 nm were collected and counted by a 
liquid scintillation counter. The two fractions with higher radioactivity (24,575 
and 9,575 dpm/10 µl) were collected to be used as a substrate for the 
radiochemical MraY assays. The obtained [
14
C]-UDPMurNAc-pentapeptide is 
labelled at the D-Ala residues at position 4 and 5. The procedure is described in 
detail in Section 7.18. The radiolabelled product gave a peak for the negatively 
doubly charged ion of the UDPMurNAc-pentapeptide (m/z [M-2H]
2-
: 595.70 
predicted 595.66) by electrospray mass spectrometry. The MS analysis of the 
radiolabelled UDPMurNAc-pentapeptide was performed by Susan Slade at the 
Life Sciences Department of the University of Warwick (Appendix 3, Figure A 
22). 
2.4.2 Radiochemical MraY assay development 
The specific activity of the radiochemical and the fluorescence MraY assays was 
calculated by P. Brandish with 1.28 nmol min
-1
 mg
-1
 and 2.66 FAU min
-1
 mg
-1
 
respectively. It was concluded that the sensitivity of the two assays were within 
the same range and both assays could detect the same concentrations of enzyme 
activity
13
.  
2.4.2.1 General procedure for the radiochemical MraY assays 
The radiochemical MraY assay follows the transfer of phospho-MurNAc-L-Ala-γ-
D-Glu-m-Dap-[
14
C]-D-Ala-[
14
C]-D-Ala from UDPMurNAc-L-Ala-γ-D-Glu-m-
Dap-[
14
C]-D-Ala-[
14
C]-D-Ala to undecaprenyl or heptaprenyl phosphate catalysed 
by MraY to form [
14
C]-lipid I (Figure 2-43). 
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Figure 2-43: Schematic representation of the radiochemical MraY assay 
100 µl total volume contained 1-4 nCi/sample of UDPMurNAc-L-Ala-γ-D-Glu-
m-Dap-[
14
C]-D-Ala-[
14
C]-D-Ala, 23.3 µg/ml undecaprenyl phosphate or 
heptaprenyl phosphate, 90 mM Tris pH 7.5, 23 mM MgCl2, 4.0 % (vol/vol) 
glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 to which was added 20-
50 µg E. coli (C43) membranes containing overexpressed MraY or M. flavus 
membranes. Mixtures were incubated for 30 minutes at 35 ºC. Reactions were 
stopped by the addition of 100 µl 6 M pyridinium acetate at pH 4.2. Lipid 
products were extracted into 200 µl 1-butanol and quantified by liquid 
scintillation counting (see Section 7.19). 
2.4.2.2 MraY activity and inhibition in the wild type E. coli 
membranes 
Figure 2-44 shows an example for the radiochemical MraY assay where inhibition 
with known inhibitors such as tunicamycin (125 µg/ml), E peptide (100 µg/ml), 
pacidamycin D (3 µg/ml) and a capuramycin analogue, A-503083 B (1.2 µg/ml) 
can be observed.  
extraction into 1-butanol 
[
14
C]-UDPMurNAc- 
pentapeptide  
                       
[
14
C]-lipid I 
6 M pyridinium acetate pH 4.2 
liquid scintillation counting 
undecaprenyl phosphate  
or heptaprenyl phosphate 
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Figure 2-44: Inhibition of MraY and activity in the wild type E. coli membranes with the 
radiochemical MraY assay 
The total volume of 100 µl sample contained 1.7 µM 
14
C-labelled UDPMurNAc-
pentapeptide (3.38 nCi, 7,500 dpm), 27 µg/ml heptaprenyl phosphate and 40 µg 
protein containing overexpressed E. coli C43 membranes in 90 mM Tris pH 7.5, 
23 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-
100. The radioactivity was counted (dpm) after 30 minutes reaction time in a 
volume of 200 µl from the butanol layer. The volume of the whole butanol layer 
was normally ~250 µl. The measured radioactivity in the samples should always 
be corrected with the measured radioactivity from the sample lacking the MraY 
enzyme “no membranes“, before the product is quantified or % activity is 
calculated because we have to exclude the radioactivity from the measurement 
originating from the amount of 
14
C-labelled UDPMurNAc-pentapeptide that 
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extracted into butanol. The sample that lacked membranes (“no membranes”) had 
slightly higher radioactivity (63 dpm) than the background (45 dpm) where 200 µl 
butanol was pipetted into scintillation liquid and counted. This value for 
background radioactivity (63 dpm) was used for the corrections.  
From 7,500 dpm total radioactivity in one sample, 3,159 dpm was counted in 
200 µl butanol for the control MraY reaction without inhibitor. This number was 
corrected with the background (63 dpm) and the radioactivity was calculated to 
250 µl organic phase: 
(3159-63) dpm*1.25 = 3870 dpm. 
The conversion was around 52 %, 1.74 nCi containing lipid product got extracted 
into 250 µl butanol phase. (Conversions into the butanol phase were typically 
observed in the range of 50-75 %.) Since the specific activity of the L-alanine is 
10 µCi/µmol, and two molar eq. D-alanine are incorporated into one molar eq. 
14
C-labelled lipid I product, the yield was calculated as:  
1.74*10
-3
 µCi / (2*10 µCi/µmol) = 8.7*10
-5
 µmol 
14
C-labelled lipid I product. 
The lipid I product contains a mixture of C35-lipid I from the added heptaprenyl 
phosphate and C55-lipid I from the endogenous undecaprenyl phosphate (both 
14
C-
labelled and unlabelled).  
Table 2-6 shows the calculated % inhibition for the known inhibitors of MraY, the 
negative control (no inhibitor) taken as 100 % activity (or 0 % inhibition). 
E peptide showed 61 %, tunicamycin 93 %, pacidamycin D 98 % and the 
capuramycin analogue 89 % inhibition against MraY in the radiochemical assay. 
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Table 2-6: % inhibition of known inhibitors against MraY by the radiochemical assay 
 
E peptide 
(100 µg/ml) 
tunicamycin 
(100 µg/ml) 
pacidamycin D 
(3 µg/ml) 
Capuramycin 
analogue:  
A-503083 B   
(1.2 µg/ml) 
% inhibition 60.8 ± 2 93.4 ± 8 97.5 ± 2 89.4 ± 5 
 
The wild type E. coli showed 16.1 ± 2 % of the activity of the overexpressed 
E. coli MraY membranes, therefore the wild type E. coli generated 1.4*10
-5
 µmol 
14
C-labelled and unlabelled lipid I product that was extracted into a volume of 
250 µl butanol. Thus, the overexpression of E. coli MraY resulted in a 6 fold 
increase in lipid I production over 30 minutes. 
2.4.2.3 Investigation of D, D-carboxypeptidase activity 
D,D-carboxypeptidase activity from the membranes could release free [
14
C]-D-
Ala from the labelled substrate and interfere with the measurement. The following 
experiment aimed to investigate the presence of D,D-carboxypeptidase activity. 
Each sample contained 1,800 dpm in total, 27 µg/ml heptaprenyl phosphate and 
40 µg protein containing overexpressed E. coli C43 membranes in 90 mM Tris 
pH 7.5, 23 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % 
Triton X-100. The first two columns in Figure 2-45 following the “no 
membranes” control contained 100 µg/ml ampicillin in order to stop D,D-
carboxypeptidase activity. The third and the fourth columns did not contain 
ampicillin. Based on the nearly identical amount of radioactivity that got extracted 
into 1-butanol from the ampicillin treated and the control samples, it was 
concluded that there is no significant D,D-carboxypeptidase activity in the 
membranes that would interfere with the MraY assay.  
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Figure 2-45: No significant D,D-carboxypeptidase activity in the membranes 
2.4.2.4 Background activity from the endogenous undecaprenyl 
phosphate in E. coli C43 membranes  
Another experiment was carried out to investigate the background activity of the 
endogenous undecaprenyl phosphate in E. coli C43 membranes (see Figure 2-46). 
2.4 nCi (5,275 dpm) was the total radioactivity in each sample with no 
heptaprenyl phosphate in 90 mM Tris pH 7.5, 23 mM MgCl2, 4.0 % (vol/vol) 
glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 . The MraY reaction was 
started with the addition of 40 µg protein containing E. coli (C43) membranes.  
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Figure 2-46: low background activity from endogenous undecaprenyl phosphate from E. coli 
C43 MraY membranes 
Only 4.5 % conversion was achieved in the butanol extract 
[189 (dpm)*100*1.25/5,275 (dpm)] meaning the low abundance of the 
endogenous undecaprenyl phosphate in the membranes. The control experiment 
containing 27 µg/ml heptaprenyl phosphate resulted in 75 % conversion. This 
means that for every 1 molar eq. C55 lipid I, there was 15.7 molar eq. C35 lipid I 
product in the butanol extracted sample. 
2.4.2.5 The time-course of the MraY reaction by the 
radiochemical assay 
In order to investigate the time-course of the MraY reaction, the reaction was 
stopped at 1, 5 10 and 15 minutes after the membrane addition. Lipid products 
were extracted each time into butanol as described in Section 2.4.2.1 and 
radioactivity was measured by liquid scintillation counting. The membranes were 
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diluted to a concentration where it was possible to see the time-course of the 
reaction. 
100 µl total volume contained 1.7 µM 
14
C-labelled UDPMurNAc-pentapeptide 
(3.4 nCi), 27 µg/ml heptaprenyl phosphate and 40 µg protein containing 
overexpressed E. coli (C43) membranes in 90 mM Tris pH 7.5, 23 mM MgCl2, 
4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100. The 
experiment was repeated with the addition of 40 µg protein overexpressed 
B. subtilis, 35 µg protein overexpressed S. aureus, 20 µg protein overexpressed 
P. aeruginosa in E. coli (C43) membranes and 40 µg M. flavus membranes.  
 
Figure 2-47: Time-course profile of the MraY reaction by the radiochemical assay, 40 µg 
protein overexpressed E. coli and B. subtilis, 35 µg protein overexpressed S. aureus and 20 µg 
protein overexpressed P. aeruginosa in E. coli (C43) membranes and 40 µg M. flavus 
membranes 
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After 10-15 minutes of the membrane addition the reactions seemed to reach 
equilibrium in the case of the five MraYs, (E. coli, S. aureus, B. subtilis, 
P. aeruginosa and M. flavus) and there was no significant increase in product 
formation after 5 minutes apart from the M. flavus MraY. 
2.4.2.6 Overproduction of enzyme activity in the overexpressed 
E. coli MraY membranes and comparison with the wild 
type M. flavus 
In order to investigate the overproduction of the radiolabelled lipid I product 
during the MraY reaction, we quantified the forming radiolabelled lipid product 
after 30 minutes reaction time using overexpressed MraY E. coli and M. flavus 
membranes. Lipid products were extracted each time into butanol as described in 
Section 2.4.2.1 and radioactivity of 200 µl butanol was measured by liquid 
scintillation counting. 100 µl total volume contained 1.7 µM 
14
C-labelled 
UDPMurNAc-pentapeptide (3.4 nCi), 27 µg/ml heptaprenyl phosphate and 40 µg 
protein containing overexpressed E. coli (C43) membranes in 90 mM Tris pH 7.5, 
23 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-
100. The experiment was repeated with the addition of 40 µg protein 
overexpressed B. subtilis, 35 µg protein overexpressed S. aureus, 20 µg protein 
overexpressed P. aeruginosa in E. coli (C43) membranes and 40 µg M. flavus 
membranes (Table 2-7). 
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Table 2-7: Comparison of the level of radiolabelled lipid I production for 1 mg protein 
containing E. coli membranes overexpressed with MraY from E. coli, S. aureus, B. subtilis 
and P. aeruginosa with the wild type E. coli membranes and radiolabelled lipid I production 
for M. flavus membranes over 30 minutes reaction time by the radiochemical assay 
over-
expressed 
MraY 
mg 
protein 
(total) 
dpm in 
200 µl 
butanol 
nCi in 
200 µl 
butanol 
nmol 
lipid I 
product 
in 200 µl 
butanol 
nmol 
lipid I 
product/
mg 
protein 
over-
production 
of  lipid I 
wild type E. 
coli C43 
0.040 502 0.226 1.13*10
-2
 0.282 - 
E. coli 0.040 3096 1.39 6.85*10
-2
 1.71 6 fold 
S. aureus 0.035 3437 1.55 7.75*10
-2
 2.21 8 fold 
B. subtilis 0.040 3182 1.43 7.15*10
-2
 1.79 6 fold 
P. aeruginosa 0.020 2525 1.14 5.70*10
-2
 2.85 10 fold 
M. flavus 0.040 1088 0.490 2.45*10
-2
 0.613  2 fold 
 
Table 2-7 shows the amount of radioactivity measured in 200 µl organic phase, 
and the converted number in nCi. Knowing the specific activity for the 
radiolabelled lipid I product (20 µCi/µmol), it was possible to calculate the yield 
in nmol for 200 µl butanol. (The total yield would have to be multiplied with 1.25 
for the total volume of 250 µl butanol.) Then, the production of lipid I was 
calculated for 1 mg total protein. These calculations resulted in 6-10 fold 
overproduction of the radiolabelled lipid I by the overexpressed MraY membranes 
compared to the wild type E. coli membranes. The M. flavus membranes produced 
double the amount of lipid I than the wild type E. coli. 
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2.4.2.7 Determination of IC50s by means of the radiochemical 
MraY assay for compounds that interfere with 
fluorescence 
IC50s were determined by the means of the radiochemical MraY assay for 
compounds that interfere with fluorescence (see Sections 3.3.1.1, 5.2, 5.3.2 and 
5.4). Activity which is directly related to the amount of product, was plotted 
versus inhibitor concentrations, taking the measured radioactivity (dpm) 
(corrected with the background) of the control MraY reaction as 100 % activity. 
The same curve fitting program was used in GenStat to determine inhibitor 
concentrations at 50 % inhibition as for the continuous fluorescence assay in 
Section 2.2.6. 
  
 
134 
 
3 Screening of the Diversity Set of the National 
Cancer Institute  
The Development Therapeutics Program at the U.S National Cancer Institute 
maintains a large screening collection of over 140,000 compounds that have been 
evaluated as potential anticancer and anti-HIV agents. Among these compounds 
there are synthetic compounds and natural products representing unique structural 
diversity. The National Cancer Institute also possesses a small library of around 
2,000 compounds, ideal for beginning a screening process. Since many 
hospitalised cancer patients treated with anticancer agents develop life-threatening 
bacterial infections, the National Cancer Institute will send their diversity set to 
academic groups who can demonstrate a microtitre-based assay for an 
antibacterial target enzyme. Following a request from Professor T. D. H. Bugg, 
the NCI sent the diversity set of 1,717 compounds in 2012. 
We were sent the diversity set III (20 plates) and the natural products set II 
(2 plates) as a starting package by A. Martinkosky from the NCI 
Chemotherapeutic Agents Repository. Plates were stored at -20 ºC. 
The diversity set III plates held 20 µL of a 10 mM DMSO solution in 96 well 
polypropylene microtitre plates with 80 compounds per plate.  
The natural products set II consist of 120 compounds which were selected from 
the open repository of 140,000 natural products of the National Cancer Institute. 
This set was created in order to help drug discovery research groups intending to 
study a variety of scaffold structures having multiple functional groups. These 
compounds were selected by purity (> 90 % by ELSD, major peak has correct 
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mass ion), structural diversity and availability. These natural products were also 
stored in 96 well polypropylene microtitre plates with 60 compounds per plate. 
Each well contained 0.2 µmoles compound and 1 µl glycerol.  By the addition of 
19 µl of DMSO we obtained a 10 mM solution in 20 µl volume. The information 
about the diversity set was provided by A. Martinkosky. 
Our aim was to test these compounds at 100 µM concentrations against E. coli 
MraY by the fluorescence enhancement assay (Figure 2-2) in 96-well plates. We 
hoped to find potential MraY inhibitors by this rapid screening method which 
would have been tested further by the continuous fluorescence assay to study the 
reaction kinetics. We also planned to test promising MraY inhibitors with MraY 
enzymes from P. aeruginosa, S. aureus, B. subtilis and M.  flavus.  
3.1 Initial screening data for the diversity set of the 
National Cancer Institute 
In our research group, the fluorescence enhancement MraY assay was first used in 
a 96-well microtitre format by S. Bagga in 2004
145
. 
The assays were carried out in a 100 µl total volume, containing 85 µl master mix 
(containing 11.2 µM dansyl-labelled UDPMurNAc-pentapeptide, 17 µg/ml 
heptaprenyl phosphate in a buffer 85 mM Tris, 21.25 mM MgCl2), 5 µl test 
compound solution at 100 µM concentration and 10 µl 40 µg total protein 
containing E. coli MraY membranes. Note that the assay always contains 3.4 % 
glycerol and 0.1 % Triton X-100 from the buffer that the heptaprenyl phosphate 
solution was made. The presence of detergent is essential for the MraY assay. The 
10 mM compound solutions from the diversity set were diluted to 2 mM in the 
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assay buffer (200 mM Tris at pH 7.5, 50 mM MgCl2) and 5 µl of these solutions 
was added to the assay at 100 µM final concentration. 25 µg/ml tunicamycin was 
used as a positive control, the negative control (no inhibitor) contained 5 µl 20 % 
(v/v) DMSO and the control “no membranes” contained 10 µl “membrane buffer” 
(50 mM Tris pH 7.5, 2 mM -mercaptoethanol, 1 mM MgCl2) instead of the 
membranes. The samples for the test compounds were carried out in duplicates, 
the first and the last column was used for the controls (16 wells). The conditions 
of the screening are described in Section 7.20. The arrangement in a 96-well 
microtitre plate for testing 40 compounds from the diversity set is shown in Figure 
3-1. 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A No inhibitor A2 A2 A3 A3 A4 A4 A5 A5 A6 A6 
No 
membranes 
B No inhibitor B2 B2 B3 B3 B4 B4 B5 B5 B6 B6 
No 
membranes 
C No inhibitor C2 C2 C3 C3 C4 C4 C5 C5 C6 C6 tunicamycin 
D No inhibitor D2 D2 D3 D3 D4 D4 D5 D5 D6 D6 tunicamycin 
E tunicamycin E2 E2 E3 E3 E4 E4 E5 E5 E6 E6 No inhibitor 
F tunicamycin F2 F2 F3 F3 F4 F4 F5 F5 F6 F5 No inhibitor 
G tunicamycin G2 G2 G3 G3 G4 G4 G5 G5 G6 G6 No inhibitor 
H tunicamycin H2 H2 H3 H3 H4 H4 H5 H5 H6 H6 No inhibitor 
 
 
Figure 3-1: Arrangements of the test compounds (wells A2-H6 from a diversity set plate) and 
controls (no inhibitor, 100 µg/ml tunicamycin and no membranes) in 96-well plate format 
Before the reaction was started by the addition of 10 µl E. coli MraY membranes 
the plate was tested for high fluorescence compounds by a fluorescence 
Test compounds at 100 µM concentrations 
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measurement with excitation at 340 nm and emission at 353 nm. These high 
fluorescence compounds make it impossible to monitor relatively small 
fluorescence changes during the MraY reaction due to the fact that the instrument 
calculates arbitrary fluorescence units based on relative fluorescence in the wells. 
Figure 3-2 shows an example of 40 compounds that were tested at the same time 
in 96-well plate format from the diversity set III, plate: 4737067/4737.  
 
Figure 3-2: Eliminating compounds with high fluorescence from the wells before the MraY 
reaction, compounds A4 (3130 FAU), A5 (6,445 FAU), E2 (44,153), E4 (6,844), 
F6 (4,789 FAU), G3 (3,023) and H5 (13,007) with higher fluorescence had to be removed 
from the assay λex: 340 nm, λem: 535 nm 
By eliminating the compounds with obvious high fluorescence first (A5, E2, E4, 
F6 and H5) and repeating the measurement, we got to the conclusion that 
compounds A4 (3,130 FAU), A5 (6,445 FAU), E2 (44,153), E4 (6,844), 
F6 (4,789 FAU), G3 (3,023) and H5 (13,007) had significantly higher 
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fluorescence than the controls and had to be removed from the assay before we 
started the reaction. 
Another way of establishing which compounds will interfere with our 
measurement is to do an analysis of variance for the set of samples and calculate 
the “Least Significant Difference” (LSD) between the highest and the lowest 
means. The LSD was calculated for this particular set of data in GenStat at 5 % 
level between the highest (44,153 FAU, measured for E2) and the lowest means 
(2358 FAU measured for D6) and gave a value of 344.4 FAU. Therefore every 
compound with higher fluorescence than the controls plus the LSD (2971 FAU) 
had to be eliminated from the experiment above red line in Figure 3-2, which lead 
to the removal of the very same compounds that we found by repeated 
measurements. 
It is possible to measure the fluorescence at several time-points during the MraY 
reaction. We chose to measure the fluorescence every 5 minutes up to 20 minutes 
reaction time e.g. 0, 5, 10, 15 and 20 minutes after the addition of the membranes 
with excitation at 340 nm and emission at 350 nm. Figure 3-3 shows the time-
course assay of 7 selected compounds and the controls from the diversity set III, 
plate: 4737067/4737. 
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Figure 3-3: Time-course of the fluorescence MraY assay in microtitre plate format (0, 5, 10, 
15 and 20 minutes) 
After 30 minutes reaction time, we took a final measurement (λex: 340 nm, λem: 
535 nm) to screen compounds with lower fluorescence enhancement activity than 
80 %. Figure 3-4 shows the measured fluorescence values and the compounds 
with less than 80 % fluorescence enhancement activity, which were chosen for 
further testing (under the red line).  
The LSD was calculated for the final set of data (30 minutes) from the 
fluorescence microtitre plate assay in GenStat at 5 % level between the highest 
(45,176 FAU, measured for B2) and the lowest means (31,157 FAU, measured for 
the “no membranes” control) and gave a value of 2054.1 FAU. These calculations 
were in agreement with the limit that we set for 80 % for this set of data. 
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Figure 3-4: Screening compounds with lower fluorescence enhancement activity than 80 % 
Compounds A2, C5, D3, D6, F3 and F4 from the diversity set III, plate: 
4737067/4737, were chosen for further testing by the continuous fluorescence 
MraY assay. From the original 1,717 compounds, 134 compounds (8 %) showed 
low fluorescence in the initial microtitre plate screen, and were then analysed by 
the continuous fluorescence assay. 
The low fluorescence compounds were tested at 60 µM concentration in a total 
volume of 170 µl containing 15 µM dansyl-labelled UDPMurNAc-pentapeptide 
35 µg/ml heptaprenyl phosphate, 83 mM Tris pH 7.5, 21 mM MgCl2, 6 % 
glycerol and 0.15 % Triton X-100. The reaction was started by the addition of 
60 µg E. coli MraY membranes. Figure 3-5 shows that all of the compounds in 
this group interfered with fluorescence, because as soon as they were added to the 
cuvette, a significant decrease in fluorescence was observed.  
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Figure 3-5: The hits tested at 60 µM from the initial screen of the diversity set interfered 
with fluorescence: low fluorescence (LF) compounds and low fluorescence compounds with 
fluorescence enhancement activity (LFA), 15 µM dansyl pentapeptide, 35 µg/ml heptaprenyl 
phosphate, 60 µg protein, λex: 340 nm, λem: 530 nm  
In this set, the test compounds A2 and F3 were classified as low fluorescence (LF) 
compounds, since after the initial mixing effect; they showed no fluorescence 
enhancement activity in the MraY assay. On the other hand, compounds C5, D3, 
D6 and F4 showed some fluorescence enhancement activity, therefore, they were 
classified as low fluorescence with activity (LFA) compounds. 
Unfortunately, all of our 134 apparent hits from the initial screen were found to 
interfere with fluorescence. However, it is said to be a very common phenomenon 
while screening by fluorescence-based assays
208
. There are various reasons for a 
test compound to interfere with the fluorescence measurement, it could be due to 
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intrinsic fluorescence, fluorescence quenching or the compound absorbs light at 
the excitation or the emission wavelength
208
.  
The compounds that interfered with fluorescence from our screen fell into three 
categories: 
1. compounds with high fluorescence (HF) that were impossible to test  in 
the fluorescence plate reader MraY assay (Figure 3-2), 
2. compounds with low fluorescence (LF) that were tested by the continuous 
florescence MraY assay (Figure 3-5), 
3. and low fluorescence compounds with fluorescence enhancement activity 
(LFA) that we also tested by the continuous fluorescence MraY assay 
(Figure 3-5). 
Table 3-1 shows the results from our initial screen of the NCI diversity set. Out of 
1,717 compounds 1,340 did not show inhibition at 100 µM concentrations in the 
fluorescence MraY assay (78 %). However, 22 % of the test compounds interfered 
with fluorescence and it was impossible to exclude the possibility of inhibition for 
these compounds. An independent assay was needed in order to examine the 
possibility of MraY inhibition by these compounds. 
Table 3-1: Categories of test compounds from the NCI diversity set 
High fluorescence (HF) 243 14 % 
Low fluorescence with activity (LFA) 83 5 % 
Low fluorescence (LF) 51 3 % 
No inhibition 1,340 78 % 
Total number of compounds 1,717 100 % 
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The detailed results for each plate from the NCI diversity set are shown in 
Appendix 4. 
3.2 Testing of Low Fluorescence compounds with the 
radiochemical assay 
The radiochemical MraY assay (Figure 2-43) was our chosen method for testing 
the compounds that interfered with the fluorescence MraY assay. The 
radiochemical MraY assay (Section 2.4) is not a high-throughput assay; therefore 
we had to target a smaller group of compounds than the 417 compounds that 
interfered with fluorescence. Our first choice were the low fluorescence 
compounds (LF) because they did not show fluorescence enhancement activity in 
the fluorescence assay and also because it was a smaller group of compounds 
(51 compounds). These were tested in four groups of 10 and one group of 
11 compounds at five occasions by the radiochemical MraY assay at 100 µM 
concentrations in a total volume of 100 µl which contained 1.2 µM 
14
C-labelled 
UDPMurNAc-pentapeptide (2.4 nCi), 27 µg/ml heptaprenyl phosphate in 90 mM 
Tris pH 7.5, 23 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 
0.1 % Triton X-100. The reaction was started by the addition of 40 µg protein 
containing overexpressed E. coli C43 membranes (see Section 7.22).  
Figure 3-6 shows an example of seven low fluorescence compounds tested against 
E. coli MraY by the radiochemical assay at 100 µM concentrations. The limit was 
set at 20 % inhibition. 
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Figure 3-6: Testing low fluorescence compounds (LF) by the radiochemical MraY assay 
However, there was no inhibition greater than 20 % observed for the LF 
compounds by the radiochemical MraY assay at 100 µM concentrations. Three of 
the low fluorescence compounds where inhibition seemed ≥ 10 % (green in Figure 
3-6), were tested again at 500 µM concentration, however, no inhibition over 
10 % was observed at 500 µM so no hits were obtained from this group of 
compounds. 
 
0
10
20
30
40
50
60
70
80
90
100
110
N
o
 i
n
h
ib
it
o
r 
c
o
n
tr
o
l
tu
n
ic
am
y
ci
n
 (
1
2
5
 µ
g
/m
l)
2
0
 B
1
0
2
0
 F
6
2
0
 G
9
2
1
 A
3
2
1
 E
3
2
1
 F
3
2
1
 F
1
0
2
1
 G
1
0
2
2
 D
8
2
3
 A
6
2
3
 B
7
2
3
 A
4
2
3
 B
8
2
3
 B
1
0
2
3
 C
3
2
3
 C
1
0
2
3
 D
1
1
2
3
 E
8
2
3
 G
4
2
3
 H
5
2
4
 A
6
2
4
 G
3
2
4
 G
8
2
5
 E
9
2
5
 H
5
2
6
 B
1
1
2
6
 C
1
1
2
7
 G
1
1
2
8
 H
6
3
0
 F
8
3
2
 C
2
3
2
 F
2
3
2
 H
7
3
3
 F
4
3
3
 H
1
0
3
4
 A
8
3
5
 B
6
3
5
 E
8
3
6
 B
1
1
3
6
 C
6
3
6
 G
6
3
7
 A
2
3
7
 A
7
3
7
 E
1
1
3
7
 F
3
3
7
 F
7
2
7
 F
8
3
8
 B
5
3
9
 A
1
0
3
9
 D
8
3
9
 G
7
A
ct
iv
it
y
 (
%
) 
  
 
145 
 
3.3 Testing of high fluorescence (HF) and low 
fluorescence with activity (LFA) natural products 
with the radiochemical assay 
Since the chemical structures of the natural products set appeared structurally 
more diverse than the diversity set III, a decision was made to concentrate our 
attention to the natural products set II which contained only 120 compounds. 
There were no LF compounds on these natural products plates, 13091250 and 
13091251 each holding 60 compounds. However, there were 11 LFA compounds 
and 21 HF compounds that we tested at 500 µM concentrations by the 
radiochemical MraY assay. The conditions for the assay were the same as for the 
LF compounds (see Section 3.2). Figure 3-7 shows the LFA and HF compounds 
from the NCI diversity set plate 13091251 that were tested by the radiochemical 
MraY assay.  
 
Figure 3-7: Testing high fluorescence and LFA compounds from the NCI diversity set plate 
13091251, LSD calculated in GenStat: 162.5 dpm for the highest and lowest means at 5 % 
level, compound F8 in yellow, tunicamycin in red  
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Only one compound, F8 from the NCI diversity set plate 13091251, showed more 
than 20 % inhibition against E. coli MraY by the radiochemical assay at 500 µM 
concentrations. None of the other compounds showed more than the set limit, 
20 % inhibition in the assay from the two natural products plates. The compound 
that showed 60 % inhibition at 500 µM was identified by its NSC number 
(661755) as an alkaloid, michellamine B. This was one of the high fluorescence 
compounds. 
3.3.1 Testing michellamine B against MraY 
The michellamines are naturally occurring dimeric naphthylisoquinoline 
alkaloids, isolated from a West African plant called Ancistrocladus abbreviatus 
(Ancistrocladaceae). Michellamine B is well-known antiviral agent with high 
cytotoxic activity against the human immunodeficiency virus (HIV1 and HIV-
2)
209, 210, 211
. Michellamine B was also found to inhibit protein kinase C (PKC)
212
 
and human lipoxygenases (12-hLO and 15-hLO-1)
213
 which makes it an 
interesting agent for anti-cancer research (see Section 3.3.2). The chemical 
structure of the michellamine B di-acetate salt is shown in Figure 3-8. 
 
Figure 3-8: Chemical structure of Michellamine B as defined by the National Cancer 
Institute, Exact mass: 876.38 
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3.3.1.1 Inhibition of michellamine B against the MraY enzyme by 
the radiochemical assay 
A second sample of michellamine B from the National Cancer Institute was tested 
again by the radiochemical MraY assay (Figure 2-43) against E. coli MraY as 
described in Section 7.23. 100 µl assay contained 3.2 nCi (7,094 dpm) [
14
C]-
UDPMurNAc-pentapeptide, 27 µg/ml heptaprenyl phosphate in 90 mM Tris pH 
7.5, 23 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % 
Triton X-100. Michellamine B was tested at 125, 250 and 500 mg/ml final 
concentrations, the reaction was started by the addition of 40 µg protein 
containing overexpressed E. coli MraY membranes. IC50 was determined with the 
standard error by a plot of % activity versus michellamine B concentrations with 
the help of a curve fitting program in GenStat (see Section 2.2.6) with a value of 
400 ± 50 µg/ml as seen in Figure 3-9. A repeat experiment gave a value of 
402 ± 60 µg/ml for IC50. 
 
Figure 3-9: IC50 for Michellamine B against MraY: 400 ± 50 µg/ml 
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This IC50 value (458 µM) is significantly higher than we aimed for the screening 
(100 µM). However, it is the only compound that we were able to screen and 
showed some inhibition from the NCI set.  
This compound was then tested in duplicate against S. aureus, P. aeruginosa, 
B. subtilis and M. flavus MraYs at 500 µg/ml concentration (Table 3-2). 
Table 3-2: Michellamine B inhibition against S. aureus, P. aeruginosa, B. subtilis and 
M. flavus MraYs at 500 µg/ml concentration and comparison with two known inhibitors of 
MraY, tested by the radiochemical MraY assay 
MraY from 
various organisms 
% inhibition of 
michellamine B 
% inhibition of 
pacidamycin D  
(3 µg/ml) 
% inhibition of 
tunicamycin 
(125 µg/ml) 
S. aureus no inhibition 98.4 ± 2 93.7 ± 4 
P. aeruginosa 37.6 ± 1 99.5 ± 3 72.3 ± 8 
B. subtilis 75.7 ± 11, 93.9 ± 3 96.8 ± 3 
M. flavus 14.2 ± 2  77.3 ± 7 86.3 ± 10 
E. coli 62.8 ± 7 97.5 ± 2 93.4 ± 8 
 
Michellamine B did not inhibit S. aureus MraY despite repeated experiments but 
showed inhibition against P. aeruginosa (38 %), B. subtilis (76 %) and 
M. flavus (14 %) MraYs, tested at 500 µg/ml concentration. M. flavus was not 
significantly inhibited by michellamine B, but interestingly the two known 
inhibitors, pacidamycin D and tunicamycin were less effective as well compared 
to the inhibition of MraYs from other organisms with 77 % and 86 % inhibition 
respectively. It is notable, that tunicamycin only showed 72 % inhibition against 
P. aeruginosa MraY at 125 µg/ml concentrations.  
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The IC50 of michellamine B (Figure 3-10) was estimated for the B. subtilis MraY 
under the same conditions as for the E. coli MraY (Section 7.23). The reaction 
started with 40 µg overexpressed B. subtilis MraY membranes.  
 
Figure 3-10: Michellamine B inhibition against B. subtilis MraY, IC50: 338 ± 54 µg/ml 
Michellamine B inhibited B. subtilis MraY with an IC50 value of 338 ± 54 µg/ml. 
3.3.1.2 Testing Michellamine B for antibacterial activity 
Michellamine B was tested for antibacterial activity against E. coli, B. subtilis and 
P. putida. 3 x 10 ml LB medium was inoculated by a single colony of one of the 
three strains picked from an LB agar plate and incubated and shaken overnight at 
37 ºC. 10 µl of the overnight culture was used to inoculate 10 ml LB which was 
incubated at 37 ºC and shaken at 180 rpm until OD600 was 0.6. This culture was 
diluted 100 fold. 95 µl of the diluted culture was placed in 96-well plates and to 
each well 5 µl antibiotic solution was added up to a total volume 100 µl. A two-
fold serial dilution of michellamine B was prepared at 125, 62.5, 31.3, 15.6, 7.81, 
3.91 and 1.95 µg/ml final concentrations. The samples were prepared in 
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triplicates. 6 wells contained 100 µl LB for checking bacterial contamination. 5 µl 
water or 5 µl DMSO containing solutions were added for the negative control and 
5 µl kanamycin solutions between 0.391 and 50 µg/ml final concentrations for the 
positive control. The plates were incubated and shaken at 37 ºC and bacterial 
growth was monitored by the naked eye
59, 214
. 
Michellamine B had no effect on the growth of E. coli and P. putida at 125 µg/ml 
final concentration, but it inhibited the growth of B. subtilis. The lowest 
concentration of michellamine B at which there was no visible growth of 
B. subtilis gave an MIC value of 15.6 µg/ml (3 repeats). The inhibition was 
confirmed by an agar plate filter disc assay
214
, where a small zone of inhibition 
was observed at 50 µg/ml concentration against B. subtilis (see Section 7.24).  
Figure 3-11 shows the inhibition zone on B. subtilis agar plate caused by 
michellamine B. 
 
 
 
 
 
 
 
Figure 3-11: Picture of michellamine B inhibition of B. subtilis, from the top clockwise: 25 µl 
DMSO, 25 µl of 2.5, 1,25 and 0.05 mg/ml stock solutions of michellamine B (M), 25 µl of 
2 mg/ml kanamycin and 25 µl 1 mg/ml ampicillin 
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3.3.2 Michellamine family of natural products 
This section describes what is known about the biological activities of the alkaloid 
michellamine B and its mechanism of action on known target enzymes. 
3.3.2.1 Isolation and structure of michellamines 
The National Cancer Institute carried out a search for novel drug development 
candidates for anti-HIV agents and reported two new antiviral compounds from 
their in vitro screen in 1991, the atropisomeric pair alkaloids michellamine A and 
B
210
.  
Boyd et al reported the isolation and the absolute configuration of michellamine 
A, B and C in 1994. They were isolated from a newly discovered plant that they 
named Ancistrocladus korupensis using methods such as solvent-solvent 
partitioning, centrifugal partition chromatography, size exclusion 
chromatography, and HPLC
215
. The stereo-structures of the michellamines were 
determined by 
1
H and 
l3
C NMR and CD spectroscopy
215, 216
.  
The michellamines have a unique dimeric naphthylisoquinoline alkaloid structure; 
their three phenolic OH and the one secondary amino group in each monomer 
give them high polarity. They also have some rare C-5/C-8’ coupling between the 
naphthalene and the isoquinoline ring systems, which means they possess six 
elements of chirality in total (Figure 3-12)
215
. 
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Figure 3-12: Chemical structures of michellamines A, B and C, six elements of chirality 
The biosynthetic precursors of the michellamines are presumed to be the 
korupensamines (Figure 3-13). Korupensamine A and B exhibit good antimalarial 
activities in vitro and in vivo. They were isolated from the same plant 
Ancistrocladus korupensis and they structurally also possess axial chirality 
between the naphthalene and the tetrahydroisoquinoline rings, three elements of 
chirality in total
217
.  
 
Figure 3-13: Chemical structure of michellamine B and korupensamine A and B 
Examples for other monomeric naphthylisoquinoline alkaloids are the 
dioncophyllines
218
, the ancistrobrevines, the ancistrocladines and the hamatines
219
 
shown in Figure 3-14. 
michellamine B 
korupensamine A 
korupensamine B 
michellamine B michellamine A michellamine C 
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Figure 3-14: Chemical structure of monomeric naphthylisoquinoline alkaloids, three 
elements of chirality in the monomer units 
The isolation of further anti-HIV michellamine isomers (D, E and F) and the anti-
malarial korupensamine E from A. korupensis have also been reported
216
 and 
several approaches were developed for the total synthesis of the michellamines
220, 
221
. 
3.3.2.2 Biological activities of michellamine B 
A. Antiviral activity against the human immunodeficiency virus 
Michellamines A, B, and C have shown antiviral activity against HIV-1 and HIV-
2 in cell culture and michellamine B, the most prevalent in A. korupensis extracts, 
was found to be the most active with an EC50 value of 1-18 µM for various HIV 
strains
215
. The fact that michellamine B has activity against HIV-2 is rare amongst 
anti-HIV agents and has stimulated further studies
220
. The investigations 
suggested that michellamine B did not block the initial binding of HIV to target 
cells but inhibited reverse transcriptases from both HIV-1 and HIV-2 
noncompetitively with respect to deoxynucleoside triphosphates
222
. 
Michellamine B also inhibited dipyridodiazepinone-resistant HIV-1 reverse 
dioncophylline B 
ancistrobrevine B 
ancistrocladine 
hamatine 
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transcriptase mutants
222
 suggesting a different site of interaction for the alkaloid 
than the previously described hydrophobic pocket for the dipyridodiazepinone 
drug Nevirapine
223
. Michellamine B also demonstrated a potent dose-dependent 
inhibition of cellular fusion and syncytium formation with an IC50 value of 
20 µM
222
.  
The di-acetate salt of michellamine B was suggested for pre-clinical development 
but the NCI discontinued further studies because it was concluded from infusion 
studies in dogs
224
 that the alkaloid had unacceptable levels of neurotoxicity and a 
narrow therapeutic index
225
. The narrow therapeutic index could be partially 
explained by michellamine B’s inhibitory activity against cellular DNA 
polymerases
222, 225
. 
B. Michellamines acting as antioxidants 
The michellamines were also reported to be potent antioxidants by inhibiting the 
azo-induced oxidation of β-phycoerythrin with IC50 values ranging from 0.5 to 
0.8 µM which means they were as active as trolox, a vitamin E analogue
226
. 
Moreover, it was shown that rat liver mitochondria was protected against lipid 
peroxidation by michellamine B
226
. 
C. Inhibition of protein kinase C 
The michellamines (A, B and C) were investigated for protein kinase C (PKC) 
inhibition because of their structural similarity to other PKC inhibitors 
(perylenequinones
227
)
212
.  
PKC isoforms are a family of enzymes that play an important role in signal 
transduction pathways, therefore in a wide range of cellular processes such as cell 
proliferation. These enzymes can also act as a receptor for the tumour-promoting 
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phorbol esters which makes them an interesting target for inhibitor development 
in cancer research
212
. They transfer the γ-phosphate of ATP or GTP to an alcohol 
phenol group of proteins. They have a phospholipid-dependent regulatory domain 
that can be activated by diacylglycerol or Ca
2+
, and an ATP and peptide substrate 
binding catalytic domain which is relatively conserved in the enzyme family
212, 
228
. 
The michellamines (A, B and C) showed inhibition against rat brain PKC with 
IC50 values ranging from 15–35 µM. The most potent inhibitor, michellamine B 
inhibited the kinase domain of PKC in a non-competitive manner with respect to 
ATP (Ki value of 20 µM) and mixed-type inhibition was assumed for the peptide 
substrate (Ki’ value of 3 µM). Michellamine B inhibited the kinase domain both in 
the presence or absence of phospholipid and Ca
2+
. The authors developed a model 
where the michellamines bind to the active site cleft of the kinase domain not to 
the regulatory domain of PKC and block both the ATP and the peptide substrate 
binding sites
212
. 
D. Inhibition of human lipoxygenases 
Human lipoxygenases are a family of iron-containing enzymes catalysing the 
incorporation of oxygen into polyunsaturated fatty acids to form hydroperoxy 
acids while their metal cofactor changes its oxidation state (Fe
2+
 to Fe
3+
)
213
. They 
are involved in various diseases such as inflammatory responses, cancers, and 
kidney diseases, however different isoenzymes have different biological activities, 
therefore their inhibitors should be selective
229
.  
Deschamps et al developed a high-throughput 384-well plate xylenol orange assay 
in order to screen libraries from the NCI diversity set and the UC Santa Cruz 
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marine library against platelet type 12-hLO that is largely implied in cancer 
regulation (pancreatic, breast and prostate cancer). They also tested the hits 
against 15-hLO-1 and 2. 15-hLO-1 is also associated with colorectal and prostate 
cancer. On the other hand 15-hLO-2 was suggested to play an anti-tumorigenic 
role in prostate cancer. One of their hits from the NCI diversity set was 
michellamine B, which was found to inhibit 12-hLO and 15-hLO-1 with IC50 
values of 4.9 µM and 7.6 µM and did not inhibit 15-hLO-2. This discovery also 
made michellamine B a potentially interesting anti-tumour agent
213
. 
3.4 Summary of screening the NCI diversity set 
Table 3-3 summarises the process of screening the diversity set of the National 
Cancer Institute against E. coli MraY. 
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Table 3-3: Summary of screen 
Total of 1,717 compounds in diversity set III and natural products set II 
 
Assay method 
diversity set III, 
1,597 compounds 
natural products 
set II, 120 compounds 
   
Fluorescence 
microtitre plate assay, 
compounds tested at 
100 µM 
1,252 compounds with 
no inhibition, 
222 HF compounds 
123 low fluorescence 
compounds 
88 compounds with no 
inhibition, 
21 HF compounds 
11 LFA compounds 
   
Continuous 
fluorescence assay, 
compounds tested at 
60 µM 
 
72 LFA compounds 
51 LF compounds 
 
11 LFA compounds 
 
   
Radiochemical assay, 
compounds tested at 
100 and/or 500 µM 
 
51 LF compounds 
tested at 100 µM, 0 hits, 
3 out of 51 LF 
compounds also 
checked at 500 µM, 
0 hits 
 
21 HF and 11 LFA 
compounds tested at 
500 µM,  
0 hits from LFA 
compounds, 
1 hit from HF 
compounds,  
michellamine B 
 
 
We tested 1, 597 compounds from the diversity set III and 120 compounds from 
the natural products set II plates against E. coli MraY by the microtitre plate 
fluorescence assay at 100 µM concentrations. 1,252 plus 88 compounds showed 
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less than 20 % inhibition in the assay and therefore were excluded from further 
tests (no inhibition). 222 compounds plus 21 natural products showed high 
fluorescence and could not be tested by the fluorescence method (λex: 340 nm, 
λem; 535 nm). A total of number of 134 compounds was tested by the continuous 
fluorescence assay against E. coli MraY, where 51 was classified as low 
fluorescence compounds and 83 as low fluorescence compounds with 
fluorescence enhancement activity. The 51 low fluorescence compounds were 
tested by a radiochemical MraY assay against E. coli MraY at 100 µM and their 
activity was above the 80 % limit that we set. However, three of them with 10 % 
apparent inhibition were tested at 500 µM as well but the results showed that there 
was no inhibition at higher concentrations.  
Finally, we tested 11 LFA and the 21 HF compounds by the radiochemical MraY 
assay from the natural products set II, and found 1 hit with 60 % inhibition. The 
compound is called michellamine B. IC50s were determined for michellamine B 
against E. coli and B. subtilis MraYs, 400 ± 50 and 338 ± 54 µg/ml respectively. 
Interestingly, the compound showed antibacterial activity (MIC: ~15.6 µg/ml) 
against B. subtilis, the bacteria against which the MraY inhibition was the 
strongest.  
3.5 Future work in the field of naphthylisoquinoline 
alkaloids 
Professor Gerhard Bringmann's research group (University of Würzburg) works in 
the field of natural products isolated from tropical plants for the search for novel 
bioactive agents against infectious diseases such as malaria and African sleeping 
sickness.  
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For future work, in collaboration with Professor Gerhard Bringmann’s group, it 
would be interesting to test some of the monomeric naphthylisoquinoline 
analogues (Figure 3-14) against MraY. Perhaps, it would be even more interesting 
to test the structurally related novel naphthylisoquinoline dimers (Figure 3-15) 
isolated from Congolese Ancistrocladus species that possess a rotationally 
hindered biaryl axis between the two monomer units, an additional seventh 
element of chirality (in red in Figure 3-15) compared to the michellamines with 
six elements of chirality.  
 
Figure 3-15: Chemical structure of jozimine A2, the structurally related 
shuangancistrotectorine and mbandakamine A and B, the seventh element of chirality is the 
rotationally hindered biaryl axis between the two monomer units (in red) 
jozimine A2 
shuangancistrotectorine 
mbandakamine A 
mbandakamine B 
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One of the options for testing naphthylisoquinoline dimers against MraY would 
be jozimine A2 with excellent antiplasmodial activity, the first dioncophyllaceae-
type naphthylisoquinoline alkaloid 
219
 and shuangancistrotectorine a structurally 
closely related natural alkaloid 
219
. Another interesting option would be the anti-
malarial mbandakamine A and mbandakamine B
230
. These molecules too have an 
exceptionally high steric hindrance in the bi-naphthalene core, thus they also 
possess seven elements of chirality
230
. 
The testing of further naphthylisoquinoline analogues could make it possible to 
perform some structure-activity relationship studies which would help to elucidate 
the mechanism of action of michellamine B inhibition and perhaps locate a novel 
site of interaction with MraY. 
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4 Screening for new natural product inhibitors 
Streptomyces belong to the group of soil-dwelling, filamentous Gram-positive 
bacteria with high guanine-cytosine containing genome, called Antinomycetes
231, 
232
. Antinomycetes produce over two-thirds of the clinically useful antimicrobial 
agents of microbial origin as well as anti-tumour agents and immunosuppressants. 
In the soil they play a crucial role in carbon recycling by degrading insoluble 
remains of other organisms, such as lignocellulose and chitin
233
. Most of them 
develop a mycelial habit at some stage in their complex life-cycle such as 
Streptomyces coelicolor that differentiates by forming specialized, spore-bearing 
hair-like aerial mycelia on the colony surface that grow into the air. On the other 
hand, mutant colonies have a smooth, undifferentiated appearance which gave the 
name ‘bld’ (bald) to the genes required for the initiation of aerial mycelium 
formation
234
. The complete genome of Streptomyces coelicolor A(3)2 as a model 
organism for pathogenic bacteria from the same taxonomic order such as 
Mycobacterium tuberculosis, M. leprae and Corynebacterium diphtheria, has 
been sequenced by Bentley et al (2001)
233
. 
The antibiotic production (Figure 4-1) of Streptomyces is growth phase-
dependent. In liquid culture, antibiotic production begins in stationary phase, 
while in solid media it starts with morphological differentiation. The antibiotics 
are secondary metabolites of biosynthetic pathways where around 20-30 genes are 
responsible for the production of one compound
235
. The onset of antibiotic 
synthesis is regulated by several factors such as growth rate, γ-butyrolactone 
signalling molecules
236
, imbalances in metabolism
237
 and physiological 
stresses
235
.  
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Figure 4-1: Antibiotic droplet from a Streptomyces colony (Higher Education and Research 
Opportunities, the John Innes Centre) 
Table 4-1 shows examples for antibacterial drugs currently used in medicine 
produced by Antinomycetes
235
. 
 
Figure 4-2: Chemical structures of A-94964 and A-90289 A and B 
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Table 4-1: Examples for antibacterial agents produced by Antinomycetes
235
 
Antibiotic Producer Chemical class Target 
Chloramphenicol S. venezuelae 
N-dichloroacyl 
phenylpropanoid 
“ribosome inhibitor” 
Chlortetracycline S. aureofaciens Tetracycline polyketide “ribosome inhibitor” 
Clavulanic acid S. clavuligerus β-lactam β-lactamase inhibitor 
Cycloserine S. orchidaceus 
Substituted cyclic 
peptide 
peptidoglycan 
biosynthesis 
Daptomycin S. roseosporus Lipopeptide 
lipoteichoic acid 
biosynthesis 
Erytromycin Sac. erythraea Macrolide polyketide “ribosome inhibitor” 
Fortimicin 
Micromonospora 
olivoasterospora 
Aminoglycoside “ribosome inhibitor” 
Fosfomycin S. spp. Phosphoric acid 
peptidoglycan 
biosynthesis 
Gentamicin Micromonospora spp. Aminoglycoside “ribosome inhibitor” 
Kanamycin S. kanamyceticus Aminoglycoside “ribosome inhibitor” 
Lincomycin S. lincolnensis Sugar-amide “ribosome inhibitor” 
Neomycin S. fradiae Aminoglycoside “ribosome inhibitor” 
Nocardicin Nocardia uniformis β-lactam 
peptidoglycan 
biosynthesis 
Novobiocin S. niveus Coumerin glycoside DNA gyrase 
Oleandomycin S. antibioticus Makrolide polyketide “ribosome inhibitor” 
Oxytetracycline S. rimosus 
Teteracycline 
polyketide 
“ribosome inhibitor” 
Rifamycin 
Amycolatopsis 
mediterranei 
Ansamycin polyketide RNA polymerase 
Ristocetin Nocardia lurida Glycopeptide 
peptidoglycan 
biosynthesis 
Spectinomycin S. spectabilis Aminocyclitol “ribosome inhibitor” 
Spiramycin S. ambofaciens Macrolide polyketide “ribosome inhibitor” 
Streptogramins S. graminofaciens Macrocyclic lactones “ribosome inhibitor” 
Streptomycin S. griseus Aminoglycoside “ribosome inhibitor” 
Teichoplanin 
Actinoplanes 
teichomyceticus 
Glycopeptide 
peptidoglycan 
biosynthesis 
Tetracycline S. aureufaciens Tetracycline polyketide “ribosome inhibitor” 
Thienamycin S. cattleya β-lactam 
peptidoglycan 
biosynthesis 
Tobramycin S. tenebrarius Aminoglycoside “ribosome inhibitor” 
Vancomycin 
Amycolatopsis  
orientalis 
Glycopeptide 
peptidoglycan 
biosynthesis 
 
The nucleoside natural product inhibitors of the MraY enzyme are all secondary 
metabolites of various Streptomyces strains such as the pacidamycins, produced 
by S. coeruleorubidus (Section 5.1.3). 
Researchers have used microtitre plate fluorescence-based assays to screen for 
MraY inhibitors, and successfully identified a novel nucleoside antibiotic,          
  
 
164 
 
A-94964 (IC50: 1.1 µg/ml) from culture broth Streptomyces sp. SANK 60404 with 
a unique structure, partially resembling to tunicamycin
238
 (Figure 4-2). In 
addition, two liposidomycin related compounds, A-90289 A and B (Figure 4-2), 
were identified from SANK 60405 with IC50 values of 36.5 and 33.8 ng/ml 
respectively
239
. 
Since three other research groups in the Chemical Biology Cluster work with 
Streptomyces natural product producers, the aim of this chapter was to investigate 
the possibility of detecting inhibition directly from Streptomyces culture 
supernatants and cell extracts of the known pacidamycin producer, 
S. coeruleorubidus by the fluorescence or the radiochemical MraY assays. We 
were to use these methods in order to identify potentially new natural product 
inhibitors of MraY from a range of Streptomyces strains.  
4.1 Assay of culture supernatants 
We first wanted to test a strain which is known to produce an MraY inhibitor, as a 
positive control. S. coeruleorubidus grown on 20 % (w/v) mannitol and soya 
containing agar plates (MS agar) was a gift from Dr. Rebecca Goss (University of 
St Andrews). 10 ml of a rich medium (ISP2) containing 4 g yeast extract, 10 g 
malt extract, 4 g glucose / litre, was inoculated with 10 µl spore stock solution of 
S. coeruleorubidus and incubated at 30 ºC for 2 days at 30 ºC. Then, 50 µl of the 
culture were used to inoculate 10 ml ISP2 and 1 % lactose containing minimal 
medium (Lac-MM), and the cultures were incubated for 8 days at 30 ºC. The 
cultures were centrifuged for 2 minutes at 5,000 x g and 10 µl of the supernatants 
were tested against MraY by the continuous and microtitre plate fluorescence 
MraY assays against E. coli MraY. B. subtilis was used as a control strain, as not 
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known to produce MraY inhibitors, as well as ISP2 and Lac-MM medium was 
used as negative controls.  
The continuous fluorescence assay (Figure 2-2) was carried out as described in 
Section 7.10. A total volume of 180 µl contained 30 µM dansyl-labelled 
UDPMurNAc-pentapeptide, 35 µg/ml heptaprenyl phosphate in 83 mM Tris 
pH 7.5, 21 mM MgCl2 and the reaction was started by the addition of 60 µg 
overexpressed E. coli MraY membranes (Figure 4-3). 
 
  
 
 
 
 
 
 
The S. coeruleorubidus culture supernatants tested in 8 % assay volume (15 µl in 
180 µl) from both Lac-MM and ISP2 media showed over 93 % and 91 % 
inhibition respectively in the continuous fluorescence MraY assay after 8 days of 
incubation at 30 ºC. However, it was not possible to detect the presence of any of 
the known pacidamycins in the sample by LC-MS due to the low abundance of 
the compounds. 
120
140
160
180
200
220
0 180 360 540
FAU 
Time (sec) 
120
140
160
180
200
220
0 180 360 540
FAU 
Time (sec) 
S. coeruleorubidus  
day 7 (black)   
S. coeruleorubidus day 8 
B. subtilis (green) 
ISP2 controls (blue and red) 
B. subtilis (green) 
Lac-MM controls (blue and red) 
S. coeruleorubidus 
Figure 4-3: S. coeruleorubidus grown in Lac-MM (left) and ISP2 media (right) and tested by 
the continuous fluorescence MraY assay after 8 days incubation at 30 ºC, λex: 340 nm, λem: 
530 nm 
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4.1.1 Screening Streptomyces culture supernatants 
S. venezuelae, S. fungicidicus, S. longispororubes, S. ambofacient, S. albus, 
S. avermitilis DSM 41443, S. coelicolor A3(2) and eight S. coelicolor mutants 
were also grown in Lac-MM and ISP2 media and tested against E. coli MraY by 
the continuous and the microtitre plate-reader fluorescence MraY assay (see 
Section 7.25.1.1). Figure 4-3 shows the example for the culture supernatants from 
Lac-MM media. 
 
Figure 4-4: Streptomyces strains grown in Lac-MM media, tested in the fluorescence MraY 
assay, λex: 340 nm, λem: 535 nm 
No inhibition was found in the culture supernatants from ISP2 or Lac-MM media. 
4.2 Assay of Streptomyces cell extracts from John Sidda 
John Sidda works in the field of natural products in Dr. Christophe Corre’s 
research group at the University of Warwick. They recently published the 
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inactivation of gbnR, a pathway specific transcriptional repressor gene, in 
S. venezuelae which induced the production of a novel group of compounds, the 
gaburedins (γ-aminobutyrate ureas, see Figure 4-5)240 and which may induce the 
production of other natural products. The deletion of gbnB in the gbnR mutant 
abolished gaburedin production which was consistent with the hypothesis of gbnA 
and gbnB genes being responsible for their production
240
.  
 
Figure 4-5: Chemical structure of gaburedin A, the conserved GABA fragment is shown in 
the red box 
John Sidda generously provided us with some of his cell extracts from 
S. venezuelae gbnR mutants and the wild type. These strains were grown by John 
Sidda on a supplemented minimal agar medium (SMMS) for three days, the 
acidified agar medium was extracted with ethyl acetate and dried and re-
suspended in 50 % methanol/water
240
: 
 JDS349 S. venezuelae wild type culture extract 
 JDS369 S. venezuelae gbnR mutant, which produces novel compounds 
that are not characterized yet 
 JDS374 S. venezuelae gbnB/gbnR mutant, which only produces some of 
the novel compounds that have not been fully characterized yet, but does 
not produce gaburedins 
 JDS198 S. venezuelae gbnR mutant, which overproduces gaburedin-Val 
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 JDS352 S. venezuelae gbnR mutant, which overproduces gaburedin-
GABA 
 JDS316 S. venezuelae gbnR mutant, which overproduces gaburedin-Pro 
These cell extracts were tested by the microtitre plate fluorescence assay and the 
most active samples were also tested by the radiochemical MraY assay (Figure 
2-43) against recombinant E. coli MraY. 
 
 
 
 
 
 
 
 
The cell extract JDS374, the S. venezuelae gbnB/gbnR mutant, was found to be 
the most active against E. coli MraY with 95 % inhibition in the fluorescence 
assay and 99 % inhibition by the radiochemical assay. Even the wild type 
S. venezuelae (JDS349) showed 50 % and 65 % inhibition in the fluorescence and 
the radiochemical assay respectively (Figure 4-6). The apparent weaker inhibition 
of the samples in the fluorescence assay can be explained by the fact that some of 
the cell extracts showed high fluorescence, such as JDS 316 with the highest 
fluorescence, which was confirmed by the continuous fluorescence assay.  
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Figure 4-6: John's Sidda's cell extracts tested by the microtitre plate fluorescence assay (left) 
and the radiochemical assay (right) against E. coli MraY 
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The cell extract JDS374 was fractionated by John Sidda by preparative HPLC 
using a linear gradient of methanol/water from 5 % up to 100 % methanol over 
35 minutes. John Sidda took a sample of 7 ml for 30 seconds every 2 minutes 
(from 5 to 31 minutes). The fractions were tested again by the fluorescence 
microtitre plate MraY assay but no inhibition was found (Figure 4-7). The 
methanol was then evaporated and the samples were assayed again but no 
inhibition was found.  
 
Figure 4-7: Testing the fractionated JDS374 cell extract by the microtitre plate fluorescence 
assay, fractions collected from 5 to 31 minutes (5f-31f) 
Possibly, the compound was missed during the HPLC separation. John Sidda also 
provided us with his low resolution LC-MS data on the JDS374 cell extract 
sample. We analysed his data and at 29 minutes retention time a peak was 
observed at m/z [M+H]
+
:
 
879.5 corresponding to a compound of molecular weight 
878.5 Da. This is similar to the molecular weight range for the 
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pacidamycin/mureidomycin family of uridyl-peptide natural products (Mw: 765-
899), but this mass and the isotopic pattern for the positively and singly charged 
ion do not match any of the known compounds. It could in theory be a novel 
member of this family, but it could be completely unrelated, and we do not know 
whether the observed MraY inhibition is due to this compound.  
4.3 Screening Streptomyces cell extracts from solid media  
John Sidda’s cell extract preparation procedure for Streptomyces strains grown on 
supplemented minimal agar media
240
 was used to prepare more cell extracts for 
screening against E. coli MraY. We wished to test the wild type S. venezuelae and 
various Streptomyces strains and mutants in solid media as well, despite the fact 
that they did not inhibit in liquid culture (Section 4.1).  
10 µl of stock spore collections was spread on MS agar plates and incubated for 
10 days (only S. venezuelae and S. coeruleorubidus) or SMMS plates and 
incubated for 3 days at 30 ºC. Secondary metabolites were extracted by ethyl 
acetate in equal volume to the volume of culture media used. The ethyl acetate 
layer was removed by filtration and evaporated under reduced pressure. The 
remaining residue was re-dissolved in 500 μl 50:50 HPLC grade methanol/water. 
Because some of the cell extracts interfered with fluorescence, all the samples 
were tested by the radiochemical MraY assay. 
The total volume of 100 µl sample contained 1.7 µM 
14
C-labelled UDPMurNAc-
pentapeptide (3.38 nCi, 7,500 dpm), 27 µg/ml heptaprenyl phosphate and 40 µg 
protein containing overexpressed E. coli C43 membranes in 90 mM Tris pH 7.5, 
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23 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-
100. The assays were carried out as in Section 7.19. 
 
 
Figure 4-8: Streptomyces cell extracts from solid media tested by the radiochemical assay 
against E. coli MraY, all the strains were grown for 3 days on SMMS media and 
S. coeruleorubidus and S. venezuelae were grown on MS agar plates as well, the control 
contains 10 % methanol/water (1:1)  
Interestingly, from the pacidamycin producer S. coeruleorubidus cell extract, no 
inhibition was detected from SMMS media, suggesting that on that media it will 
not produce the pacidamycin analogues in detectable quantity. However, grown 
on MS agar plate, the cell extract showed 29 % inhibition, which is still 
significantly lower than the 93 % and 91 % inhibition that we detected from 10 µl 
liquid culture.  
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The S. venezuelae cell extract that was extracted from SMMS media showed only 
16 % inhibition compared to John Sidda’s wild type cell extract with 65 % 
inhibition in the radiochemical MraY assay. A further attempt was made to grow 
the wild type S. venezuelae for longer (incubation time 10 days) but this time no 
inhibition at all was detected in the sample. When S. venezuelae was grown on 
MS agar, the cell extract showed 26 % inhibition. One important difference 
compared to John Sidda’s procedure is that he acidified the solid media using 
hydrochloric acid during the extraction protocol which could lead to the 
decomposition of metabolites in the cell extract.  
None of the other Streptomyces cell extracts showed inhibition against E. coli 
MraY (Figure 4-8). 
Nevertheless, we have identified from John Sidda’s cell extracts that 
S. venezuelae appears to produce a natural product MraY inhibitor, which is not 
one of the already identified gaburedins, because the gbnB gene was deleted in the 
most active gbnR mutant. However, the production of this compound must require 
very specific conditions. It is quite possible that this is a known uridyl-peptide 
inhibitor, but it would require additional work to confirm this. 
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5 Assay of novel and known MraY inhibitors 
5.1 Inhibition of translocase MraY by uridyl-peptide 
natural products and their synthetic analogues  
The uridyl-peptide natural products were suggested to target the active site of 
MraY at the cytoplasmic face of the membrane (see Section 1.3.1). Previously 
uridyl-peptide natural products were tested by P. Brandish against translocase 
MraY by the means of the continuous fluorescence enhancement assay (1992-95). 
Availability of other MraY enzymes allows us to compare specificity of inhibition 
for five MraY enzymes; also new synthetic uridyl-peptide analogues have become 
available to us during the project.  
The general procedure applies for the continuous fluorescence assays (Figure 2-2), 
unless otherwise specified (see Section 7.10). The graphs showing % activity vs. 
inhibitor concentration for IC50 determination, if not featuring in this chapter, are 
shown in Appendix 5. 
5.1.1 Inhibition by a synthetic muraymycin derivative 
The muraymycins nucleoside-lipopeptide antibiotics were first isolated from 
Streptomyces sp. They show antimicrobial activity against Gram-positive bacteria 
such as Staphylococcus aureus and Enterococcus strains which makes them 
attractive candidates for drug development because of the emergence of MRSA 
and VRE strains
186
. 
A new synthetic muraymycin analogue, the 5’-deoxy muraymycin as the bis-TFA 
salt (Figure 5-1), was sent by Professor Christian Ducho (Paderborn University) 
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whose group developed a modular tripartite synthetic approach towards 
synthesising this group of nucleoside peptide MraY inhibitor
241
. We wished to test 
this compound against E. coli and S. aureus MraY because the muraymycins have 
antibacterial activity against S. aureus MraY. 
 
Figure 5-1: Chemical structure of the synthetic muraymycin analogue, Mw: 1012.5973 and 
the parent compound with the aminosugar (muraymycin D2) 
The inhibitory activity of the compound was investigated against MraY by the 
means of the continuous fluorescence assay in a total volume of 170 µl containing 
23 µM dansyl-labelled UDPMurNAc-pentapeptide, 29 µg/ml heptaprenyl 
phosphate in buffer 83 mM Tris pH 7.5, 21 mM MgCl2, and the reaction was 
started by the addition of 90 µg protein containing recombinant E. coli or 
S. aureus MraY membranes (Figure 2-23, Figure 5-2, A 23 and A 24 in 
Appendix 5a).  
 
 
R  =  H for 5’-deoxy muraymycin bis-TFA salt 
R  = for the parent compound with the 
aminosugar, muraymycin D2 
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The muraymycin derivative inhibited recombinant MraY from E. coli and 
S. aureus in the low µM range (IC50: 1.6 ± 0.3 µM for E. coli and 1.6 ± 0.2 µM 
for S. aureus MraY). This inhibitory potency is very similar to the one for 
tunicamycin (IC50: 1.9 µM
143
). However, the parent compound with the 5’O-
aminoribose unit had been reported to be significantly more active (IC50: 
0.01 µM
187
) indicating the importance of this sugar unit in MraY binding. The 
IC50 for the parent compound was determined by a radiochemical TLC assay 
against purified B. subtilis MraY and the compound showed no antibacterial 
activity which was explained by the lack of a lipophilic side chain
187
. 
In addition, the muraymycin analogue also showed inhibition against 
P. aeruginosa, B. subtilis and M. flavus MraY at 50 µM concentrations with 
estimated 98 %, 89 % and 85 % inhibition (Figure 5-3). 
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Figure 5-2: Muraymycin analogue inhibition against E. coli MraY, λex: 340 nm, λem: 
530 nm, 90 µg protein (left), IC50: 1.6 ± 0.3 µM (right) 
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The uridyl-peptide antibiotics interact with MraY at the catalytic binding site on 
the cytoplasmic phase of the membranes where the suggested catalytic residues 
are conserved for all five organisms. Therefore, it is not surprising to see 
inhibition of MraY from all five organisms. 
The aminosugar of the liposidomycin and the caprazamycin uridyl-peptide 
antibiotics were shown to be important for activity
156
, so it is interesting that the 
5’-deoxy muraymycin analogue retains inhibitory activity. The results suggest that 
the peptide chain is involved in binding to the active site of MraY. 
0 µM 
B. subtilis MraY 
50 µM 
0 µM (blue) 
0.05 µM (purple) 
5 µM 
25 µM 
50 µM 
50 µM 
M. flavus MraY 
P. aeruginosa MraY 
0 µM 
Figure 5-3: Muraymycin analogue inhibition against P. aeruginosa, B. subtilis and M. flavus 
MraY, 40-90 µg protein, λex: 340 nm, λem: 530 nm 
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5.1.2 Inhibition by caprazamycin derivatives 
The caprazamycins, potent liponucleoside inhibitors of MraY were isolated from 
Streptomyces sp. MK730-62F2. They have potent antibacterial activity against 
mycobacteria and do not exhibit significant toxicity in mice
177-180
. Hirano et al 
synthesized a palmitoylcaprazol analogue which had antimicrobial activity against 
MRSA (MIC: 6.25 µg/ml) and VRE (MIC: 12.5 µg/ml)
180
. 
The caprazamycins are structurally related to liposydomycins and their structure is 
derived from 5'-(β-O-aminoribosyl)-glycyluridine with a unique N,N'-
dimethyldiazepanone ring. The name of the caprazamycin analogues (A–G) 
comes from the attached β-hydroxy-fatty acids of different chain length. The 
absence of a sulphate group at the 2’’-position of the aminoribose and the 
presence of a permethylated L-rhamnose makes them different to 
liposidomycins
173, 174
. Figure 5-4 shows the chemical structure for 
caprazamycin A and E. 
 
 
Figure 5-4: Chemical structure of caprazamycin A on the left (Exact mass: 1145.58) and 
caprazamycin E on the right (Exact mass: 1117.55), the additional unit compared to 
hydroxyacyl-caprazol A and E are circled in red 
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In order to develop clinically useful drugs the permeability of caprazamycin 
analogues into bacterial cells should be improved by optimizing the lipophilic side 
chain. In addition, work needs to be done on simplifying the hydrophilic core 
structures, and reducing the size of the molecules
180
. 
The biosynthetic gene clusters of the caprazamycins and the liposidomycins were 
compared, and the set of genes responsible for the sulphating of the 
liposidomycins were identified as well as similar genes were found adjacent to the 
caprazamycin gene cluster leading to the identification of new sulphated 
caprazamycin derivatives
177, 242
. Sulphating considerably alters the compounds 
solubility, charge and size
242
 which are important features in drug design. 
Professor Bertolt Gust’s research group at the University of Tübingen works in 
the field of liponucleoside and uridyl-peptide MraY inhibitors and sent us new 
caprazamycin analogues to test their inhibitory potential against E. coli MraY in 
order to establish some structure-activity relationship. The following samples 
were sent to be analysed: hydroxyacyl-caprazol A and E, compounds generated 
enzymatically from hydroxyacyl-caprazol E (hydroxyacyl-caprazol E-acetate and 
hydroxyacyl-caprazol E-butyrate) and sulphated caprazamycin aglicon A and E. 
All of the samples lack the permethylated L-rhamnose unit from their structure. 
The sulphated caprazamycin aglycons have exactly the same chemical structure as 
members of the liposidomycins. Figure 5-5 shows the chemical structure of the 
samples, the units that make them different from the hydroxyacyl caprazol core 
structure are circled in red. 
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The caprazamycin analogues were tested by the continuous fluorescence assay 
against recombinant E. coli MraY in a total volume of 180 µl containing 30 µM 
dansyl-labelled UDPMurNAc-pentapeptide, 35 µg/ml heptaprenyl phosphate in 
buffer 83 mM Tris pH 7.5, 21 mM MgCl2 and the reaction was started by the 
addition of 90 µg protein containing recombinant E. coli MraY membranes.  
Figure 5-6 shows the example for one of the interesting new compounds, 
hydroxyacyl-caprazol E-acetate, which proved to be less active by the 
fluorescence assay against E. coli MraY than hydroxyacyl-caprazol E. 
 
 
hydroxyacyl-caprazol E  
Monoisotopic mass:  
801.5 
hydroxyacyl-caprazol A  
Monoisotopic mass: 
829.6 
hydroxyacyl-caprazol E-
acetate  
Monoisotopic mass:  
843.4 
hydroxyacyl-caprazol E-butyrate   
Monoisotopic mass:  
871.4  
sulphated CPZ aglycon E  
Monoisotopic mass: 
1009.4 
sulphated CPZ aglycon A  
Monoisotopic mass: 
1037.4  
Figure 5-5: Chemical structure of caprazamycin analogues, the additional groups 
compared to hydroxyacyl-caprazol E and A are circled in red 
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Table 5-1 summarizes the results for the measured IC50s for all of the 
caprazamycin analogues (Figures A 25 - A 30 in Appendix 5b). 
Table 5-1: IC50s of caprazamycin analogues against E. coli MraY 
Caprazamycin analogue IC50 against E. coli MraY 
hydroxyacyl-caprazol A 0.339 ± 0.035 µg/ml, 0.41 µM 
hydroxyacyl-caprazol E 0.602 ± 0.019 µg/ml, 0.75 µM 
hydroxyacyl-caprazol E-acetate 1.21 ± 0.13 µg/ml, 1.4 µM 
hydroxyacyl-caprazol E-butyrate 5.78 ± 0.41 µg/ml, 6.6 µM 
sulphated CPZ aglycon E 0.314 ± 0.042 µg/ml, 0.31 µM 
sulphated CPZ aglycon A 0.250 ± 0.035 µg/ml, 0.24 µM 
 
The A analogues with the 2-unit longer lipophilic chain seem to be slightly more 
active than E. The most active compound in the fluorescence assay against E. coli 
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Figure 5-6: Hydroxyacyl-caprazol E-acetate inhibition against E. coli MraY, IC50: 
1.21 ± 0.13 µg/ml 
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MraY is the sulphated caprazamycin aglycon A with an IC50 value of 0.24 µM. 
The presence of the sulphate group makes the structure identical to the 
liposidomycins. The sulphated caprazamycin aglycon E has very similar 
inhibitory activity with 0.31 µM, perhaps it is a marginally less active compound. 
The IC50 values of the butyrate and acetate derivatives of hydroxyacyl-caprazol E 
increased nine and two fold respectively which means that the less polar esters are 
significantly less active than hydroxyacyl-caprazol E or the sulphated 
caprazamycin aglycons.   
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5.1.3 Inhibition by pacidamycin derivatives 
The pacidamycins are uridyl tetra/pentapeptide antibiotics structurally related to 
the mureidomycins and the napsamycins
10
. Pacidamycins 1-7 were isolated from 
S. coeruleorubidus strain AB 1183-64
163-165
 and pacidamycin D, 4N and 5T were 
isolated from strain NRRL 18730
166
. They show antibacterial activity against 
Pseudomonas species
165
, and pacidamycin D was found to be active against 
P. aeruginosa as well
166
. Figure 5-7 shows the chemical structure for pacidamycin 
1, 2 and D.  
 
 
 
 
 
 
 
 
The pacidamycin 1,2 and D samples were provided by Antoine Abou Fayad 
(University of St Andrews) and tested in a total volume of 180 µl containing 
30 µM dansyl-labelled UDPMurNAc-pentapeptide, 35 µg/ml heptaprenyl 
phosphate in buffer containing 83 mM Tris pH 7.5, 21 mM MgCl2 against E. coli 
and P. aeruginosa MraY (90 µg protein). Since the pacidamycins show 
Figure 5-7: Chemical structure for pacidamycin 1, 2 and D 
pacidamycin 1 
Exact mass: 876.38 
pacidamycin 2 
Exact mass: 835.35 
pacidamycin D 
Exact mass: 711.30 
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antibacterial activity against P. aeruginosa, it was of interest to test the 
compounds against P. aeruginosa MraY.  
Figure 2-22 and Figure 5-8 show the graphs for the fluorescence measurements. 
 
 
 
 
 
 
 
Table 5-2 shows the IC50s that were measured by the continuous fluorescence 
assay against E. coli and P. aeruginosa MraY. The remaining graphs for 
% activity vs. inhibitor concentration are shown in Figures A 31 - A 34 in 
Appendix 5c. 
Table 5-2: Pacidamycin 1,2 and D inhibition against E. coli and P. aeruginosa MraYs, IC50s 
Pacidamycin analogue E. coli MraY IC50  P. aeruginosa MraY IC50  
Pacidamycin 1, 2  83 ± 7 ng/ml, 97 nM 114 ± 5 ng/ml, 130 nM 
Pacidamycin D  46 ± 7 ng/ml, 65 nM 27 ± 4 ng/ml, 38 nM 
Pacidamycin D was a more active compound than the pacidamycin 1,2 sample, 
and showed two-fold higher activity against P. aeruginosa MraY whereas 
pacidamycin 1,2 was slightly less active against P. aeruginosa.  
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Figure 5-8: Pacidamycin 1,2 inhibition against P. aeruginosa MraY tested between 0-
0.88 µg/ml, 90 µg protein, , λex: 340 nm, λem: 530 nm, IC50: 114 ± 5 ng/ml 
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5.1.4 Inhibition by tunicamycin 
The tunicamycins are well known reversible
143
 nucleoside disaccharide inhibitors 
of MraY and commercially available (Sigma), therefore it was used as a positive 
control during assay development. They were first isolated from S. lysosuperficus 
and have antibacterial activity against Gram-positive bacteria
150
. Unfortunately, 
tunicamycin can not be used as an antibacterial agent because it inhibits GlcNAc-
1-phosphate transferase in mammalian N-linked glycoprotein biosynthesis
153
: 
 
 
 
Figure 5-9: Chemical structure of tunicamycins, n: 7-11, and the reaction they inhibit in 
mammalian N-linked glycoprotein biosynthesis 
Tunicamycin was tested in our research group by the continuous fluorescence 
MraY assay, and the determined IC50s are shown in Table 5-3 for MraY from 
E. coli, P. aeruginosa, S. aureus and B. subtilis with values ranging between 0.6-
4.4 µg/ml.  
Dolichyl phosphate + UDPGlcNAc Dolichyl-pyrophosphoryl-GlcNAc + UMP 
GlcNAc-1-phosphate transferase 
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Table 5-3: Tunicamycin inhibition by a fluorescence assay against MraYs from E. coli, 
P. aeruginosa, S. aureus, B. subtilis and M. flavus, a: determined by P. Brandish
143
, 
b: determined by A. O’Reilly 
MraY Tunicamycin IC50 (µg/ml) 
E. coli MraY  1.0
a
 
P. aeruginosa MraY 4.44 ± 1.38  
S. aureus MraY  1.4
b
 
B. subtilis MraY  0.6
b
 
M. flavus MraY 95 % inhibition at 83 µg/ml 
 
Tunicamycin was tested against P. aeruginosa in a total volume of 180 µl 
contained 30 µM dansyl-labelled UDPMurNAc-pentapeptide, 35 µg/ml 
heptaprenyl phosphate in 83 mM Tris pH 7.5, 21 mM MgCl2 and the reaction was 
started by the addition of 45 µg recombinant P. aeruginosa MraY membranes (see 
general procedure in Section 7.10). IC50 was determined as 4.44 ± 1.38 µg/ml 
(data in Appendix 5d, Figure A 35) which is 4 fold higher than the IC50 for E. coli, 
S. aureus and B. subtilis MraYs. In addition, evidence from the radiochemical 
assays shows (Table 3-2) that tunicamycin is less active against P. aeruginosa 
MraY (72 % inhibition) than against E. coli, S. aureus and B. subtilis MraY (93-
97 % inhibition) at high concentrations (125 µg/ml). 
5.1.5 Inhibition by capuramycin derivatives 
Samples of well-known capuramycin analogues, A-503083 F and A-503083 B, 
were sent by Steven Van Lanen (University of Kentucky). The reason for testing 
these compounds against E. coli MraY was to assay them against two MraY 
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mutants (F288L and E287A) as well and compare the IC50 values in order to 
investigate a potential second binding site on MraY. However, this work was 
carried out for Maria T. Rodolis’s project and the results have not been published 
yet. For this thesis, one of the compounds, A-503083 B was chosen to 
demonstrate uridyl-peptide inhibition against B. subtilis MraY as an example. 
Capuramycins are nucleoside antibiotics first isolated from S. griseus
188
. They 
have antibacterial activity against mycobacteria
190
. 
A-503083 F and A-503083 B (Figure 5-10) were isolated from Streptomyces 
species SANK 62799 broth cultures and they are 2’-O-carbamoyl derivatives of 
A-500359 F and B
190
. A-500359 F (2.4 µM) was found to be significantly less 
active against E. coli MraY than B (18 nM), due to the lack of the 
aminocaprolactam ring
192
.  
 
 
 
 
 
 
 
 
 
A-503083 B  
Exact mass: 610.22 
A-503083 F  
Exact mass: 500.14 
Figure 5-10: Chemical structures of the capuramycin analogues, A-500359 F and B, and 
A-503083 F and B  
A-500359 F 
Exact mass: 457.13 
A-500359 B 
Exact mass: 567.22 
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A-503083 F has no antibacterial activity while A-503083 B was found to be 
active against Streptococcus pneumoniae, Streptococcus pyogenes, 
Mycobacterium smegmatis and Moraxella catarrhalis. The IC50s for E. coli MraY 
inhibition were determined by a fluorescence assay with 17.9 µM and 38 nM 
respectively by Muramatsu et al
190
. These values meant that the presence of the 
2’-O-carbamoyl unit reduced the activity 8 and 2 fold respectively. Moreover, A-
503083 F was less active than B which highlighted once more the important role 
of the aminocaprolactam ring in MraY inhibition
190
.  
The two samples of capuramycin analogues (A-503083 F and A-503083 B) were 
tested against E. coli MraY by the continuous fluorescence MraY assay in a total 
volume of 180 µl containing 30 µM dansyl-labelled UDPMurNAc-pentapeptide, 
35 µg/ml heptaprenyl phosphate in buffer 83 mM Tris pH 7.5, 21 mM MgCl2 
against E. coli MraY (60 µg protein). Table 5-4 shows the results (Figures A 36 
and A 37 in Appendix 5e). 
Table 5-4: Inhibition and IC50s of capuramycin analogues against E. coli and B. subtilis 
MraYs 
Capuramycin 
analogue 
E. coli MraY B. subtilis MraY 
A-503083 F 4.8 ± 0.6 µg/ml not tested 
A-503083 B 0.139 ± 0.016 µg/ml 0.062 ± 0.006 µg/ml 
 
The IC50 for A-503083 F was half the value determined by Mutamatsu et al and 
we saw a 6-fold increase in the IC50 for A-503083 B compared to the published 
value which could be explained by the differences in the assay conditions, such as 
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concentration of the substrates, detergent, Mg
2+
 or other salts present
208
. 
Therefore, in order to compare IC50s, it is important to keep these factors constant.  
The more active compound, A-503083 B, was tested against B. subtilis MraY 
under the same conditions where the reaction was started with 60 µg protein 
containing recombinant B. subtilis MraY membranes (Figure 2-24). The measured 
IC50 value was estimated as 62 ± 6 ng/ml (Figure 5-11) against B. subtilis MraY. 
It is half of the IC50 for the E. coli MraY which means that the inhibitory potency 
of this compound against B. subtilis MraY is slightly higher.  
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Figure 5-11: A-503083 inhibition against B. subtilis MraY, IC50: 62 ± 6 ng/ml 
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5.2 Inhibition of MraY by vancomycin 
During the search for a natural product producing bacterial strain as a positive 
control for testing Streptomyces cell extracts against E. coli MraY, the inhibitory 
potential of vancomycin was tested against MraY.  
The glycopeptide antibiotic vancomycin that was isolated from Amycolatopsis 
orientalis (formerly known as S. orientalis)
112
 is the last line of defence against 
life-threatening Gram-positive infections, such as the ones caused by MRSA
243
. 
Vancomycin is not thought to penetrate the cell membrane therefore unable to 
inhibit enzymes from the cytoplasmic phase of the membranes
9, 244
, or interact 
with proteins in the bacterial cell but was reported to inhibit bacterial 
peptidoglycan biosynthesis by binding to the D-alanine-D-alanine termini of lipid 
II which leads to sterically preventing their transglycosylation (Section 1.1.3.1) 
and transpeptidation steps and eventually weakens the forming peptidoglycan cell 
wall
112, 243, 245, 246
.  
Vancomycin could complex the D-Ala-D-Ala unit of UDPMurNAc-pentapeptide, 
lipid I and lipid II
112
, however it has very rarely been reported as an MraY 
inhibitor. At one occasion, this natural product was used by Solapure et al. as a 
positive control for their development of a scintillation proximity assay for MraY 
where they measured an IC50 value of 20 µM for vancomycin inhibition. Their 
assay contained 5 µM UDPMurNAc-pentapeptide and 12.5 µg protein from wild 
type E. coli membranes
147, 247
. It was suggested that higher concentration of 
membrane protein could affect the inhibitory potency of vancomycin because it 
can bind to pre-existing peptidoglycan fragments on the membranes
147
. 
Ravishankar et al. showed that vancomycin inhibits MurG but the IC50 of 
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vancomycin largely depended on the quantity of lipid I (~9 µM), because it binds 
to vancomycin neutralizing its inhibitory effect
149
. In addition, the use of large 
quantity of enzyme was found unfavourable for vancomycin inhibition once 
again
149
.  
The hydrogen bond formation between vancomycin and the D-Ala-D-Ala 
terminus of peptidoglycan precursors is shown in Figure 5-12. Vancomycin 
resistant bacteria learned to synthesise and use e.g. D-Ala-D-Lac instead of D-
Ala-D-Ala for building its precursors and polymerising the peptidoglycan chain 
and the mutation from amide to ester disrupts the hydrogen bonding network with 
vancomycin
245
. 
  
Figure 5-12: Representation of the vancomycin : N-acyl-D-Ala-D-Ala complex (left), and 
vancomycin : N-acyl-D-Ala-D-Lac complex in vancomycin resistant bacteria (right), dashed 
lines represent H-bonds
245
 
Vancomycin interfered with fluorescence in our assay (λex: 340 nm λem: 530 nm) 
and was tested by the radiochemical MraY assay (Figure 2-43). 100 µl assay 
contained 1.1 µM (2.12 nCi)/assay) [
14
C]-UDPMurNAc-pentapeptide, 23.3 µg/ml 
heptaprenyl phosphate, 70 mM Tris pH 7.5, 17.5 mM MgCl2, 4.0 % (vol/vol) 
glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100, and the reaction was started 
disrupted H-bond by  
vancomycin resistant  
bacteria 
N-acyl-D-Ala-D-Ala N-acyl-D-Ala-D-Lac 
vancomycin 
191 
 
by the addition of recombinant E. coli, or S. aureus or P. aeruginosa MraY 
membranes, containing 40, 35 and 20 µg protein (see general procedure in Section 
7-19). The % activity versus vancomycin concentration graph for E. coli MraY 
inhibition is shown in Figure 5-13. 
 
Figure 5-13: Vancomycin inhibition against E. coli MraY 
IC50 values were estimated and are shown in Table 5-5. The data for IC50 
determination for S. aureus and P. aeruginosa are shown in Figures A 39 and      
A 40 in Appendix 6. 
Table 5-5: Vancomycin inhibition against E. coli, S. aureus and P. aeruginosa MraYs 
Vancomycin inhibition 
against MraY 
IC50 
E. coli 61.6 ± 8 µg/ml, 43 µM 
S. aureus 130 ± 12 µg/ml, 90 µM 
P. aeruginosa 288 ± 44 µg/ml, 199 µM 
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The strongest inhibition was observed against E. coli MraY (IC50: 43 µM for 
1.1 µM [
14
C]-UDPMurNAc-pentapeptide), where a 43 fold molar excess was 
needed to complex UDPMurNAc-pentapeptide for the half maximal inhibitory 
concentration. The inhibitory potential of vancomycin did not seem to be strong 
enough (IC50 > 10 µM) to use this natural product as a positive control for testing 
cell extracts. 
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5.3 Inhibition by E peptide, antimicrobial peptides and 
P1 peptide 
E protein (see Section 1.3.2) is known to inhibit E. coli MraY
197, 198
. In this 
section its inhibition against MraY from other organisms was investigated. 
Moreover, we tested some antimicrobial peptides, which have a similar motif to 
E protein in their sequences against E. coli MraY, and the cell wall synthesis 
targeting P1 peptide was tested against MraY and MurG. 
5.3.1 Testing E peptide against E. coli, S. aureus, P. aeruginosa, 
B. subtilis and M. flavus MraYs 
Bacteriophage ɸ174 uses a single lysis gene, E, to cause lysis of the host cell and 
the encoded 91-amino-acid membrane protein
196
 was shown to inhibit E. coli 
MraY
197, 198
. Only the 29 amino-terminal amino acids of the transmembrane 
domain of E protein were found to be essential for lytic function
248-250
. A 100 % 
α-helical 37-amino-acid synthetic peptide (MALDI-TOF m/z (M+H)+: 4334.7) 
containing the N-terminal transmembrane domain of E protein was shown to be 
effective against membrane-bound E. coli MraY by a microtitre plate fluorescence 
enhancement assay (IC50: 0.8 µM)
200
. The amino acid sequence of the synthetic 
E peptide is the following
200
: 
H2N-MVRWTLWDTLAFLLLLSLLLPSLLIMFIPSTFKRPVS-CO2H 
A sample of the above mentioned 37-amino-acid peptide was tested by the 
continuous fluorescence MraY assay (Figure 2-2) against E. coli, S. aureus, 
P. aeruginosa, B. subtilis and M. flavus MraYs in a total volume of 180 µl 
containing 30 µM dansyl-labelled UDPMurNAc-pentapeptide, 35 µg/ml 
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heptaprenyl phosphate in a buffer 83 mM Tris pH 7.5, 21 mM MgCl2, 6 % 
glycerol, 0.15 % Triton X-100. The reactions were started by the addition of 40-
60 µg protein containing membranes (see Section 7.10). Significant inhibition was 
only detected against E. coli MraY, where IC50 was determined as 
17.2 ± 2.11 µg/ml (Figure 5-14). 
   
Figure 5-14: E peptide inhibition against E. coli MraY, IC50: 17.2 ± 2.11 µg/ml 
Phe-288 is known to be an essential residue of E. coli MraY for the E protein 
mediated lysis, mutation of this residue to lysine resulted in resistance to 
E protein
197
. There is no phenyl-alanine residue at the same position for S. aureus, 
B. subtilis, P. aeruginosa and M. flavus MraYs (Figure 5-15). 
 
Figure 5-15: Position of F288 of E. coli MraY compared to S. aureus, B. subtilis, 
P. aeruginosa and M. flavus MraYs 
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gi|388476208|ref|YP_488392.1|       MLVWLAEHLVKYYSGFNVFSYLTFRAIVSLLTALFISLWMGPRMIAHLQK 50 E.coli 
gi|386064140|ref|YP_005979444.      MLLLLAEYLQQFYKGFGVFQYLTLRGILSVLTALSLSLWLGPWMIRTLQI 50 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        ------------------------MIFVYALLALVITFVLVPVLIPTLKR 26 S.aureus 
gi|305674250|ref|YP_003865922.      --------------------MLEQVILFTILMGFLISVLLSPILIPFLRR 30 B.subtilis 
gi|239917864|ref|YP_002957422.     ----------------------MIGLLIGGVLGLVLSAAGTPLFIRFLVK 28 M.luteus 
                                                              :.  : .: ::    * :*  *   
 
gi|388476208|ref|YP_488392.1|       LSFGQVVRNDGPESHFSKRGTPTMGGIMILTAIVIS--------VLLWAY 92 E.coli 
gi|386064140|ref|YP_005979444.      RQIGQAVRNDGPQSHLSKKGTPTMGGALILTAIAIS--------TLLWAD 92 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        MKFGQSIREEGPQSHMKKTGTPTMGGLTFLLSIVITSLV-----AIIFVD 71 S.aureus 
gi|305674250|ref|YP_003865922.      LKFGQSIREEGPKSHQKKSGTPTMGGVMIILSIIVTTIV-----MTQKFS 75 B.subtilis 
gi|239917864|ref|YP_002957422.      RGYGQFVRDDGPTTHKTKRGTPTMGGAVIIGSLVLAYLITHGLLAVLGVD 78 M.luteus 
                                       ** :*::** :* .* *******  :: :: ::               
 
gi|388476208|ref|YP_488392.1|       PSNPY--VWCVLVVLVGYGVIGFVDDYRKVVRKDTKGLIARWKYFWMSVI 140 E.coli 
gi|386064140|ref|YP_005979444.      LSNRY--VWVVLVVTLLFGAIGWVDDYRKVIEKNSRGLPSRWKYFWQSVF 140 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        QANP---IILLLFVTIGFGLIGFIDDYIIVVKKNNQGLTSKQKFLAQIGI 118 S.aureus 
gi|305674250|ref|YP_003865922.      EISPE--MVLLLFVTLGYGLLGFLDDYIKVVMKRNLGLTSKQKLIGQIII 123 B.subtilis 
gi|239917864|ref|YP_002957422.      FGGPTASGLILLLLTVGMAFVGFVDDFTKITKQRSLGLTPRGKIILQALI 128 M.luteus 
                                      .       :*.: :  . :*::**:  :  : . ** .: * :    : 
 
gi|388476208|ref|YP_488392.1|       ALGVAFALY----------LAGKDTPATQLVVPFFKDVMPQLG-LFYILL 179 E.coli 
gi|386064140|ref|YP_005979444.      GIGAAVFLY----------MTAETPIETTLIVPMLKSVEIQLG-IFFVVL 179 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        AIIFFVLSN----------VFHLVNFSTSIHIP-FTNVAIPLS-FAYVIF 156 S.aureus 
gi|305674250|ref|YP_003865922.      AIVFYA-------------VYHYYNFATDIRVP-GTDLSFDLG-WAYFIL 158 B.subtilis 
gi|239917864|ref|YP_002957422.      GTAFAVLALNFPDERGLTPASTAISFARDIPWLDLAFAGPAIGVILFVIW 178 M.luteus 
                                    .                            :           :.   :.:  
 
gi|388476208|ref|YP_488392.1|       AYFVIVGTGNAVNLTDGLDGLAIMPTVFVAGGFALVAWATGNMNFASY-- 227 E.coli 
gi|386064140|ref|YP_005979444.      TYFVIVGSSNAVNLTDGLDGLAIMPTVMVAGALGIFCYLSGNVKFAEY-- 227 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        IVFWQVGFSNAVNLTDGLDGLATGLSIIGFTMYAIMSFVLG--------- 197 S.aureus 
gi|305674250|ref|YP_003865922.      VLFMLVGGSNAVNLTDGLDGLLSGTAAIAFGAFAILAWNQS--------- 199 B.subtilis  
gi|239917864|ref|YP_002957422.      SNLITTATTNAVNLTDGLDGLATGATAMITGAYVLISLFQSSQSCALEGT 228 M.luteus 
                                      :  ..  ************    : :      :..   .          
 
gi|388476208|ref|YP_488392.1|       LHIPYLRHAGELVIVCTAIVGAGLGFLWFNTYPAQVFMGDVGSLALGGAL 277 E.coli 
gi|386064140|ref|YP_005979444.      LLIPNVPGAGELIVFCAALVGAGLGFLWFNTYPAQVFMGDVGALALGAAL 277 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        --------ETAIGIFCIIMLFALLGFLPYNINPAKVFMGDTGSLALGGIF 239 S.aureus 
gi|305674250|ref|YP_003865922       --------QYDVAIFSVAVVGAVLG LVFNAHPAKVFMGDTGSLALGGAI 241 B.subtilis 
gi|239917864|ref|YP_002957422.      RGCYEVRDPMDLALLAAILTGSLLGFLWWNTSPAKIFMGDTGSLGLGGAL 278 M.luteus 
                                               : :..  :  : **** :*  **::****.*:*.**. : 
 
gi|388476208|ref|YP_488392.1|       GIIAVLLRQEFLLVIMGGVFVVETLSVILQVGSFKLRG-QRIFRMAPIHH 326 E.coli 
gi|386064140|ref|YP_005979444.      GTIAVIVRQEIVLFIMGGVFVMETLSVMIQVASFKLTG-RRVFRMAPIHH 326 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        ATISIMLNQELSLIFIGLVFVIETLSVMLQVASFKLTG-KRIFKMSPIHH 288 S.aureus 
gi|305674250|ref|YP_003865922.      VTIAILTKLEILLVIIGGVFVIETLSVILQVISFKTTG-KRIFKMSPLHH 290 B.subtilis 
gi|239917864|ref|YP_002957422.      AGFAIFTRTEILVAVLAGLMVAITLSVIIQVGWFKVSGGKRVFLMAPLQH 328 M.luteus 
                                      :::: . *: : .:. ::*  ****::**  **  * :*:* *:*::* 
 
gi|388476208|ref|YP_488392.1|       HYELKGWPEPRVIVRFWIISLMLVLIGLATLKVR------------- 360 E.coli 
gi|386064140|ref|YP_005979444.      HFELKGWPEPRVIVRFWIITVILVLIGLATLKLR------------- 360 P.aeruginosa 
gi|15926765|ref|NP_374298.1|        HFELIGWSEWKVVTVFWAVGLISGLIGLWIGVH-------------- 321 S.aureus 
gi|305674250|ref|YP_003865922.      HYELVGWSEWRVVVTFWTAGLLLAVLGIYIEVWL------------- 324 B.subtilis 
gi|239917864|ref|YP_002957422.      HFELKGWAEVTVVVRFWLLSLMCVTVGLAIFYGDWLIRQGGLAGVTP 375 M.luteus 
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No inhibition was observed against S. aureus, B. subtilis, P. aeruginosa and 
M. flavus MraYs at 83 µg/ml concentrations by the continuous fluorescence MraY 
assay (Figure 5-16). 
 
 
 
 
 
 
 
 
 
 
 
The lack of inhibition was confirmed against S. aureus, P. aeruginosa, B. subtilis 
and M. flavus MraYs when E peptide was tested by the radiochemical MraY assay 
(see general procedure in Section 7.19) at 150 µg/ml concentrations. 
E peptide against S. aureus MraY 
E peptide against M. flavus MraY E peptide against P. aeruginosa MraY 
E peptide against B. subtilis MraY 
Figure 5-16: E peptide inhibition against S. aureus, B. subtilis, P. aeruginosa and M. flavus 
MraYs, control (no inhibitor) in blue, 125 µg/ml E peptide in orange, 40-90 µg protein, λex: 
340 nm, λem: 530 nm 
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5.3.2 Testing antimicrobial peptides against MraY 
Cationic antimicrobial peptides, also named as host defence peptides, are 
produced by various organisms, such as plants, insects, amphibians, even human 
beings. These peptides can be directly antimicrobial or can play an important role 
in the innate immune and inflammatory responses
251-254
. The natural cationic 
peptides are generally 12-50 amino acids in length, have a net positive charge due 
to an excess of basic lysine and arginine residues over acidic residues, and contain 
approximately 50 % hydrophobic amino acids
255
. Four major structural categories 
are shown in Figure 5-17 based on their amphiphilic conformations forming 
before or after membrane interaction and insertion
256-258
. 
 
Figure 5-17: Major structural conformations of natural antimicrobial peptides, charged 
regions in blue and hydrophobic residues in green, A: β-structures with 2-4 β-strands, 
stabilized by two to four disulphide bridges, B: α-helical peptides, C: loop structures with 
one disulphide bridge, D: extended structures
255
. 
Cationic antimicrobial peptides interact with bacterial cell membranes by binding 
to their negatively charged surfaces and then insert through a combination of 
A 
B 
C D 
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electrostatic and hydrophobic interactions. Insertion into eukaryotic cell 
membranes which have zwitterionic lipids at their surfaces is more difficult
251
.  
These peptides have a broad spectrum of activity against Gram-positive and 
negative bacteria, as well as fungi, viruses and parasites they can kill multidrug 
resistant bacteria and not highly affected by antibiotic-resistance mechanisms
259
. 
They are also capable of neutralizing endotoxemia and sepsis as well as 
stimulating the innate immune response
260
. Moreover, several antimicrobial 
peptides have been reported to have anticancer activity
261, 262
.  
However, there are obstacles in their widespread clinical use resulting from the 
high cost of preparation, their unknown toxicities and their rapid degradation by 
proteases in the digestive tract. More structure-activity relation studies need to be 
done in order to increase their specificity and tolerability
260
.  
Cherkasov et al used peptide array technology to create 9-amino-acid peptide 
libraries and applied quantitative structure-activity approaches based on some 
physicochemical properties of the peptides, such as polar and hydrophobic 
characteristics of the constituent amino acids. The best of these 9-amino-acid 
peptides were effective even against multidrug-resistant “Superbugs”, especially 
tryptophan- and arginine-rich peptides that also exist in nature but longer and less 
active
251
. Examples for tryptophan- and arginine-rich peptides are indolicidin, a 
13-amino acid cationic antimicrobial peptide isolated from bovine neutrophils 
with very high tryptophan content
263
 and a parent compound MX-226 which has 
shown to be an effective antimicrobial agent in phase III clinical trials
264
.  
Professor Timothy D. H. Bugg noticed that these antimicrobial peptides contain 
an arginine-tryptophan motif (N…-R-W-X-X-W-…C) near their N-terminus 
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similarly to E protein. Since Professor Timothy D. H. Bugg developed a model for 
the E protein MraY interaction where there are hydrophobic interactions between 
Trp-4 and Trp-7 of E protein with Phe-288 of E. coli MraY and electrostatic 
interactions between Arg-3 of E protein and Glu-287 of E. coli MraY
265
, these 
peptides were interesting to test against MraY. 
The antimicrobial peptides such as indolicidin, MX-226, Kai-47, Kai-50, 1002 
and Sub-6 were provided by Professor Robert E. W. Hancock (University of 
British Columbia). It was not possible to test them by the fluorescence assay 
because they showed high fluorescence (λex: 340 nm, λem: 530 nm). They were 
tested against E. coli MraY by the radiochemical MraY assay (see general 
procedure in Section 7.19 and Figure 2-43) at 100 µg/ml concentrations. E peptide 
was used as a positive control and gave 87 ± 7 % inhibition at 150 µg/ml 
concentrations. Table 5-6 shows that the peptides inhibited E. coli MraY between 
30-61 % by the radiochemical assay. 
Table 5-6: Inhibition against E. coli MraY by antimicrobial peptides determined by a 
radiochemical MraY assay
265
 
Antimicrobial peptides Sequence Inhibition % 
Indolicidin  N-RRWPWWPWKWPLI-C 30 ± 5 % 
MX-226  C-KRRWPWWPWRLI-N 55 ± 5 % 
Kai-47  N-KRWKWWRFKWKIF-C 52 ± 5 % 
Kai-50  N-ILRWKWRWWRWWRR-C 61 ± 3 % 
1002  C-KRIRWVILWRQV-N 41 ± 3 % 
Sub-6  N-RWWKIWVIRWWR-C 58 ± 4 % 
 
These assays were run for Maria T. Rodolis whose PhD project studied the role of 
the arginine-tryptophan motif of E protein using synthetic peptides
265
. Maria T. 
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Rodolis measured MIC values (8-150 µg/ml) for these peptides against E. coli. 
Inhibition normally leads to an increase in MIC with the presence of more enzyme 
while the MIC should not change if the compounds are inactive. Maria T. Rodolis 
also measured the MICs (2-63 µg/ml) for cells overexpressing E. coli MraY 
where there was a 2-4 fold decrease in the MIC values. This observation was 
explained by the possibility of interaction of these peptides at another site, where 
the higher level of MraY would assist the insertion of these peptides into the 
membranes and therefore the MIC values would decrease
265
. 
5.3.3 Testing the P1 lytic peptide from phage AP205 against 
MraY 
The ORF1 in Acinetobacter phage 205 (AP205) was proposed 
to encode a lysis peptide (P1) containing 35 amino acids, 
MKKRTKALLPYAVFIILSFQLTLLTALFMYYHYTF (Mw: 4242.16 Da), and 
expression of this peptide into E. coli was shown to cause cell lysis
266
. Dr. Roger 
Levesque’s research group at the Laval University is interested in the 
characterization of the lytic mechanism of P1 by using a combination of in vitro 
and in vivo approaches. They found that P1 is a bacterial cell wall inhibitor by 
enzymatic assays against MurA, MurB and MurE with IC50 values of 30 μM, 
210 μM and 33 μM, respectively. P1 was found to compete for the Mg2+ binding 
site in MurE. Gene dosage and cell rescue experiments suggested that MraY and 
MurG are also possible targets for P1. P1 was suggested to be a competitive 
inhibitor of these enzymes by binding to their Mg
2+
 binding site. The information 
about the P1 peptide inhibition of bacterial cell wall synthesis was found on the 
website of the Laval University. 
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The 35 amino acid containing P1 lytic peptide and the shortened version of it 
without the C terminal end were provided by Dr. Roger Levesque. The two 
samples showed high fluorescence in the fluorescence MraY assay and were 
tested at 300 µg/ml concentration against E. coli MraY by the radiochemical assay 
(Figure 2-43). 100 µl assay contained 1.1 µM (2.12 nCi)/assay) [
14
C]-
UDPMurNAc-pentapeptide, 23.3 µg/ml undecaprenyl phosphate, 70 mM Tris 
pH 7.5, 17.5 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % 
Triton X-100, and the reaction was started by the addition of 40 µg protein 
containing overexpressed E. coli MraY membranes. P1 peptide and its shortened 
version gave 68 ± 5 % and 26 ± 3 % inhibition respectively.  
IC50 was determined for the more active compound (P1 peptide) against E. coli 
MraY using a dilution series at 75-300 µg/ml concentrations (Figure 5-18) with a 
value of 157 ± 9 µg/ml.  
 
Figure 5-18: P1 peptide inhibition against E. coli MraY (radiochemical assay) IC50: 
157 ± 9 µg/ml 
P1 peptide was also tested at 300 µg/ml concentrations by the radiochemical assay 
against P. aeruginosa and S. aureus MraY, but inhibition was not detected. This 
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enzyme selectivity could suggest that the P1 peptide interacts with E. coli MraY at 
a different site from the site of the uridyl-peptide inhibitors. 
5.3.4 Testing the P1 lytic peptide against MurG 
P1 peptide was assayed against MurG using a coupled radiochemical assay, as 
described by Trunkfield et al. (2010)
85, 267
. Lipid I was generated from 
UDPMurNAc-pentapeptide and undecaprenyl phosphate by recombinant E. coli 
MraY membranes and then converted in the presence of [
3
H]-UDPGlcNAc and 
E. coli MurG to give radiolabelled lipid II (Figure 5-19). 
 
 
Figure 5-19: Schematic representation of the coupled radiochemical MraY-MurG assay 
100 μl total volume contained 100 µM UDPMurNAc-pentapeptide, 23.3 µg/ml 
undecaprenyl phosphate, 6.6 µM [
3
H]-UDPGlcNAc (2.53 nCi/assay), 70 mM Tris 
pH 7.5, 17.5 mM MgCl2, 4.0 % glycerol (vol/vol), 2.3 % (vol/vol) DMSO, 0.1 % 
Triton X-100 to which was added 60 µg E. coli membranes containing 
overexpressed E. coli MraY, and 60 µg E. coli MurG solution. The purified MurG 
solution was provided by Anita Catherwood from the Life Sciences Department 
[
3
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lipid II 
extraction into 1-butanol  
 
liquid scintillation counting  
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3
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of the University of Warwick. The mixture was incubated at 35 ˚C for 20 minutes 
and reactions were stopped by the addition of 100 µl 6 M pyridinium acetate, 
pH 4.2. The lipid products were extracted into 200 µl 1-butanol and quantified by 
liquid scintillation counting. Assays were carried out in duplicates in the presence 
of inhibitor at concentrations of 18-300 µg/ml, and inhibition by ramoplanin was 
used as a positive control. Ramoplanin was a gift from Dr. Adrian Lloyd.  
 
Figure 5-20: P1 against E. coli MurG 
P1 peptide and its shortened version did not seem to inhibit E. coli MurG (Figure 
5-20). However, the assay was repeated with M. flavus membranes as the unique 
source of the MraY and MurG enzymes (Section 7.27.2 and Figure 5-21).  
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Figure 5-21: P1 against M. flavus MurG 
Very little inhibition was observed if any, since 300 µg/ml P1 peptide showed 
31 ± 2 % inhibition, and the shortened version of P1 showed 16 ± 2 % inhibition 
against M. flavus MurG. The positive control 640 µg/ml ramoplanin showed 
85 ± 7 % inhibition. 
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5.4 Testing of halogenated fluorescein derivatives versus 
MraY and MurG 
Zawadzke et al performed a high-throughput screen for MraY-MurG inhibitors by 
a coupled E. coli MraY-MurG scintillation proximity assay
69
. They reported the 
structures of four hits, which included a di-iodo fluorescein and a tetra-bromo 
fluorescein analogue (Figure 5-22) with IC50 values of 16.2 and 7.1 µM 
respectively. The MIC values against S. aureus were determined as >128 and 
16 µg/ml for the two compounds. Further analogues were tested, and it was 
concluded that the compounds with antimicrobial activity displayed high 
cytotoxicity which is an undesirable trait for antimicrobial agents. Therefore the 
inhibition mechanism of the halogenated fluorescein analogues was not 
investigated any further
69
. 
 
Figure 5-22: Halogenated fluorescein analogues from the hits of the combined MraY-MurG 
screen of Zawadzke et al, di-iodo fluorescein (Mw: 584.10) on the left and tetra-bromo 
fluorescein analogue (Mw: 697.93) on the right 
Fluorescein is known to have some antimicrobial activity against 
Streptococcus pneumonia, Haemophilus influenzae and Moraxella catarrhalis but 
not for S. aureus or P. aeruginosa
268
. Moreover, halogenated fluoresceins were 
reported to inhibit S. aureus growth
269
.  
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An undergraduate chemistry student Justin Slikas synthesised 2,7-dichloro and 
2,7-dibromo fluorescein analogues during his summer project in 2011 in Professor 
Timothy D. H. Bugg’s group, the structures are shown in Figure 5-23. Attempts to 
synthesise the tetrabromo fluorescein were unsuccessful, but he managed to make 
the mono-bromo-resorcinol as an intermediate which led to the synthesis of the di-
bromo fluorescein analogue
270
. He tested the compounds for antibacterial activity, 
but they showed no growth inhibition against E. coli or B. subtilis.  
We wished to explore whether these compounds were inhibitors of either MraY or 
MurG. Since they are highly fluorescent, they could only be assayed by the 
radiochemical assay which was not working at the time of Justin Slikas’s project. 
 
Figure 5-23: 2,7-dichloro fluorescein analogue (Mw: 401.20) and 2,7-dibromo fluorescein 
analogue  (Mw: 490.10) synthesised by Justin Slikas  
The compounds were tested by the radiochemical MraY assay (Figure 2-43) in 
100 µl sample containing 1.1 µM (2.12 nCi/assay) [
14
C]-UDPMurNAc-
pentapeptide, 23.3 µg/ml undecaprenyl phosphate, 70 mM Tris pH 7.5, 17.5 mM 
MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100, and 
the reaction was started by the addition of 40 µg protein containing overexpressed 
E. coli MraY membranes. No inhibition was found against E. coli MraY at 
165 µg/ml concentrations for the 2,7-dichloro and 325 µg/ml concentrations for 
the 2,7-dibromo fluorescein (Figure 5-24). 
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Figure 5-24: Testing halogenated fluorescein analogues against E. coli MraY 
The 2,7-dichloro and 2,7-dibromo fluorescein analogues were also tested against 
E. coli MurG (Figure 5-19) in a 100 μl total volume that contained 100 µM 
UDPMurNAc-pentapeptide, 23.3 µg/ml undecaprenyl phosphate, 6.6 µM [
3
H]-
UDPGlcNAc (2.53 nCi/assay), 70 mM Tris pH 7.5, 17.5 mM MgCl2, 4.0 % 
glycerol (vol/vol), 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 to which was 
added 60 µg E. coli membranes containing overexpressed E. coli MraY, and 
60 µg E. coli MurG solution (see Section 7.27.1). 
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Figure 5-25: Testing halogenated fluorescein analogues against E. coli MurG 
Figure 5-25 shows that the 2,7-dicholoro and the 2,7-dibromo fluorescein did not 
inhibit E. coli MurG at 165 and 325 µg/ml concentrations respectively. It 
therefore appeared that these compounds do not inhibit MraY or MurG, contrary 
to the report by Zawadzke et al., although the compounds they reported were di-
iodo and tetra-bromo fluorescein analogues. These results suggest that the 
substitution pattern maybe crucial for inhibition. 
It was shown by Rasooly and Weisz that tetra-chlorinated fluorescein analogues 
significantly inhibit the growth of S. aureus and the increase in the number of 
substituting halogens in the hydroxy-xanthene unit results in an increase in 
inhibitory activity. Phloxine B, a red dye currently used in cosmetics and as a 
colour additive in food, was shown to have activity against seven MRSA strains 
and killed 99 % of mid-log phase S. aureus cultures at 100 µg/ml with an MIC of 
25 µg/ml
269
.  
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The halogenated xanthene dyes are reported insecticides as well because of their 
photodynamic action. It means that the illumination of the dyes in the presence of 
oxygen generates singlet oxygen which causes a toxic effect on living cells by 
reacting with nucleic acids, lipids and proteins
271
. 50 % of 
Agrobacterium tumefaciens, a bacterial pathogen in plants, was shown to be killed 
by 0.05 µM phloxine B under continuous illumination
272
.  
Phloxine B’s antibacterial activity was investigated further and it was shown that 
it selectively inhibited the growth of Gram-positive bacteria (S. aureus, B. subtilis, 
B. cereus, B. thuringiensis and B. mycoides) in a light-dependent manner. The 
growth of Gram-negative bacteria (E. coli, Salmonella choleraesuis and 
Shigella flexneri) was only inhibited in the presence of EDTA by increasing their 
membrane permeability. The growth inhibition of EDTA-treated Gram-negative 
organisms was also light-dependent and required longer incubation time
273
.  
We decided to investigate the potential inhibitory activity of phloxine B, the 
disodium salt of 2’,4’,5’,7’-tetrabromo-4,5,6,7-tetrachloro fluorescein (Figure 
5-26) which is a commercially available dye (Acros), against MraY and MurG. 
 
Figure 5-26: Chemical structure of phloxine B, Mw: 829.63 
Phloxine B was tested by the radiochemical MraY assay (Section 7.19 and Figure 
2-43) at 0-500 µg/ml in 100 µl sample containing 3.2 nCi [
14
C]-UDPMurNAc-
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pentapeptide, 27 µg/ml undecaprenyl phosphate, 70 mM Tris pH 7.5, 17.5 mM 
MgCl2, 4.0 % (vol/vol) glycerol, 1 % (vol/vol) DMSO, 0.1 % Triton X-100, and 
the reaction was started by the addition of 40 µg protein containing overexpressed 
E. coli MraY membranes. 500 µg/ml phloxine B showed 99 ± 9 % inhibition 
against E. coli MraY and an IC50 value of 26.4 ± 1.0 µg/ml was calculated in 
GenStat (Figure 5-27). 
 
 
 
 
 
 
 
 
The inhibitory activity of phloxine B was assayed against S. aureus, B. subtilis, 
P. aeruginosa and M. flavus MraY under the same conditions using 35 µg, 40 µg, 
20 µg and 40 µg protein containing membranes to start the reactions. Table 5-7 
shows the estimated IC50 values (see Figures A 41 - A 45 in Appendix 7). 
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Figure 5-27: Phloxine B inhibition against E. coli MraY, IC50: 26.4 ± 1.0 
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Table 5-7: Phloxine B inhibition against S. aureus. B. subtilis, P. aeruginosa, M. flavus and 
E. coli MraY 
MraY from various 
organisms 
IC50 (µg/ml) 
S. aureus 211 ± 29 
B. subtilis 137 ± 20 
P. aeruginosa 106 ± 23 
M. flavus 162 ± 25 
E. coli 26.4 ± 1.0 
 
The inhibitory activity of phloxine B was the strongest against E. coli MraY (IC50: 
26.4 ± 1.0 µg/ml, 31.8 µM) and the weakest inhibition was estimated for the 
S. aureus MraY with an estimated IC50 value of 211 ± 29 µg/ml (254 µM). The 
estimated IC50 values for P. aeruginosa, B. subtilis and M. flavus MraY increased 
4, 5 and 6 fold compared to the E. coli MraY. 
The phloxine B inhibition assay against E. coli MraY was repeated in the dark to 
exclude the possibility of light-activated oxidation of the enzyme as apparent 
inhibition. An IC50 value of 24.2 ± 1.7 µg/ml was measured (A 46 in Appendix 7) 
which was almost identical to the previous measurement.  
Phloxine B was also tested at 500 µg/ml against M. flavus MurG (see Section 
7.27.2 and Figure 5-19) in a 100 μl total assay volume that contained 84 µM 
UDPMurNAc-pentapeptide, 23.3 µg/ml heptaprenyl phosphate, 23.0 µM [
3
H]-
UDPGlcNAc (8.83 nCi/assay), 70 mM Tris pH 7.5, 17.5 mM MgCl2, 4.0 % 
glycerol (vol/vol), 2.3 %  (vol/vol) DMSO, 0.1 % Triton X-100 to which was 
added 40 µg protein containing M. flavus membranes. 
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Figure 5-28: Inhibition of phloxine B in the combined M. flavus MraY-MurG assay 
500 µg/ml phloxine B showed 87.1 ± 3.5 % inhibition in the combined M. flavus 
MraY-MurG assay which is probably due to MraY inhibition (Figure 5-28). 
5.4.1 Conclusion 
In conclusion, the di-chloro and di-bromo fluorescein analogues did not show 
inhibition against E. coli MraY of MurG at 411 µM and 663 µM respectively. 
However, when we tested a tetra-bromo fluorescein analogue, phloxine B, a 
compound structurally more similar to the tetra-bromo fluorescein analogue tested 
by Zawadzke et al, it showed inhibition against E. coli MraY with an IC50 value 
of 31.8 µM. The inhibition we saw in the combined M. flavus MraY-MurG assay 
is probably the result of very potent MraY inhibition at 603 µM concentration of 
phloxine B. Therefore, phloxine B is definitely an MraY inhibitor. The 
substitution pattern seems to be important for MraY inhibition for halogenated 
fluorescein analogues. The increase in the number of substituting bromines in the 
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hydroxy-xanthene unit from two to four resulted in potent MraY inhibition with 
IC50 values of 7.1 µM for the compound in Zawadzke et al
69
 and 31.8 µM for 
phloxine B.  
Phloxine B is widely used as colour additive in food, drug and cosmetics so it has 
already met safety specifications
271, 274
. However, it is worrying that bacteria are 
constantly exposed to small amounts of phloxine B and therefore they are given 
the opportunity to develop resistance against it
269
. 
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6 Conclusions 
Bacterial drug resistance is an increasingly serious problem that threatens public 
health, and researchers need to develop new drugs. The biosynthetic pathway of 
the bacterial peptidoglycan is a known and selective target for the development of 
novel antibacterial agents.  
This research project focused on the first lipid-linked step of peptidoglycan 
biosynthesis. The enzyme required for this step is the integral membrane protein, 
Phospho-MurNAc-pentapeptide Translocase MraY. The aim of this work was to 
screen for novel inhibitors of MraY. An existing continuous fluorescence MraY 
assay was further developed by gathering evidence for the formation of the 
dansyl-labelled lipid I product of the reaction using LC-MS (Section 2.2). The 
fluorescence assay was optimised and used to test known and potential MraY 
inhibitors, such as nucleoside natural products, antimicrobial peptides and 
structurally new, small molecule potential inhibitors.  
The known family of MraY inhibitors, the uridyl-peptide natural products, were 
suggested to target the active site of MraY at the cytoplasmic face of the 
membrane. Previously uridyl-peptide natural products were tested by P. Brandish 
against E. coli MraY by means of the continuous fluorescence enhancement assay 
(1992-95)
13
. The availability of other MraY enzymes allows us to compare the 
specificity of inhibition for five MraY enzymes; such as E. coli, P. aeruginosa, 
S. aureus, B. subtilis and M. flavus (Section 2.1). In addition, new synthetic 
uridyl-peptide analogues became available during the project. A novel synthetic 
muraymycin analogue from the University of Paderborn, the 5’-deoxy 
muraymycin as the bis-TFA salt was tested against E. coli MraY and the 
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antibacterial target S. aureus MraY by the continuous fluorescence assay with an 
IC50 value of 1.6 µM for each MraY enzyme. The compound also showed 98 %, 
89 % and 85 % inhibition against P. aeruginosa B. subtilis and M. flavus MraYs 
at 50 µM (Section 5.1.1). The uridyl-peptide antibiotics interact with MraY at the 
catalytic binding site on the cytoplasmic phase of the membranes where the 
suggested catalytic residues are conserved for all five organisms. Therefore, it is 
not surprising to see inhibition of MraY from all five organisms. In addition, new 
caprazamycin derivatives from the University of Tübingen were tested aginst 
E. coli MraY using the continuous fluorescence assay with IC50 values of 1.4 µM 
and 6.6 µM for the hydrocyacyl-caprazol E-acetate and hydrocyacyl-caprazol E-
butyrate respectively (Section 5.1.2). 
Bacteriophage ɸ174 uses a single lysis gene, E, to cause lysis of the host cell and 
the encoded 91-amino-acid membrane protein
196
 was shown to inhibit E. coli 
MraY
197, 198
. A 100 % α-helical 37-amino-acid synthetic peptide containing the N-
terminal transmembrane domain of E protein was shown to be effective against 
membrane-bound E. coli MraY by a microtitre plate fluorescence enhancement 
assay (IC50: 0.8 µM)
200
. Phe-288 on the periplasmic face of the membrane is 
known to be an essential residue of E. coli MraY for the E protein mediated lysis. 
Mutation of this residue to lysine resulted in resistance to E protein
197
. There is no 
phenyl-alanine residue at the same position for S. aureus, B. subtilis, 
P. aeruginosa and M. flavus MraYs. No inhibition was observed against 
S. aureus, B. subtilis, P. aeruginosa and M. flavus MraYs at 83 µg/ml 
concentrations by the continuous fluorescence MraY assay. The lack of inhibition 
was later confirmed against S. aureus, P. aeruginosa, B. subtilis and M. flavus 
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MraYs when E peptide was tested by a radiochemical MraY assay at 150 µg/ml 
concentrations (Section 5.3.1).  
The fluorescence assay was adapted to a high-throughput fluorescence assay in 
microtitre plate format and around 2,000 compounds were screened from the 
diversity set of the U.S. National Cancer Institute (NCI) against MraY in order to 
identify novel inhibitors. However, around 22 % of the test compounds from the 
diversity set interfered with fluorescence and an independent method was needed 
to complete the testing (Section 3.1).  
An attempt was made to develop an HPLC assay that monitors the formation of 
N-labelled derivatives of lipid I. Consequently; N-labelled UDPMurNAc-
pentapeptides at the third position amino acid were prepared with DNP, 
fluorescamine and dansyl labels in order to make UV-active derivatives. 
Although, evidence was found for the presence of the labelled lipid I derivatives 
upon incubation of the UV active UDPMurNAc-pentapeptide derivatives with 
MraY membranes by LC-MS, the HPLC detection of the lipid I products did not 
seem to be reproducible and sensitive enough to be used for an MraY assay. 
Increasing the concentrations of the substrates in the samples could improve 
HPLC detection but did not seem to be a cost effective solution (Section 2.3).  
Therefore, a radiochemical MraY assay was developed using a 
14
C-labelled 
UDPMurNAc-pentapeptide substrate (Figure 2-43), which was enzymatically 
synthesised, to test compounds that interfered with fluorescence (Section 2.4).  
It is important to note of that MraY is an integral membrane protein with ten 
transmembrane domains (Section 1.2.4). Moreover, one of the substrates of the 
reaction, the lipid acceptor, undecaprenyl phosphate, or heptaprenyl phosphate 
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that was also used during the project, needs the use of detergents to be solubilised. 
Therefore, all MraY assays were carried out in the presence of 0.5 % Triton X-
100 which would eliminate the danger of protein aggregates appearing as enzyme 
inhibitors.  
We eventually identified one potential MraY inhibitor from the NCI diversity set 
by means of the radiochemical MraY assay, the naphthylisoquinoline alkaloid, 
michellamine B (Figure 6-1), with IC50 values of 400 and 340 µg/ml against 
E. coli and B. subtilis MraY respectively. Interestingly, michellamine B was 
shown to inhibit reverse transcriptases from both HIV-1 and HIV-2
211
, protein 
kinase C
212
 and human lipoxygenases
213
. However, we have not been able to 
establish yet if michellamine B’s mechanism of inhibition of these is related to 
MraY inhibition. The compound also showed antibacterial activity against 
B. subtilis with an MIC value of 16 µg/ml (Section 3.3.1). For future work, it 
would be interesting to synthesise and test some monomeric naphthylisoquinoline 
analogues against MraY for establishing some structure-activity relationship. 
The expression of P1 into E. coli, a 35-amino acid lysis peptide from the ORF1 in 
Acinetobacter phage 205, was shown to cause cell lysis
266
. Dr. Roger Levesque’s 
research group at Laval University is interested in the characterization of the lytic 
mechanism of P1 by using a combination of in vitro and in vivo approaches. They 
established that P1 is a bacterial cell wall inhibitor by enzymatic assays against 
MurA, MurB and MurE with IC50 values of 30 μM, 210 μM and 33 μM, 
respectively. Gene dosage and cell rescue experiments suggested that MraY and 
MurG are also possible targets for P1. P1 was suggested to be a competitive 
inhibitor of these enzymes by binding to their Mg
2+
 binding site. Therefore, IC50 
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was determined for the P1 peptide against E. coli MraY by means of the 
radiochemical MraY assay with a value of 157 ± 9 µg/ml. P1 peptide was also 
tested at 300 µg/ml concentrations by the radiochemical assay against 
P. aeruginosa and S. aureus MraY, but inhibition was not detected. This enzyme 
selectivity could suggest that the P1 peptide interacts with E. coli MraY at a 
different site from the site of the uridyl-peptide inhibitors and it may or may not 
act similarly to E peptide (Section 5.3.3). 
It was also established during the project that MraY inhibition from the uridyl-
peptide pacidamycin producer, S. coeruleorubidus, was detectable directly from 
culture supernatants by the fluorescence and by the radiochemical MraY assays 
(Chapter 4). Therefore, we tested culture supernatants and cell extracts from 
various Streptomyces strains. MraY inhibition was observed using cell extracts 
from Streptomyces venezuelae, and higher levels of inhibition were observed from 
a gbnB/gbnR S. venezuelae mutant of John Sidda, athough it was not possible to 
identify the active species present. The production of this compound must require 
very specific conditions. It is quite possible that this is a known uridyl-peptide 
inhibitor, but it would require additional work to confirm this (Section 4.2). 
Following an earlier report of halogenated fluoresceins identified from a 
combined MraY/MurG screen, we also tested several halogenated fluoresceins 
(Section 5.4). The di-bromo and di-chloro fluorescein analogues did not inhibit 
E. coli MraY or MurG. However, the antibacterial dye, phloxine B (Figure 6-1), a 
tetra-bromo fluorescein analogue, was an inhibitor of E. coli MraY with an IC50 
value of 32 µM, and also inhibited MraY from P. aeruginosa, B. subtilis, 
M. flavus and S. aureus with IC50 values ranging between 100 and 210 µg/ml. The 
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substitution pattern seems to be important for MraY inhibition for halogenated 
fluorescein analogues. The increase in the number of substituting bromines in the 
hydroxy-xanthene unit, from two to four resulted in potent MraY inhibition with 
IC50 values of 7.1 µM for the compound in Zawadzke et al
69
 and 32 µM for 
phloxine B. 
 
Figure 6-1: Chemical structures of novel MraY inhibitors, michellamine B and phloxine B 
For future work, it would be interesting to investigate the sites of interactions of 
michellamine B, and phloxine B with MraY, the mechanism of action of which 
may or may not be related. These novel inhibitors of MraY possibly target the 
previously suggested active site on the cytoplasmic face of the membrane, where 
three highly conserved aspartate residues, Asp-115, Asp-116 and Asp-267 in 
E. coli MraY, were identified (Section 1.2.3). Alternatively, they target 
completely different sites on MraY and act by completely different mechanisms 
of inhibition.  
Since, the crystal structure of Aquifex aeolicus MraY became available in 2013 
(Section 1.2.4); it would be interesting to investigate the binding site of 
michellamine B and phloxin B with MraY by molecular docking. They could 
represent new lead compounds for a structure-based design of novel MraY 
inhibitors. 
michellamine B phloxine B  
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7 Experimental methods 
7.1 Preparation of E. coli C43 MraY membranes, 
overexpressed with either E. coli, or S. aureus or 
B. subtilis MraY 
Transformation protocol for plasmids carrying the mraY gene: 
E. coli C43 chemically competent cells were defrosted on ice. A volume of 1-2 l 
plasmid DNA was pipetted into 50 l of bacteria and the tube was flicked gently 
in order to mix. The tube was placed back on ice and incubated for 30 minutes. 
Then the tubes were placed at 42 °C for 45 seconds. After that the tubes were 
placed back on ice and 250 l of LB media was added. Then the tubes were 
incubated at 37 °C for 1 hour. 20 l and 100 l of bacteria were added onto LB 
agar plates containing the antibiotic resistance marker (100 g/ml ampicillin or 
50 µg/ml kanamycin).  
An overnight culture derived from a single colony of E. coli C43 pJFY3c 
(LB + 100 g/ml ampicillin) was used to inoculate (5 % final concentration) 4 x 
1 l of LB/ampicillin in 5 l flasks. The cultures were grown at 37 °C for 4-6 hours 
with shaking at 180 rmp to an OD600nm  1 (zero on media). IPTG was added to a 
final concentration of 1 mM and the cultures incubated for a further 3-4 hours 
before harvesting by centrifugation (4,400 x g, 10 min). Cell pellets were flash 
frozen in liquid nitrogen and stored overnight at -20 °C. Cells were re-suspended 
in membrane buffer (50 mM Tris pH 7.5, 2 mM -mercaptoethanol, 1 mM 
MgCl2), 3 ml/g cells at 4 C. All further steps were carried out at 4 °C or on ice. 
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Lysozyme 2.5 mg/ml was added and a drop of DNAse (Deoxyribonuclease I, 
bovine pancreas). This suspension was stirred for 1 hour and then cells were 
broken by passage through a cell disrupter (28 kpsi). Whole cells and debris were 
removed by centrifugation (24,000 x g, 20 minutes). Membranes were pelleted 
from the supernatant by ultracentrifugation (150,000 x g, 40,700 rpm, 1 hour). 
Pellets were re-suspended in ice cold membrane buffer (up to 7 ml). Bradford 
assay was used to estimate the protein concentration (40-60 mg/ml). The 
suspension was then flash frozen in liquid nitrogen in 1.5 ml aliquots and stored at 
-80 °C
13
. The same procedure was used to overexpress S. aureus and B. subtilis 
MraYs in C43 E. coli membranes. 
7.2 Preparation of E. coli C43 membranes 
An overnight culture derived from a single colony of E. coli C43 was used to 
inoculate (5 % final concentration) 4 x 1 l of LB in 5 l flasks. The cultures were 
grown at 37 °C shaking at 180 rmp to OD600nm>1 (zero on media), which took 4-6 
hours. The cells were harvested by centrifugation (4,400 x g, 10 min). Cell pellets 
were flash frozen in liquid nitrogen and stored overnight at -80 °C. Cells were re-
suspended in membrane buffer (50 mM Tris pH 7.5, 2 mM -mercaptoethanol, 
1 mM MgCl2), 3 ml/g cells at 4 C. (All further steps were carried out under 4 C.) 
Lysozyme 2.5 mg/ml was added and a drop of DNAse (Deoxyribonuclease I, 
bovine pancreas). This suspension was stirred for 1 hour. Cells were broken 
through a French Press. Whole cells and debris were removed by centrifugation 
(24,000 x g, 20 minutes). Membranes were pelleted from the supernatant by 
ultracentrifugation (150,000 x g, 40,700 rpm, 1 hour). Pellets were re-suspended 
in ice cold membrane buffer (up to 7 ml max). Bradford assay was carried out to 
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estimate the protein concentration (15 mg/ml). The suspension was then flash 
frozen in liquid nitrogen in 1.5 ml aliquots and stored at -80 °C. 
7.3 Preparation of P. aeruginosa HMS174 pMON2320 
membranes (MraY overexpression) 
4 x 1 l Terrific media with 50 g/ml kanamycin was inoculated with 40 ml of an 
overnight culture of HMS174 carrying the PMON2320 plasmid. Cells were 
incubated at 37 °C with agitation at 180 rpm until OD600nm 0.4-0.5 was reached. 
The protein expression was induced with IPTG (1 mM final concentration) for 
four hours. Cells were harvested by centrifugation (4,400 x g, 10 min). Cell 
pellets were flash frozen in liquid nitrogen and stored overnight at -80 °C. Cells 
were re-suspended in membrane buffer (50 mM Tris pH 7.5, 2 mM -
mercaptoethanol, 1 mM MgCl2), 3 ml/g cells in the cold room. (All further steps 
were carried out under 4 °C.) Lysozyme 2.5 mg/ml was added and a drop of 
DNAse (Deoxyribonuclease I, bovine pancreas). This suspension was stirred for 
30 minutes. Cells were broken using a French Press. Whole cells and debris were 
removed by centrifugation 2 times (30,000 x g, 16,000 rpm, 20 minutes). 
Membranes were pelleted from the supernatant by ultracentrifugation 
(150,000 x g, 40,700 rpm, 1 hour). Pellets were re-suspended in ice cold 
membrane buffer (up to 7 ml max). Bradford assay was carried out to estimate the 
protein concentration (12.6 mg/ml). The suspension was then flash frozen in 
liquid nitrogen in 1.5 ml aliquots. These were stored at -80 °C. 
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Composition of 1 l Terrific broth media:  
12 g Bacto tryptone 
24 g yeast extract 
9.4 g dipotassium phosphate 
2.2 g monopotassium phosphate 
4 ml glycerol 
7.4 Preparation of M. flavus membranes 
An overnight culture derived from a single colony of Micrococcus flavus was 
used to inoculate (5 % final concentration) 4 x 1 l of TSB media in 5 l flasks. The 
cultures were grown at 37 °C shaking at 180 rmp to OD600nm > 1 (zero on media), 
which took 30 hours. Pellets were harvested by centrifugation (4,400 x g, 10 min). 
Cell pellets were flash frozen in liquid nitrogen and stored overnight at -80 °C. 
Cells were re-suspended in membrane buffer (50 mM Tris pH 7.5, 2 mM -
mercaptoethanol, 1 mM MgCl2), 3 ml/g cells in the cold room. (All further steps 
were carried out under 4 °C.) Lysozyme 2.5 mg/ml was added and a drop of 
DNAse (Deoxyribonuclease I, bovine pancreas). This suspension was stirred for 
30 minutes. Cells were broken by sonication on ice. Whole cells and debris were 
removed by centrifugation 2 times (30,000 x g, 16,000 rpm, 20 minutes). 
Membranes were pelleted from the supernatant by ultracentrifugation 
(150,000 x g, 40,700 rpm, 1 hour). Pellets were re-suspended in ice cold 
membrane buffer (up to 4 ml max). Bradford assay was carried out to estimate the 
protein concentration. And membranes were diluted to achieve 6 mg protein/ml. 
The suspension was then flash frozen in liquid nitrogen in 1.5 ml aliquots. These 
were stored at -80 °C. 
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7.5 Preparation of UDPMurNAc-pentapeptide from 
Bacillus subtilis cells 
UDPMurNAc-pentapeptide was isolated from cultures of Bacillus subtilis W23. 
4 x 500 ml of PYP media was inoculated by an overnight culture of B. subtilis at 
2 % and grown to OD600 = 1.2 shaken at 37 ˚C. The cultures were chilled on ice 
and cells pelleted by centrifugation at 4,400 x g for 10 minutes at 4 ˚C. Pellets 
were re-suspended in 50 ml CWSM. This was added to 500 ml of prewarmed 
CWSM in a 5 l flask and incubated at 37 ˚C for 45 minutes. The cultures were 
chilled on ice again and cells collected by centrifugation at 4,400 x g and at 4 ˚C 
for 10 minutes and stored at -20 ˚C overnight. Thawed cells (~6 g wet weight) 
were re-suspended in ice-cold 5 % (w/v) TCA (5 ml/g cells). The pellet was 
extracted two more times with half volumes of ice-cold TCA. The supernatants 
(60 ml) were pooled and extracted three times with an equal volume of ice-cold 
diethyl ether (3 x 60ml). The aqueous phase was neutralised with 3 M NaOH, The 
traces of ether were evaporated by rotary evaporation and the sample was 
lyophilised overnight. Two ml of the sample was clarified by microcentrifugation 
and subjected to gel filtration (Sephadex G25, 3 x 80 cm) eluting with water. The 
highest molecular weight fractions with absorbance at 260 nm were pooled and 
lyophilised. UDPMurNAc-pentapeptide was identified by LC-MS, m/z [ESI
-
] 
1192.30 (M-H)
- 
and HR LC-MS 1192.3359 (M-H)
-
.  
PYP medium (pH 7.2) contained bacteriological peptone (20 g/l), yeast extract 
(1.5 g/l) and K2HPO4 (4.5 g/l). 
Cell wall synthesis medium (CWSM), (pH 7.4) contained the following 
ingredients in Table 7-1.  
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Table 7-1: CWSM medium 
Na2HPO4 0.26 g/l 
NH4Cl 2,0 g/l 
KCl 4.0 g/l 
MgCl2 4.0 g/l 
Na2SO4 0.15 g/l 
FeSO4 0.1 g/l 
glucose 2.0 g/l 
uracil 40 mg/l 
L-glutamic acid 120 mg/l 
L-lysine 500 mg/l 
meso-diaminopimelic acid  120 mg/l 
L-alanine 50 mg/l 
chloramphenicol 50 mg/l 
ampicillin 50 mg/l 
vancomycin 12.5 mg/l 
 
PYP and CWSM media were sterilised by autoclaving without FeSO4 and 
antibiotics
13, 145
. 
7.6 Conditions for high resolution LC-MS (HR LC-MS) 
The high resolution LC-MS analysis was performed by Philip Aston and 
Dr. Lijiang Song from the Mass Spectrometry Facility of the Chemistry 
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Department of the University of Warwick by a run on a Dionex Ultramate3000 
uHPLC with the Bruker MaXis Mass Spectrometer. 
LC parameters and conditions (Table 7-2): 
Solvent A: water with 0.1 % ammonium 
Solvent B: methanol with 0.1 % ammonium 
Flow rate: 0.2 ml/min 
Injection volume: 2 µl 
UV: 210 nm 
Table 7-2: LC conditions for HR LC-MS 
Time (min) Solvent B (%)  
0 1 
5 1 
25 100 
30 100 
32 1 
40 1 
 
Column: Eclipse plus C18 1.8 um 2.1 x 100 mm  
7.7 Conditions for LC-MS analysis 
LC-MS analysis was performed by a run on an Agilent 1200 HPLC with a Bruker 
HCT Ultra Mass Spectrometer. 
MS conditions: 
Mode: 
Mass Range Mode: Ultra Scan 
Ion Polarity: negative 
Ion Source Type: ESI 
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Alternating Ion Polarity: off 
Current Alternating Ion Pol: Negative 
Divert Valve: to Waste 
Tune SPS: 
Target Mass: 1250 m/z 
Compound Stability: 100 % 
Trap drive Level: 100 % 
Optimize: Normal 
Smart Parameter Setting: active 
Tune Source: 
Trap Drive: 94.8 
Octopole RF Amplitude: 200.0 Vpp 
Lens: 60.0 Volt 
Capillary Exit: -184.8 Volt 
Dry Temp (Set): 300 ºC 
Nebulizer (Set): 40.00 psi 
Dry Gas (Set): 10.00 l/min 
HV Capillary: 4000 V 
HV End Plate Offset: -500 V 
Trap 
Rolling: off 
Scan Begin: 50 m/z 
Scan End: 3000 m/z 
Averages: 5 Spectra 
Max. Accu Time: 200,000 µs 
(Smart) ICC Target: 70,000 
ICC: on 
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LC parameters and conditions (Table 7-3 and Table 7-4): 
Solvent A: water with 0.1 % ammonium 
Solvent B: methanol with 0.1 % ammonium 
Flow rate: 0.8 ml/min 
Injection volume: 20 µl 
Table 7-3: LC conditions for LC-MS analysis of the UDPMurNAc-pentapeptide and the 
dansyl-labelled UDPMurNAc-pentapeptide 
Time (min) Solvent B (%) 
0 5 
3 5 
8 100 
11 100 
16 5 
21 5 
 
Table 7-4: LC conditions for the LC–MS analysis of lipid products 
Time (min) Solvent B (%)  
0 5 
5 5 
30 100 
35 100 
40 5 
45 5 
50 5 
 
Column: Agilent Eclipse XDB-C18 5 µm 4.6 x 150 mm 
Detector: Agilent DAD G1315B 
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7.8 Preparation of UDP-N-acetylmuramyl-L-Ala-γ-D-
Glu-(N
ε
-dansyl)-m-Dap-D-Ala-D-Ala (dansyl-labelled 
UDPMurNAc-pentapeptide) 
UDPMurNAc-pentapeptide (2.5 mol, 3 mg) was dissolved in 3 ml 0.5 M 
NaHCO3 pH 9.0. Dansyl chloride (240 mol, 64 mg) was dissolved in 3 ml 
acetone and added to the aqueous solution. The reaction mixture was stirred at 
room temperature in the dark for 2 hours. After the last addition acetone was 
removed by rotary evaporation and the yellow solid was removed by 
microcentrifugation. The dansyl pentapeptide was separated from dansic acid by 
passage down a gel filtration Sephadex G25 column (80 x 3 cm) eluting with 
water, collecting 5 ml fractions. All fractions were monitored on a PerkinElmer 
UV spectrophotometer (absorbance maxima at 250 and 330 nm), and on a 
PerkinElmer fluorimeter enabling the isolation of the fractions of interest. The 
fractions of interest were pooled and lyophilised overnight
141
. The dry powder 
(yield ~60 %) was dissolved in water to a 1-4 mg/ml stock solution. Negative ion 
HR LC-MS and LC-MS were performed for analysis of the compound m/z (M-H)
-
 
1425.38. 
7.9 Incubation of the dansyl-labelled UDPMurNAc-
pentapeptide with MraY membranes 
2 x 400 µl of ~100 µM dansyl-labelled UDPMurNAc-pentapeptide (in water), 
~80 µg/ml undecaprenyl phosphate (in membrane buffer see Section 7.10) and 
240 µg protein containing MraY membranes were incubated in a buffer 
containing 100 mM Tris pH 7.5, 25 mM MgCl2, 6 % glycerol and 0.15 % 
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Triton X-100. One of the samples also contained 83 µg/ml tunicamycin. A total of 
150 l of these mixtures was used to record the fluorescence emission spectrum 
on a PerkinElmer fluorimeter with excitation at 340 nm at 25 ºC a few minutes 
after sample preparation, 30 minutes later and again straight after 0.1 mM UMP 
addition. 
7.10 General procedure for the continuous fluorescence 
enhancement MraY assays  
The continuous fluorescence assays were performed at 25 ºC in a PerkinElmer 
fluorimeter. The final volume in the cuvette was 180 µl (150 µl master mix, 15 µl 
test compound and 15 µl membranes) or 170 l (150 µl master mix, 5 µl test 
compound and 15 µl membranes.) The MraY reaction was monitored at 340 nm 
for excitation and at 530 nm for emission.  
Preparation of the undecaprenyl or heptaprenyl phosphate solution in a buffer: 
A volume of 40 µl undecaprenyl or heptaprenyl phosphate (10 mg/ml stock) that 
was purchased from Larodan Fine Chemicals was placed in a tube and solvents 
(chloroform/methanol (2:1) + 3 % (v/v) ammonia) removed with a stream of 
nitrogen. 4 ml of a buffer containing 50 mM Tris pH 7.5, 2 mM -
mercaptoethanol, 1 mM MgCl2, 20 % glycerol and 0.5 % TritonX-100 was added, 
vortexed and sonicated until the solution was clear (0.1 mg/ml). 
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Preparation of the master mix for the fluorescence enhancement MraY assays: 
A typical master mix contains 26 µM dansyl pentapeptide, 35 µg/ml undecaprenyl 
or heptaprenyl phosphate  in a buffer containing ~100 mM Tris pH 7.5, ~25 mM 
MgCl2 (final concentrations). Unless otherwise specified. 
An example for the composition of a 20 ml master mix and final concentrations 
are shown in Table 7-5: 
Table 7-5: Composition of the MraY assay mixture for the continuous fluorescence assays 
 stock volume 
concentration 
in the master 
mix 
final 
concentration 
in the assay 
(180 µl) 
final 
concentration 
in the assay 
(170 µl) 
 
dansyl-labelled 
pentapeptide 
(Mw: 1427.2) 
3.75 
mg/ml 
200 µl 26 µM 22 µM 23 µM 
undecaprenyl 
or heptaprenyl 
phosphate 
0.1 
mg/ml 
7 ml 35 µg/ml 29 µg/ml 31 µg/ml 
buffer 
200 mM 
Tris, 50 
mM 
MgCl2 
 
10 ml 
100 mM Tris, 
25 mM MgCl2 
83 mM Tris, 
21 mM MgCl2 
88 mM Tris, 
22 mM MgCl2 
water  2.8 ml    
 
Note that the assay always contains 6 % glycerol and 0.15 % Triton X-100 from 
the buffer that the undecaprenyl or heptaprenyl phosphate solution was made. The 
presence of detergent is essential for the MraY assay. 
A total of 150 l of the master mix was used for the fluorescence assays in the 
cuvette. The test compounds were added in 15 or 5 µl volume and for the negative 
controls the same kind and volume of the solvents was added. 
Membranes were diluted in a buffer (membrane buffer) containing a 50 mM Tris 
pH 7.5, 2 mM -mercaptoethanol, 1 mM MgCl2 in order to achieve an ideal stock 
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concentration. A volume of 15 µl of stock solution of the membranes was added 
to start the reactions.  
7.10.1 Time-course of the MraY reaction  
The master mix contained 26 µM dansyl-labelled UDPMurNAc-pentapeptide, 
30 µg/ml undecaprenyl phosphate at final concentrations in 83 mM Tris pH 7.5, 
21 mM MgCl2. The reaction was started with the addition of 90 µg protein 
containing overexpressed MraY membranes in a total volume of 180 µl. The 
reaction was monitored by a PerkinElmer fluorimeter over 15 minutes. A gradual 
increase was observed in fluorescence intensity, indicating the formation of 
dansyl-labelled lipid I. 83 µg/ml tunicamycin was used as a positive control. 
7.10.2 Experiment with inactivated MraY membranes 
The experiment was carried out in a 180 µl total volume containing 20 µM 
dansyl-labelled UDPMurNAc-pentapeptide, 30 µg/ml undecaprenyl phosphate in 
83 mM Tris pH 7.5, 21 mM MgCl2 and the reaction was started with the addition 
of 90 µg protein (membranes) as described in Section 7.10. Under the same 
conditions previously boiled MraY membranes (C43) were added (90 µg) and no 
increase in fluorescence intensity was observed over time. 
7.10.3 Reverse MraY reaction with UMP addition  
180 µl total volume contained 20 µM dansyl-labelled UDPMurNAc-pentapeptide, 
30 µg/ml undecaprenyl phosphate in the assay buffer (83 mM Tris pH 7.5, 21 mM 
MgCl2) and the reaction was started with the addition of 90 µg protein 
(membranes) as described in Section 7.10. After 13 minutes reaction time 0.1 mM 
UMP was added which resulted in a rapid decrease in fluorescence intensity. 
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7.10.4 Effect of added heptaprenyl phosphate to the fluorescence 
substrate incubated with MraY membranes 
The master mix contained 20 µM dansyl-labelled UDPMurNAc-pentapeptide but 
no heptaprenyl phosphate, 83 mM Tris pH 7.5, 21 mM MgCl2, 6 % glycerol and 
0.1 % Triton X-100. 90 µg MraY membranes (C43) were added and no increase 
in fluorescence was observed over 10-minute reaction time. 8 µg/ml (final 
concentration) heptaprenyl phosphate induced the fluorescence changes. 
 
7.11 IC50 determination of pacidamycins by the 
continuous fluorescence assays 
The continuous assays were performed as in Section 7.10. A series of dilutions of 
pacidamycin 1,2 and pacidamycin D was tested between 0-9 µg/ml concentrations 
against and P. aeruginosa MraY. The reaction mixture contained 30 µM dansyl-
labelled UDPMurNAc-pentapeptide, 30 µg/ml heptaprenyl phosphate and 60 µg 
protein in a total volume of 180 µl in in a buffer containing 83 mM Tris pH 7.5, 
21 mM MgCl2. A regression line was fitted to the data from a run of an individual 
inhibitor concentration between 140-190 seconds using GenStat. That provided an 
estimate for the slopes, e.g. the initial rates of the MraY reactions. The standard 
errors on the slopes resulting from the variations of the points (10 points/sec) were 
< 2%. The means of the slopes were then used to calculate % activity, the control 
lacking inhibitor taken as 100 % activity. A further non-linear regression was used 
to fit the activity against concentration: The calculation for 50 % activity with the 
standard error was estimated using GenStat with a curve fitting program. The 
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curve fitting program is the work of Dr. Julie Jones from the Quantitative Biology 
Centre (QuiBic) of the University of Warwick.  
 
7.12 KM determination for the dansyl-labelled 
UDPMurNAc-pentapeptide with P. aeruginosa MraY 
membranes 
A range of different dansyl-labelled UDPMurNAc-pentapeptide concentrations 
were prepared in a volume of 40 µl each. These solutions were added to a 500 µl 
85 mM Tris pH 7.5, 22 mM MgCl2 buffer containing 20 µg/ml heptaprenyl 
phosphate (total volume 540 µl). A volume of 150 µl of these solutions, 
containing different concentrations of the dansyl pentapeptide, was placed in a 
cuvette and the reactions were started each time with the addition of 15 µl 60 µg 
protein containing P. aeruginosa MraY membranes. Assays were carried out in 
duplicates. 
Final concentrations of the dansyl-labelled UDPMurNAc-pentapeptide (165 µl 
total volume) for the experiment: 8.8, 22, 44.1, 88.4 and 176 µM. The 
fluorescence intensity was recorded in time in a PerkinElmer fluorimeter, 
excitation at 340 nm, emission at 530 nm. The rate of the reactions (v) was 
determined between 80 and 130 seconds on the curves. 1/[s], 1/v and v/[s] and 
[s]/v values were calculated in order to use the graphical methods such as plotting 
v vs. [s], the Eadie-Hofstee (v/[s] vs. v), the Lineweaver-Burk 1/v vs. 1/[s]) and 
the Hanes-Woolf [s]/v vs. [s] for KM determination (Table 7-6).  
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Table 7-6: Calculations for KM determination with graphical methods 
[s] 8.8 22 44.1 88.4 176 
v 0.127 0.258 0.292 0.327 0.355 
stdev on v 0.020 0.030 0.030 0.033 0.030 
v/[s] 0.014 0.012 0.007 0.004 0.002 
[s]/v 69.074 85.238 150.924 270.750 495.495 
1/[s] 0.114 0.045 0.0227 0.011 0.006 
1/v 7.849 3.874 3.422 3.062 2.815 
 
7.13 Evidence for the presence of the dansyl-labelled 
lipid I by LC-MS 
80 µM dansyl-labelled UDPMurNAc-pentapeptide (3.75 mg/ml stock) was 
incubated with 200 µg MraY membranes and 35 µg/ml undecaprenyl or 
heptaprenyl phosphate (0.1 mg/ml stock in 50 mM Tris pH 7.5, 2 mM -
mercaptoethanol, 1 mM MgCl2, 20 % glycerol and 0.5 % Triton X-100) in a 
buffer containing 100 mM Tris pH 7.5, 25 mM MgCl2 in a total volume of 200 µl. 
The mixture was vortexed and left for 30 minutes at room temperature to form the 
lipid products. The reaction was stopped by the addition of 50 % 6 M pyridinium 
acetate (200 µl), and an additional 50 % (400 µl) 1-butanol was added. The 
mixture was vortexed for 2 minutes and centrifuged at 12 000 x g for 4 minutes. 
The butanol extracted products were analysed by a run on a Dionex 
Ultramate3000 uHPLC with Bruker MaXis by Philip Aston as in Section 7.6.  
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7.14 Preparation of UDP-N-acetylmuramyl-L-Ala-γ-D-
Glu-(N
ε
-2,4-dinitrophenyl)-m-Dap-D-Ala-D-Ala 
(DNP-labelled UDPMurNAc-pentapeptide) 
UDPMurNAc-pentapeptide (2.5 mol, 3 mg) was dissolved in 2.5 ml 0.5 M 
NaHCO3 pH 9.0. 1-Fluoro-2,4-dinitrobenzene (100 mg) was dissolved in 2.5 ml 
acetone and added to the aqueous solution. The reaction mixture was stirred at 
room temperature in the dark for 24 hours. Acetone was removed by rotary 
evaporation. The labelled pentapeptide was purified by passage down a gel 
filtration Sephadex G25 column (80 x 3 cm) eluting with water, collecting 5 ml 
fractions. All fractions were monitored on a PerkinElmer UV/Vis 
spectrophotometer (absorbance maxima at 250 and 360 nm), enabling the 
isolation of the fractions of interest. The fractions of interest were pooled and 
lyophilised overnight. The dry powder was dissolved in water. Negative ion HR 
LC-MS was performed on a Dionex Ultramate3000 uHPLC with Bruker MaXis 
as in Section 7.6. 
7.15 Preparation of UDP-N-acetylmuramyl-L-Ala-γ-D-
Glu-(N
ε
-fluorescamine)-m-Dap-D-Ala-D-Ala 
(fluorescamine-labelled UDPMurNAc-pentapeptide) 
UDPMurNAc-pentapeptide (3.8 mg) was dissolved in 3 ml 0.5 M NaHCO3 
pH 9.0. Fluorescamine (84 mg) was dissolved in 3 ml acetone and added to the 
aqueous solution. The reaction mixture was stirred at room temperature in the 
dark for 25 minutes. Acetone was removed by rotary evaporation. The 
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fluorescamine-labelled pentapeptide was purified by passage down a gel filtration 
Sephadex G25 column (80 x 3 cm) eluting with water, collecting 5 ml fractions. 
All fractions were monitored on a PerkinElmer UV spectrophotometer 
(absorbance maxima at 250 and 390 nm) enabling the isolation of the fractions of 
interest. The fractions of interest were pooled and lyophilised overnight. The dry 
powder was dissolved in water to a 1 mg/ml stock solution. Negative ion HR LC-
MS was performed on a Dionex Ultramate3000 uHPLC with Bruker MaXis as in 
Section 7.6.  
7.16 Attempt to make an HPLC-based MraY assay 
A 60 µl volume containing ~1 mg/ml UDPMurNAc-pentapeptide or one of the N-
labelled pentapeptides (300 µg/ml final concentration) was incubated with 40 µl 
0.1 mg/ml heptaprenyl phosphate in 50 mM Tris pH 7.5, 2 mM -
mercaptoethanol buffer, 1 mM MgCl2, 20 % glycerol and 0.5 % Triton-X100 
(20 µg/ml final concentration), with 40 µl of 5 mg/ml MraY membranes 
(overexpressed with various MraYs or M. flavus membranes) and with 60 µl 
buffer containing 200 mM Tris pH 7.5, 50 mM MgCl2. The mixture of 200 µl was 
vortexed and incubated at 37 ºC for 30 minutes at room temperature to form the 
lipid products. The reaction was stopped by the addition of 50 % 6 M pyridinium 
acetate (200 µl), and an additional 50 % (400 µl) 1-butanol was added. The 
mixture was vortexed for 4 minutes and centrifuged at 13,000 x g for 4 minutes. 
The butanol extracted products were analysed by LC-MS as it is described in 
Section 7.7. 
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7.17 Conversion of UDPMurNAc-tripeptide to 
UDPMurNAc-pentapeptide (before optimising the 
procedure) 
A crude enzyme preparation (E. coli extract) having alanine racemase, D-Ala : D-
Ala ligase and D-Ala-D-Ala adding activity (MurF) was made. The ingredients 
for a 500 l reaction (unlabelled) were the following: 
Buffers: 0.25 M Tris-HCl, pH 8.4, 2.5 M Tris-HCl, pH 8.4 
Reaction mixture: 
250 mM Tris-HCl, pH 8.4 46 l 
70.9 mM UDPMurNAc tripeptide 14 l (1 mol) 
80 mM L-Ala 25 l (2 mol) 
200 mM ATP 
100 l, needs neutralising, then 
dissolved in buffer 
800 mM MgCl2 50 l 
2 M KCl 5 l 
100 mM DTT (1 M stock diluted in 
2.5 M buffer) 
10 l 
8 mM Pyridoxal phosphate 50 l 
 
The last addition to the 2 ml Eppendorf was the 200 l enzyme extract 
(38.42 mg/ml protein concentration). The reaction mixture was incubated at 37 C 
for ~3 hours. The sample was boiled for 3 minutes at 100 C and 
microcentrifuged (12,000 x g for 2 minutes) to remove the denatured protein. The 
sample was purified through passage down a Sephadex G25 gel filtration column 
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and high molecular weight fractions showing absorbance maxima at 210 and 
260 nm were collected, concentrated by freeze-drying and analysed by LC-MS 
(Section 7.7).  
Preparation of an E. coli cell-free extract 
CFE (Cell Free Extract) Medium contained 10 g casamino acids, 5 g yeast extract, 
6 g Na2HPO4, 1 g KH2PO4 in 900 ml water and was autoclaved. 20 g glucose in 
100 ml water was sterilized separately and added to get 1 l media at pH 7. 100 ml 
CFE medium was inoculated with a single colony of E. coli K21 from an agar 
plate. The overnight culture was used to inoculate 2 x 2 l media at 2 %. These 
were shaken at 37 C 180 rpm for 3.5 hours up to OD600 ~0.4 (mid log-phase). 
The cells were harvested at 12,000 x g, for 20 minutes at 4 C. Pellet was re-
suspended in 10 ml 0.02 M potassium phosphate buffer pH 7, 1 mM DTT and 
1 mM EDTA. The suspension was sonicated for 4 x 30 secs (30 secs between 
bursts) on ice. The sonicated suspension was span at 13,000 x g. The supernatant 
was dialysed overnight at 4 C vs. 2 l 0.1 M potassium phosphate buffer 
containing 1 mM DTT at pH 7. 
 
Preparation of 0.1 M and 0.02 M potassium phosphate buffers at pH 7: 
Two solutions were prepared: 
1. 0.5 l of 1 M K2HPO4 (174.18 g/mol)  
2. 0.5 l of 1 M KH2PO4 (136.09 g/mol) 
In order to prepare 0.1 M potassium phosphate buffer 61.5 ml 1 M K2HPO4 and 
38.5 ml 1 M KH2PO4 was mixed and completed to 1 l with water. The 0.02 M 
potassium phosphate buffer was prepared by dilution of the 0.1 M potassium 
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phosphate buffer. The protein concentration was determined by the Bradford 
assay using albumin standards (38.42 mg/ml)
13
. 
7.18 Radiochemical synthesis of the [
14
C]-UDPMurNAc-
pentapeptide (optimised version) 
The synthesis consists of a single overnight incubation at 37 ˚C of 1 µmol UDP-
MurNAc-tripeptide with 3 µmol L-alanine (10 µCi/µmol), alanine racemase, 
DdlB, MurF, ATP and pyridoxal phosphate. The total volume of the reaction was 
450 µl. The detailed composition is shown in Table 7-7. The reaction was first 
optimised without 
14
C-L-alanine. 
Table 7-7: Reaction mixture (400 µl + 50 µl enzymes): 
250 mM Tris HCl, pH 8.4 102 µl 
160 mM L-Ala 19 µl 
0.1 mCi/ml 
14
CH3
14
CH(NH2)
14
CO2H 
300 µl (freeze-dried and 
mixed with L-Ala) 
200 mM ATP 100 µl 
8 mM pyridoxal phosphate 50 µl 
1 M MgCl2 50 µl 
2 M KCl 10 µl 
1M DTT 2 µl 
UDPMurNAc-tripeptide 67 µl 
7 mg/ml alanine racemase (E. coli) 20 µl 
3.5 mg/ml DdlB (E. coli) 20 µl 
24 mg/ml MurF (P. aeruginosa) 10 µl 
 
The enzymes were removed by ultrafiltration with a centricon membrane (cut off 
10,000 Da). The filtrate was purified by gel filtration (Sephadex G 25, 30 x 1 cm) 
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eluting with water collecting ~4 ml fractions. The fractions were monitored by a 
PerkinElmer UV-Vis Spectrophotometer. The highest molecular weight fractions 
(eluting first) with absorbance maxima at 210 and 260 nm were collected and 
counted in a scintillation counter (the neighbouring fractions that were collected 
before and after as well). The two fractions containing high counts (9,575 and 
24,575 dpm/10 µl) were put away for the assays (Table 7-8). The non-labelled 
version of the radiochemical substrate synthesis was tested by LC-MS in order to 
confirm the presence of UDPMurNAc-pentapeptide. 
Table 7-8: Radioactivity in fractions 
fraction  radioactivity in 10 µl fraction (dpm) 
3 28 
4 9,575  
5 24,575 
6 3,827 
7 2,241 
8 44,747 
9 25,979 
10 518 
11 46 
 
7.19 General radiochemical MraY assay procedure 
Assays were carried out as described by A. Lloyd et al. (2004)
130
. A solution of 
[
14
C]-UDPMurNAc-pentapeptide (1-4 nCi/assay) was incubated for 30 minutes at 
35 ºC with 27 µg/ml undecaprenyl or heptaprenyl phosphate (0.1 mg/ml stock in 
buffer, see Section 7.10) and 30-50 µg overexpressed MraY membranes in a 
buffer containing 100 mM Tris pH 7.5, 17.5 mM MgCl2, 4.0 % (vol/vol) glycerol, 
2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 a total volume of 100 µl. The mixture 
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was vortexed and left for 30 minutes at 35 ºC to form the lipid products. The 
reaction was stopped by the addition of 50 % 6 M pyridinium acetate pH 4.2 
(100 µl), and an additional 50 % (200 µl) 1-butanol was added. The mixture was 
vortexed for four minutes and centrifuged at 13,000 x g for 4 minutes. A volume 
of 200 µl of the upper butanol layer (the whole upper layer seems to be 250 µl) 
was placed in ~5 ml ScintiSafe scintillation liquid and quantified by liquid 
scintillation counting by a PerkinElmer scintillation counter (dpm). Mixtures for 
control experiments lacked MraY membranes (background) and measurements 
were corrected by subtracting the background radioactivity. Assays were carried 
out in duplicates at the presence of inhibitors at various concentrations. The 
negative control (no inhibitor) was prepared in quadruplets or sextuplets and 
inhibition by tunicamycin (125 or 250 µg/ml) or pacidamycin D (3 µg/ml) in 
duplicates was used as a positive control. IC50 was measured from a plot of 
enzyme activity vs. inhibitor concentration where the negative controls lacking 
inhibitor was taken as 100 % activity, and error calculated by the same curve 
fitting program in GenStat that was used for the fluorescence measurements. 
Typical composition of a 3 ml master mix: 
 1500 µl assay buffer (200 mm Tris pH 7, 50 mM MgCl2) 
 1000 µl heptaprenyl or undecaprenyl phosphate (0.1 mg/ml stock in 
50 mM Tris pH 7.5, 2 mM -mercaptoethanol, 1 mM MgCl2, 20 % 
glycerol and 0.5 % Triton-X100, see Section 7.10)  
 100 µl DMSO 
 120 µl 14C-labelled substrate (24,500 dpm/10 µl) 
 280 µl water 
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For the assays 80 µl master mix was placed into a 1.5 ml Eppendorf vial, then 
10 µl inhibitor solution was added and the reaction was started with the addition 
of 10 µl MraY membranes (2-5 mg/ml protein stock) in 100 µl total volume. 
7.19.1 Radiochemical assay for the wild type E. coli MraY 
The general procedure applies as in Section 7.19. The total volume of 100 µl 
sample contained 1.7 µM 
14
C-labelled UDPMurNAc-pentapeptide (3.4 nCi, 
7,500 dpm), 27 µg/ml heptaprenyl phosphate in 90 mM Tris pH 7.5, 23 mM 
MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 and 
40 µg protein containing overexpressed (C43) membranes or 40 µg wild type 
E. coli (C43) membranes. Known inhibitors were added such as tunicamycin 
(125 µg/ml), E peptide (100 µg/ml), pacidamycin D (3 µg/ml) and a capuramycin 
analogue, A-503083 B (1.2 µg/ml). 
7.19.2 Investigation of D, D-carboxypeptidase activity 
The general procedure applies as in Section 7.19. Each sample contained 
1,800 dpm in total, 27 µg/ml heptaprenyl phosphate in 90 mM Tris pH 7.5, 
23 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-
100 and the reaction was started with the addition of 40 µg protein containing 
overexpressed C43 membranes. Samples containing 100 µg/ml ampicillin in order 
to stop D,D-carboxypeptidase activity were compared to samples with no 
ampicillin. 100 µg/ml tunicamycin was used for inhibition. Samples were 
prepared in duplicates. 
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7.19.3 Background activity from the endogenous undecaprenyl 
phosphate in E. coli C43 membranes  
2.4 nCi (5,275 dpm) was the total radioactivity in each sample with no 
heptaprenyl phosphate in 90 mM Tris pH 7.5, 23 mM MgCl2, 4.0 % (vol/vol) 
glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100. The MraY reaction was 
started with the addition of 40 µg protein containing (C43) membranes. Control 
samples were prepared in quadruplets also containing 27 µg/ml heptaprenyl 
phosphate. 
7.19.4 The time-course of the MraY reaction by the radiochemical 
assay  
The general procedure applies as in Section 7.19. The reaction was stopped at 1, 5 
10 and 15 minutes after the membrane addition. Lipid products were extracted 
each time into butanol as described in Section 2.4.2.1 and radioactivity was 
measured by liquid scintillation counting. 100 µl total volume contained 1.7 µM 
14
C-labelled UDPMurNAc-pentapeptide (3.4 nCi, 7,500 dpm), 27 µg/ml 
heptaprenyl phosphate in 90 mM Tris pH 7.5, 23 mM MgCl2, 4.0 % (vol/vol) 
glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 and 40 µg protein 
containing overexpressed C43 membranes. The experiment was repeated with the 
addition of 40 µg protein overexpressed B. subtilis, 35 µg protein overexpressed 
S. aureus, 20 µg protein overexpressed P. aeruginosa in E. coli C43 membranes 
and 40 µg M. flavus membranes.  
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7.19.5 Overproduction of enzyme activity in the E. coli MraY 
membranes and comparison with the wild type M. flavus 
The forming radiolabelled lipid products were quantified after 30 minutes reaction 
time using overexpressed MraY E. coli and M. flavus membranes. Lipid products 
were extracted each time into butanol as described in Section 2.4.2.1 and 
radioactivity of 200 µl butanol was measured by liquid scintillation counting. 
100 µl total volume contained 1.7 µM 
14
C-labelled UDPMurNAc-pentapeptide 
(3.4 nCi), 27 µg/ml heptaprenyl phosphate in 90 mM Tris pH 7.5, 23 mM MgCl2, 
4.0  % (vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 and 40 µg 
protein containing overexpressed E. coli (C43) membranes. The experiment was 
repeated with the addition of overexpressed E. coli (C43) membranes with MraY 
from B. subtilis (40 µg protein), S. aureus (35 µg protein), P. aeruginosa (20 µg 
protein) and M. flavus membranes (40 µg protein). 
7.20 Fluorescence plate reader assays 
The plate reader assays were performed at room temperature in a Tecan Genios 
Plate-Reader. The final volume in each micro-well was 100 l (85 µl master mix, 
5 µl test compound, 10 µl membranes). Measurements were taken before the start 
of the reaction, then over 20 minutes at 5 minute intervals, and once again at 
30 minutes reaction time monitoring at a specified wavelength (excitation 340 nm, 
emission 535 nm).  
Preparation of the undecaprenyl or heptaprenyl phosphate solution in a buffer: 
A volume of 40 µl undecaprenyl or heptaprenyl phosphate (10 mg/ml stock) that 
was purchased from Larodan Fine Chemicals was placed in a tube and solvents 
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(chloroform/methanol (2:1) + 3 % (v/v) ammonia) removed with a stream of 
nitrogen. 4 ml of a buffer containing 50 mM Tris pH 7.5, 2 mM -
mercaptoethanol, 1 mM MgCl2, 20 % glycerol and 0.5 % Triton X-100 was 
added, vortexed and sonicated until the solution was clear (0.1 mg/ml). 
Preparation of the master mix for the plate reader assays: 
The master mix contains 13.1 µM dansyl-labelled UDPMurNAc-pentapeptide, 
20 µg/ml undecaprenyl or heptaprenyl phosphate in a buffer containing 100 mM 
Tris pH 7.5, 25 mM MgCl2 (final concentrations in the master mix). Unless 
otherwise specified.  
The typical composition of a 20 ml master mix and the final concentrations in the 
wells are shown in Table 7-9: 
Table 7-9: Composition of a 30 ml master mix for the fluorescence MraY plate reader assays 
 stock  volume 
concentration in 
the master mix 
final 
concentration in 
the assay (100 µl 
volume) 
dansyl-labelled 
UDPMurNAc-
pentapeptide 
(Mw: 1427.2) 
3.75 mg/ml 100 µl 13.1 µM 11.2 µM 
undecaprenyl 
or heptaprenyl 
phosphate 
0.1 mg/ml 4 ml 20 µg/ml 17 µg/ml 
 assay buffer 
200 mM Tris, 
50 mM MgCl2 
10 ml 
100 mM Tris, 
25 mM MgCl2 
85 mM Tris, 
21.25 mM MgCl2 
water  5.9 ml   
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Note that the assay always contains 3 % glycerol and 0.1 % Triton X-100 at final 
concentrations from the buffer that the undecaprenyl or heptaprenyl phosphate 
solution was made. The presence of detergent is essential for the MraY assay.  
A volume of 85 l of the master mix was used for the fluorescence assays in each 
well. The test compounds were added in 5 µl volume. A volume of 5 µl of a 
2 mM stock solution of compounds from the diversity set (diluted in 100 mM 
Tris, 25 mM MgCl2 from 10 mM stock in DMSO) were tested at 100 µM final 
concentrations. 
A volume of 5 µl tunicamycin (2.5 mg/ml stock in DMSO, 25 µg/ml final 
concentrations) was added as positive control (known inhibitor). A volume of 5 µl 
20 % (v/v) DMSO (diluted in 100 mM Tris, 25 mM MgCl2) was added as 
negative control. Membranes were diluted to 4 mg protein/ml for E. coli 
membranes in 50 mM Tris pH 7.5, 2 mM -mercaptoethanol, 1 mM MgCl2 
(membrane buffer). 
A volume of 10 µl of the membranes was added to start the reaction. For the 
negative control “no membranes” 10 µl membrane buffer (50 mM Tris pH 7.5, 
2 mM -mercaptoethanol, 1 mM MgCl2) was added instead of the membranes. 
7.21 Testing hits from the initial fluorescence screen of 
the NCI diversity set by the continuous fluorescence 
assay 
The hits from the microtitre fluorescence MraY assay were tested at 60 µM 
concentration in a total volume of 170 µl containing 20 µM dansyl-labelled 
UDPMurNAc-pentapeptide, 35 µg/ml heptaprenyl phosphate, 83 mM Tris pH 7.5, 
  
 
247 
 
21 mM MgCl2, 6 % glycerol and 0.15 % Triton X-100. The reaction was started 
by the addition of 60 µg MraY membranes. 14.7 µg/ml tunicamycin was used as a 
positive control. See Section 7.10. 
7.22 Testing low fluorescence and high fluorescence 
compounds from the NCI diversity set by the 
radiochemical MraY assay 
The general procedure applies as in Section 7.19. The total volume of 100 µl 
sample contained 1.2 µM [
14
C]-labelled UDPMurNAc-pentapeptide (2.4 nCi,), 
27 µg/ml heptaprenyl phosphate in 90 mM Tris pH 7.5, 23 mM MgCl2, 4.0 % 
(vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 and 40 µg protein 
containing overexpressed MraY membranes. The test compounds were added in 
5 µl volume at 100 and 500 µM concentrations. Assays were carried out in 
duplicates. 
7.23 Testing michellamine B by the radiochemical MraY 
assay 
The general procedure applies as in Section 6.19. The total volume of 100 µl 
sample contained 1.7 µM 
14
C-labelled UDPMurNAc-pentapeptide (3.2 nCi,), 
27 µg/ml heptaprenyl phosphate in 90 mM Tris pH 7.5, 23 mM MgCl2, 4.0 % 
(vol/vol) glycerol, 2.3 % (vol/vol) DMSO, 0.1 % Triton X-100 and 40 µg protein 
containing overexpressed MraY membranes. The test compounds were added in 
10 µl volume at 125, 250 and 500 µg/ml concentrations. Assays were carried out 
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in duplicates. IC50 was determined by a plot of % activity inhibitor concentrations 
with the help of a curve fitting program in GenStat. See Section 2.2.6. 
7.24 Antibacterial testing, microtitre broth dilution and 
agar plate filter disc methods  
7.24.1 Microtitre broth dilution 
Michellamine B was tested for antibacterial activity and minimal inhibitory 
concentration (MIC) against E. coli DH5α, B. subtilis (W23) and P. putida 
(ATCC 33015). 3 x 10 ml LB medium was inoculated by a single colony picked 
from an LB agar plate overnight from each strain and incubated at 37 ºC with 
shaking at 180 rpm. 100 µl of this culture was used to inoculate 9.9 ml LB 
medium, incubated at 37 ºC with shaking at 180 rpm until OD600 was 0.6. The 
culture was diluted 100 fold and 95 µl of this diluted culture was placed in 96-
well plates and to each well 5 µl inhibitor solution was added up to a total volume 
of 100 µl. Michellamine B was tested at 125, 62.5, 31.3, 15.6, 7.81, 3.91 and 
1.95 µg/ml final concentrations. The 125 µg/ml Michellamine B sample contained 
2.5 % DMSO and further dilutions were made with water. Samples were carried 
out in triplicates. For the controls wells contained 100 µl LB for checking 
bacterial contamination. For monitoring bacterial growth without antibiotics, 5 µl 
water or 5 µl DMSO containing solution was added. The concentration of DMSO 
for the negative controls was ≤ 2.5 % in the samples, three different compositions 
were used for the 5 µl solutions: DMSO:H2O ratio: 1:2, 1:4 and 1:8. 5 µl 
kanamycin solutions at 50, 25, 12.5, 6.25, 3.13, 1.56 0.781, and 0.391 µg/ml final 
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concentrations was added for the positive controls. The plates were incubated and 
shaken at 37 ºC and bacterial growth was monitored by the naked eye. 
7.24.2 Agar plate filter disc method 
3 x 10 ml LB medium was inoculated by a single colony of one of the three 
strains picked from an LB agar plate and incubated and shaken overnight at 37 ºC. 
100 µl of the overnight culture was used to inoculate 10 ml LB which was 
incubated at 37 ºC and shaken at 180 rpm until OD600 was 0.6. This culture was 
diluted 100 fold. 300 µl of the diluted culture was mixed and vortexed with 3 ml 
LB containing 0.7 % (w/v) agar, poured on top of an LB plate and spread evenly. 
Sterile filter discs were placed on the plates containing 25 µl michellamine B 
solutions at 0.05, 1.25 and 2.5 mg/ml concentrations. 25 µl of 1 mg/ml ampicillin 
and 2 mg/ml kanamycin was used as positive controls. 
A small zone of inhibition was observed around the discs containing 50, 100 and 
200 µg/ml michellamine B for the B. subtilis culture plates. No inhibition was 
observed against E. coli and P. putida. 
7.25 Assay of Streptomyces culture supernatants 
7.25.1 Streptomyces culture supernatants 
7.25.1.1 Preparation of Streptomyces culture supernatants 
Streptomyces strains were grown on MS agar plates for ten days. Spores were 
collected in sterile water and stocks were made in a 1 : 1 ratio of spore solution : 
50 % glycerol/water. 10 ml ISP2 media was inoculated with 10 µl spore stock 
solutions and incubated at 30 ºC for 2 days at 30 ºC. Then, 50 µl of the cultures 
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were used to inoculate 10 ml ISP2 and Lac-MM media, and the cultures were 
incubated for 8 days at 30 ºC. The cultures were centrifuged for 2 minutes at 
5,000 x g and the supernatants were tested against MraY by the continuous and 
the micro-titre plate reader fluorescence MraY assay against E. coli MraY. 15 µl 
culture supernatant was added to a final volume of 180 µl for the continuous 
assays and 10 µl cultures were used for the plate reader assays in a total volume of 
100 µl. See Sections 7.10 and 7.20. 
MS agar: 
agar: 20 g 
mannitol: 20 g 
soya flour: 20 g 
competed to 1 l with water 
ISP2:  
4 g yeast extract 
10 g malt extract 
4 g glucose 
Completed to 1 l with water, adjust pH to 7.3 with 1N NaOH, and autoclaved  
Lac-MM  
450 ml MM 
50 ml 10 % lactose 
MM:  
2.14 g NH4Cl 40 mM final conc.  
0.6 g MgSO4 2.4 mM final conc. 
1.74 g K2HPO4 10 mM final conc. 
20.99 g MOPS 100 mM final conc. 
0.2 ml 50 mg/ml FeSO4·2H2O  
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0.2 ml 50 mg/ml MnCl2·4H2O  
0.2 ml 50 mg/ml ZnSO4·7H2O  
0.2 ml 50 mg/ml CaCl2  
water to 900 ml (or 950 ml for MM*), adjust pH to 7 with 10 N NaOH. 
10 % lactose: dissolve 5 g lactose in a total volume of 50 ml distilled water. The 
procedure was based on Sabine Grüschow’s procedure (University of St. 
Andrews). 
7.25.1.2 Testing Streptomyces culture supernatants by the 
fluorescence and radiochemical MraY assays 
The general procedures apply. For the continuous fluorescence assays 15 µl 
culture supernatant was tested in a total volume of 180 µl (Section 7.10). For the 
fluorescence microtitre plate assays and the radiochemical assays 10 % (v/v) 
culture was used in the assays (10 µl in 100 µl). See Sections 7.19 and 7.20. 
7.25.2 Preparation of Streptomyces cell extracts 
10 µl of stock spore collections was spread on MS agar plates and grown for ten 
days or SMMS plates and incubated for 3 days at 30 ºC. Plates were stored at 4 °C 
until the time of extraction, and then ethyl acetate was added (in equal volume to 
the volume of culture media used). The ethyl acetate layer was removed by 
filtration and evaporated under reduced pressure. The remaining residue was re-
dissolved in 500 μl 50:50 HPLC grade methanol/water. Cell extracts interfered 
with fluorescence and were tested by the radiochemical MraY assay, where 10 µl 
cell extract was used in a total volume of 100 µl (see Section 7.25.2.1). 
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Modified Supplemented Minimal Medium Solid (SMMS):  
Difco casaminoacids (2 g/l),  
TES buffer (5.68 g/l)  
Bacto agar (15 g/l) were dissolved in distilled water, the pH adjusted to 7.2 using 
10 N NaOH and autoclaved.  
At the time of use, the media was re-melted and the following ingredients were 
added:  
NaH2PO4 + K2HPO4 (50 mM each, 10 ml per litre of culture),  
MgSO4.7H2O (1 M, 5 ml per litre of culture),  
glucose (50 % w/v, 18 ml per litre of culture),  
trace element solution (2 ml per litre of culture)  
Trace elements solution: 0.1 g/l each of ZnSO4.7H2O, FeSO4.7H2O, MnCl2.4H2O, 
CaCl2.6H2O and NaCl and the solution was stored at 4°C. The procedure was 
based on John Sidda’ work (University of Warwick)240. 
7.25.2.1 Testing Streptomyces cell extracts by the 
radiochemical MraY assay 
The general procedure applies (Section 7.19). 10 µl cell extract was tested in a 
total volume of 100 µl. 
7.26 Assay of P1 protein and halogenated fluorescein 
analogues by the radiochemical MraY assay 
The general procedure applies (see Section 7.19). 100 µl assay contained 1.1 µM 
(2.12 nCi)/assay) [
14
C]-UDPMurNAc-pentapeptide, 23.3 µg/ml undecaprenyl 
phosphate, 70 mM Tris pH 7.5, 17.5 mM MgCl2, 4.0 % (vol/vol) glycerol, 2.3 % 
(vol/vol) DMSO, 0.1 % Triton X-100, and the reaction was started by the addition 
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of 40 µg protein containing overexpressed E. coli MraY membranes. Assays were 
carried out in the presence of inhibitor at concentrations of 75-300 µg/ml, and 
inhibition by 125 µg/ml tunicamycin was used as a positive control. IC50 was 
measured from a plot of enzyme activity vs. inhibitor concentration with the help 
of a curve fitting program in GenStat (Section 2.2.6). Dichloro- and dibromo-
fluoresceins were tested in triplicates at 165 and 325 µg/ml final concentrations 
respectively, and phloxine B was tested in duplicate measurements in the range of 
0-500 µg/ml. 
7.27 Radiochemical MurG assay procedure 
7.27.1 E. coli MraY-MurG procedure 
Lipid I was generated from UDPMurNAc-L-Ala-γ-D-Glu-m-Dap-D-Ala-D-Ala 
and undecaprenyl phosphate by overexpressed E. coli MraY membranes and then 
converted in the presence of [
3
H]-UDPGlcNAc and E. coli MurG to give 
radiolabelled lipid II. Assays (total volume 100 μl) contained 100 µM 
UDPMurNAc-L-Ala-γ-D-Glu-m-Dap-D-Ala-D-Ala, 23.3 µg/ml undecaprenyl 
phosphate, 6.6 µM [
3
H]-UDPGlcNAc (2.53 nCi/assay), 70 mM Tris pH 7.5, 
17.5 mM MgCl2, 4.0 % glycerol (vol/vol), 2.3 % (vol/vol) DMSO, 0.1 % 
Triton X-100 to which was added 54 µg E. coli membranes containing 
overexpressed E. coli MraY, and 63 µg E. coli MurG solution. The mixture was 
incubated at 35 ˚C for 30 minutes and reactions were stopped by the addition of 
100 µl 6 M pyridinium acetate, pH 4.2. The lipid products were extracted into 
200 µl 1-butanol and quantified by liquid scintillation counting. Assays were 
carried out in duplicates in the presence of inhibitor at final concentrations of 18-
300 µg/ml P1, 165 µg/ml di-chloro-fluorescein and 325 µg/ml di-bromo-
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fluorescein. Inhibition by ramoplanin was used as a positive control. Mixtures for 
control experiments lacked E. coli MraY membranes and E. coli MurG
267
.  
7.27.2 M. flavus MraY-MurG assay procedure 
Lipid I was generated from UDPMurNAc-L-Ala-γ-D-Glu-m-Dap-D-Ala-D-Ala 
and undecaprenyl phosphate by M. flavus membranes naturally containing high 
level expression of MraY and MurG, and converted in the presence of [
3
H]-
UDPGlcNAc to give radiolabelled lipid II. Assays (total volume 100 μl) contained 
100 µM UDPMurNAc-L-Ala-γ-D-Glu-m-Dap-D-Ala-D-Ala, 23.3 µg/ml 
undecaprenyl phosphate, 4.9 µM [
3
H]-UDPGlcNAc (1.89 nCi/assay), 70 mM Tris 
pH 7.5, 17.5 mM MgCl2, 4.0 % glycerol (vol/vol), 2.3 % (vol/vol) DMSO, 0.1 % 
Triton X-100 to which was added 23 µg M. flavus membranes. The mixture was 
incubated at 35 ˚C for 30 minutes and reactions were stopped by the addition of 
100 µl 6 M pyridinium acetate, pH 4.2. The lipid products were extracted into 
200 µl 1-butanol and quantified by liquid scintillation counting. Assays were 
carried out in the presence of inhibitor concentrations at 75-300 µg/ml for 
P1 peptide and phloxine B was tested at 500 µg/ml. Inhibition by ramoplanin was 
used as a positive control. Mixtures for control experiments lacked M. flavus 
membranes
267
. Assays were carried out in triplicate. Activity or % inhibition was 
determined by taking the negative control lacking inhibitor as 100 % activity. 
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Appendices 
Appendix 1: Preparation of the dansyl-labelled 
UDPMurNAc-pentapeptide (Figures A 1 - A 3) 
 
 
 
A 1: Isotopic pattern for dansic acid by HR LC-MS 
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A 2: Isotopic pattern for the negatively charged ion of the dansyl-labelled UDPMurNAc-
pentapeptide by LC-MS 
 
A 3: Isotopic pattern for the negatively charged ion of the didansyl-labelled UDPMurNAc-
pentapeptide by LC-MS 
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Appendix 2: LC-MS results for the attempted HPLC-
based MraY assay (Figures A 4 - A 18) 
 
A 4: Isotopic pattern for the DNP-labelled UDPMurNAc-pentapeptide by HR LC-MS 
 
 
A 5: Isotopic pattern for the DNP-labelled UDPMurNAc-pentapeptide by HR-LC-MS (two 
DNP labels) 
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A 6: Isotopic pattern for the DNP-labelled UDPMurNAc-pentapeptide (three labels) by HR 
LC-MS 
 
 
A 7: Isotopic pattern for a DNP-labelled UDPMurNAc-pentapeptide fragment 
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A 8: Isotopic pattern by HR LC-MS for the fluorescamine-labelled UDPMurAc-
pentapeptide 
 
 
A 9: Isotopic pattern for the DNP-labelled C35 lipid I 
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A 10: Chemical structure for the DNP-labelled C35 lipid I 
 
 
A 11: Isotopic pattern for the fluorescamine-labelled lipid I (-H2O) by LC-MS 
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A 12: Isotopic pattern of the negatively and doubly charged ion of the fluorescamine-labelled 
lipid I (C35) by HR LC-MS and the computer simulated isotopic pattern  
 
A 13: Chemical structure of the fluorescamine-labelled C35 lipid I 
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A 14: Isotopic pattern for dansyl-labelled lipid I (C55) formed with MraY 
 
 
A 15: Isotopic pattern for the dansyl-labelled lipid I (C35) formed with MraY 
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A 16: Isotopic pattern for lipid I (C35) 
 
A 17: Isotopic pattern for lipid II (C35) 
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A 18: Control lacking the unlabelled or labelled UDPMurNAc-pentapeptides, no sign for the 
masses of lipid products (EICs) 
Appendix 3: Radiochemical synthesis of the [
14
C]-
UDPMurNAc-pentapeptide (Figures A 19 -A 22) 
 
A 19: Isotopic pattern for the UDPMurNAc-tripeptide 
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A 20: Isotopic pattern for the UDPMurNAc-pentapeptide 
 
 
A 21: Isotopic pattern for the UDPMurNAc-pentapeptide by HR LC-MS 
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A 22: ESI-MS for 
14
C-labelled UDPMurNAc-pentapeptide m/z [M-2H]
2-
: 595.70 for 
predicted 595.66, and sodium adducts, analysis was performed by Susan Slade 
 
 
UDPMurNAc pentapeptide 
sodium adducts 
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Appendix 4: Results from the NCI diversity set 
Empty cells: no inhibition in fluorescence microtitre plate MraY assay 
HF: high fluorescence in microtitre plate MraY assay 
LFA: low fluorescence with fluorescence enhancement activity in the continuous 
MraY assay 
LF: low fluorescence with no fluorescence enhancement activity in the continuous 
MraY assay 
NCI diversity set III, plates 4737067/4720 - 4737067/4739: 
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NCI diversity set natural products set II, plates 13091250 and 13091251:  
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Appendix 5a: Inhibition of E. coli and S. aureus MraY by 
a synthetic muraymycin analogue (Figures A 23 and A 
24) 
 
A 23: Muraymycin analogue inhibition against E. coli MraY, 50 µM muraymycin gave 
15 ± 2 % activity in the assay (missing from graph), IC50: 1.6 ± 0.3 µM 
 
A 24: Muraymycin analogue inhibition against S. aureus MraY, 50 µM gave 4.5 ± 0.5 % 
activity in the assay (missing from graph), IC50: 1.6 ± 0.2 µM 
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Appendix 5b: Inhibition of E. coli MraY by caprazamycin 
analogues (Figures A 25 - A 30) 
 
A 25: Hydroxyacyl-caprazol A inhibition against E. coli MraY, IC50: 339 ± 35 ng/ml, 0.41 µM 
 
 
 
A 26: Hydroxyacyl-caprazol E inhibition against E. coli MraY, IC50: 602 ± 19 ng/ml, 0.75 µM 
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A 27: Hydroxyacyl-caprazol E-acetate inhibition against E. coli MraY, IC50: 
1.21 ± 0.13 µg/ml, 1.4 µM 
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A 28: Hydroxyacyl-caprazol E-butyrate inhibition against E. coli MraY, IC50: 
5.78 ± 0.41 µg/ml, 6.6 µM 
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A 29: Sulphated CPZ-Aglycon A inhibition against E. coli MraY, IC50: 250 ± 35 ng/ml, 
0.24 µM 
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A 30: Sulphated CPZ-Aglycon E inhibition against E. coli MraY, IC50: 314 ± 42 ng/ml, 
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Appendix 5c: Inhibition of E. coli and P. aeruginosa 
MraY by pacidamycin 1,2 and pacidamycin D (Figures A 
31 - A 34) 
 
A 31: Pacidamycin 1,2 inhibition against E. coli MraY, IC50: 83 ± 7 ng/ml 
 
A 32: Pacidamycin 1,2 inhibition against P. aeruginosa MraY, IC50: 114 ± 5 ng/ml 
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A 33: Pacidamycin D inhibition against E. coli MraY, IC50: 46 ± 7 ng/ml 
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A 34: Pacidamycin D inhibition against P. aeruginosa MraY, IC50: 27 ± 4 ng/ml 
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Appendix 5d: Inhibition of P. aeruginosa MraY by 
tunicamycin (Figure A 35) 
 
 
A 35: P. aeruginosa MraY inhibition by tunicamycin, IC50: 4.44 ± 1.38 µg/ml 
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Appendix 5e: Inhibition of E. coli and B. subtilis MraY by 
capuramycin analogues (Figures A 36 and A 37) 
 
A 36: A-503083 B inhibition against E. coli MraY, IC50: 139 ± 16 ng/ml 
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A 37: A-503083 F inhibition against E. coli MraY, IC50: 4.8 ± 0.6 µg/ml  
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Appendix 6: Inhibition of E. coli, S. aureus and 
P. aeruginosa MraYs by the glycopeptide vancomycin 
(Figures A 38 - A 40) 
 
A 38: Vancomycin inhibition against E. coli MraY, IC50: 61.6 ± 8 µg/ml 
 
A 39: Vancomycin inhibition against S. aureus MraY, IC50: 130 ± 12 µg/ml 
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A 40: Vancomycin against P. aeruginosa MraY, IC50: 288 ± 44 µg/ml 
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Appendix 7: Inhibition of E. coli, S. aureus, B. subtilis, 
P. aeruginosa and M. flavus MraYs by phloxine B 
(Figures A 41 - A 46) 
 
 
 
 
 
 
 
 
 
 
 
 
A 42: Phloxine B inhibition against S. aureus MraY, IC50: 211 ± 29 µg/ml 
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A 41: Phloxine B inhibition of E. coli MraY, IC50: 26.4 ± 1.0 µg/ml 
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A 43: Phloxine B inhibition against B. subtilis MraY, IC50: 137 ± 20 µg/ml 
 
A 44: Phloxine B inhibition against P. aeruginosa MraY, IC50: 106 ± 23 µg/ml 
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A 45: Phloxine B inhibition against M. flavus MraY, IC50: 162 ± 25 µg/ml 
 
 
A 46: Phloxine B inhibition against E. coli MraY in the dark, IC50: 24.2 ± 1.7 µg/ml 
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